| Title of Invention | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSYNE KINASES |
|---|---|
| Abstract | Compounds of formula (I): and their use in the inhibition of Trk activity are described. |
| Full Text | Field of the invention The present invention relates to novel pyrazole derivatives, their pharmaceutical compositions and methods of use. In addition, the present invention relates to therapeutic methods for the treatment and prevention of cancers and to the use of these pyrazole derivatives in the manufacture of medicaments for use in the treatment and prevention of cancers. Background of the invention Receptor tyrosine kinases (RTK's) are a sub-family of protein kinases that play a critical role in cell signalling and are involved in a variety of cancer related processes including cell proliferation, survival, angiogenesis and metastasis. Currently up to 100 different RTK's including tropomyosin-related kinases (Trie's) have been identified. Trie's are the high affinity receptors activated by a group of soluble growth factors called neurotrophins (NT). The Trie receptor femily has three niembers - TrkA, TrkB and TrkC Among the NTs there are (i) nerve growth factor (NGF) which activates TrkA, (ii) team-derived growth factor (BDNF) and NT-4/5 which activate TrkB and (iii) NTS which activates TrkC. Each Trk receptor contains an extra-cellular domain (tigand binding), a trans-membrane region and an mtra-celhilar domain (including kmase domain). Upon binding of the ligand, the kinase catalyzes auto-phosphorylation and triggers downstream signal transduction pathways. Trie's are widely expressed in neuronal tissue during its development where Trie's are critical for the maintenance and survival of these cells. A post-embryonic role for the Trk/neurotrophin axis (or pathway), however, remains in question. There are reports showing that Trie's play important role hi both development and function of the nervous system (Patapoutian, A. et al Current Opinion in Neurobiology, 2001,11,272-280). In the past decade, a considerable number of literature documentations linking Trk signalling with cancer have published. For example, while Trie's are expressed at low levels outside the nervous system in the adult, Trk expression is increased in late stage prostate cancers. Both normal prostate tissue and androgen- dependent prostate tumours express low levels of Trk A and undetectable levels of Trk B and C. However, all isoforms of Trk receptors as well as their cognate ligands are up-regulated in late stage, androgen-independent prostate cancer. There is additional evidence that these late stage prostate cancer cells become dependent on the Trk/oetnrotrophin axis for their survival Therefore, Trie inhibitors may yield a class of apoptosis-indncing agents specific for androgen- independent prostate cancer (Weeraratna, A. T. et al The Prostate, 2000,45,140-148). Furthermore, very recent literature also shows mat over-expression, activation, amplification and/or mutation of Trie's are associated with secretory breast carcinoma (Cancer Cell, 2002,2,367-376), colorectal cancer (Bardelli et al Science, 2003,300,949-949) and ovarian cancer (Davidson, B. et al Clinical Cancer Research, 2003, 9,2248-2259). There are a few reports of selective Trk tyrosine kinase inhibitors. Cephalon described CEP-751, CEP-701 (George, D. et al Cancer Research, 1999, 59,2395-2341) and other indolocarbazole analogues (WO0114380) as Trk inhibitors. It was shown mat CEP-701 and/or CEP751, when combined with surgically or chemically induced androgen ablation, offered better efficacy compared with mono-therapy alone. GlaxoSmithKhne disclosed certain oxmdole compounds as TrkA inhibitors in WO0220479 and WO0220513. Recently, Japan Tobacco reported pyrazotyl condensed cyclic compounds as Trk inhibitors (JP2003231687A). In addition to the above, Vertex Pharmaceuticals have described pyrazole compounds as inhibitors of GSK3, Aurora, etc. in WO0250065, WO0262789 and WO03027111; and AstraZeneca have reported pyrazole compounds as inhibitors against IGF-1 receptor kinase (W00348133). Summary of tine invention La accordance with the present invention, the applicants have hereby discovered novel pyrazole compounds, or pharmaceuticalry acceptable salts thereof, which possess Trk kinase inhibitory activity and are accordingly useful for their anti-proliferation and/or proapoptotic (such as anti-cancer) activity and in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said pyrazole compounds, or phannaceutically acceptable salts thereof, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an anti-proliferation and/or proapoptotic effect in warm-blooded animals such as man. Also in accordance with the present invention the applicants provide methods of using such pyrazole compounds, or pharmaceutically acceptable salts thereof, in the treatment of cancer. The properties of the compounds claimed in this invention are expected to be of value in the treatment of disease states associated with cell proliferation such as cancers (solid tumours and leukaemia), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation. Furthermore, the compounds, or pharmaceutically acceptable salts thereof, of the invention are expected to be of value in the treatment or prophylaxis of cancers selected from oesophageal cancer, myeloma, hepatocellular, pancreatic, cervical cancer, ewings tumour, neuroblastoma, kaposis sarcoma, ovarian cancer, breast cancer, colorectal cancer, prostate cancer, bladder cancer, melanoma, hmg cancer - non. small cell lung cancer (NSCLC), and small cell hmg cancer (SCLC), gastric cancer, head and neck cancer, renal cancer, lymphoma and leukaemia; particularly ovarian cancer, breast cancer, colorectal cancer, prostate cancer and hmg cancer - NSCLC and SCLC; more particularly prostate cancer; and more particularly hormone refractory prostate cancer. Detailed description of the famntio» Accordingly, tbe present invention provides a cocnpound of formula (I): (Figure Remove) A is a direct bond or Q-ialkylene; wherein said Ci-ialkylene may be optionally substituted by one or more R22; Ring C is carbocyclyl or heterocyclyl; R1 and R4 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, triftuoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Ci^alkyl,' C2-6alkynyl, C^alkoxy, Ci^alkanoyl, Ci^alkanoyloxy,. yjV-(Ci^aIkyl)2caibamoyl, Ci^alkylS(OX wherein a is 0 to 2, Ci^alkoxycaibonyl, ^-{Ci^alkyl)sulphamoyl, ##-(Ci-«alkyl)2Sulphamoyl, Ci^lkylsulphonylamino, carbocycb/l or heterocyctyl; wherein R1 and R4 independently of each other may be optionally substituted on carbon by one or more R8; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R9; R2 is selected from halo, nitro, cyano, hydroxy, trifhioromethoxy, ammo, carboxy, carbamoyL, mercapto, sulphamoyl, Ci^alkyl, Cj^alkenyl, Ca-salkynyl, Ci^alkoxy, Cj^alkanoyloxy, N:-(Ci^aIkyl)amino, wherein a is 0 to 2, Ci^aDcoxycarbonyl, JV-(Ci^alkyl)sulphamoyl, Q^alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R2 may be optionally substituted on carbon by one or more R10; and wherein if said heterocyclyl contains an -NH- moiety mat nitrogen may be optionally substituted by a group selected from Rn; R3 is selected from halo, nitro, cyano, hydroxy, trifhxxomemoxy, ammo, carboxy, carbamoyl, mercapto, suhphamoyl, Ci^alkyl, Ca^alkenyl, C^aDcynyl, Ci Ci^alkanoyloxy, wherein a is 0 to 2, Ci^aDtoxycarbonyl, AT-(Ci^alkyl)suh)hamoyl, AUV^Ci^aDcyl^sulpharnoyl, Ci^aDcylsiih>honylammo, carbocyclyl or heterocych/1; wherein R3 may be optionally substituted on carbon by one or more R12; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R13; R5 is hydrogen or optionally substituted Ci^alkyl; wherein said optional substituents are selected from one or more R14; Rfi and R7 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Ci^alkyl, Cz-salkenyl, Cj^alkanoyloxy, F-(Ci^all^l)amino, , Ci^alkanoylamino, ^-(Ci^alkyl)carbamoyl, 7/,JV-(Ci^alkyl)2carbamoyl, Ci.6alkylS(O)a wherein a is 0 to 2, Ci^alkoxycarbonyl, A^Ci-6alkyl)sulphamoyl, 7y,^V-(Ci^alkyl)2Sulphamoyl, Ci^alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R6 and R7 independently of each other may be optionally substituted on carbon by one or more R15; and wherein if said heterocyclyl contains an -NH- moiety mat nitrogen may be optionally substituted by a group selected from R16; or R* and R7 together with the pyrimidine bond to which they are attached form a 5 or 6 membered carbocyclic ring or a 5 or 6 membered heterocyclic ring wherein said ring is fused to the pyrimidine of formula CO; wherein the double bonds of the resulting bicyclic ring may be further delocalised across the whole of the bicyclic ring; and wherein said carbocyclic ring or heterocyclic ring may be optionally substituted on carbon by one or more R17; and wherein if said heterocyclic ring contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R1*; n = 0,1,2 or 3; wherein the values of R3 may be the same or different; R*, R1*, Ru, R14, R15, R17 and Ra are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyL, mercapto, sulphamoyl, Ci^alkyl, , Ca^atkynyl, Ci^alkoxy, Ci^alkanoyL, Ci^aOcanoyloxy, AKCi^alkyl)amino, d^atkylS(OX wherein a is 0 to 2, Ci^alkoxycaxbonyL, moyl, Ci-calkytadphonyfanmo, carbocycryl or beterocycryl; wherein R\ R10, R12, R14, R15, R17 and R22 independently of each other may be optionally substituted on carbon by one or more Rw; and wherein if said heterocych/i contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R20; R', Ru, Ru, R", Rw and RM are independently selected from Ci^attyl, Ci^alkanoyl, Ci^alkylsulphonyl, Ci^aBcoxycarbonyl, carbamoyl, N-(Ci^alkyl)carbamoyl, ^^-(Ci^alky^carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; wherein R9, Ru, R13, R16, R18 and R20 independently of each other may be optionally substituted on carbon by on or more R21; RM and R21 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Ci-ealkyi, Cj^alkenyl, Cz^alkynyl, Ci^alkoxy, Ci^alkanoyl, Ci-ealkanoyloxy, 7V-(Ci^alkyl)amino, JV,^-(Ci^alkyl)2amino, Ci^alkanoylamino, JV-(Ci.6alkyl)carbamoyl, 7/,//-(Ci^5alkyl)2carbamoyl, Ci^aDcylS(O)B wherein a is 0 to 2, Ci^alkoxycarbonyl, JV-(Ci^alkyl)sulphamoyl, M^-(Ci-6alkyl)2Sulphamoyl, Ci^alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R19 and R21 independently of each other may be optionally substituted on carbon by one or more R23; and wherein if saidheterocycryl contains an -NH-moiety that nitrogen may be optionally substituted by a group selected from R24; R23 is selected from halo, nitro, cyano, hydroxy, trifhioromethoxy, trifluoromethyl, ammo, carboxy, carbamoyl, mercapto, sulphamoyL, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-TV-ethylamino, acetylamino, AT-methylcarbamoyL, tf-ethylcarbamoyl, AU^-dimethylcarbamoyl, A^V-diethylcarbamoyl, A^metbyl-N-ethylcarbamoyl, methyltnio, ethylthio, methylsnlphmyl, ethylsulphinyl, mesyl, ethylsulphonyl, memoxycarbonyl, emoxycarbonyl, 7V-methylsulphamoyl, 7^-etiiylsulphamoyl, JV^hrathylsulphamoyl, J^JV-diemylsulphamoyl or A^-memyl-^-eflxylsulphamoyl; and R24 is selected from d^alkyl, Ci^alkanoyl, Ci^aDcylsuh)honyL, Ci^alkoxycarbonyL, carbamoyl, AT-(Ci^aIkyl)carbamoyl) //,/^-(Ci^aIkyl)carbamoyl) benzyl, benzyloxycarbonyl, benzoyl andphenylsu^phonyl; or a pharmacenticalry acceptable salt thereof; with the proviso feat said compound is not 5-bronx)-N2-[H3-methyl-5-isoxazoryr)ethyI]-N4K5-methy^ pyrimidinediamine; 5-chloro-N2H;i^3-me%l-5-isoxazolyl)etfiylHSI4^5Hne%l- pyrimidinediaminej S-bromo-N^S-memyl-lH-pyrazol-S-yiyN^^ 5^Uoro-N4^5-memyl-lH-pyrazol-3-yl>N2-[H3-pyridmyl)propyl]-2,4-py^^ 5^UoK)-N4^5-memyl-lH-pyrazol-3-yl>N2-[H3-pyridmyl)e*hyl]-2,4-pyrinM 5-bromo-N4^5-memyl-lH-pyrazol-3-yl)-N2-[l-(3-pyridmyl)etbyl]-2,4-pyrinTid^ 5-bromcHN4^5-memyl-lH-pyi-azol-3-yl)-N2-[1^2-pyridmyl)ethyl]-2,4-pyrm^ In a further aspect of the invention there is provided a compound of formula (la) wherein: (Figure Remove) A is a valence bond or Ci.2 alkyl; C is a Cs-jaryl, C^beteroaryl, or Cj^cycloalkyl ring; R1 and R4 are H, optionally substituted Q^alkyl, optk«alh/ substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryUccoptiooalb/substituted beterocydoalkyl; R2 is optionally substituted Ci^alkyt, optionally substituted cycktaQ^l, optionatty substituted Ci-fictber, optionaUy substituted Ci^amme; optionally substituted, optionally substituted Cj^ester, or optionally substituted Ci^amide or R2 and C in combination form a fused 9 or 10 membered aryl optionally substituted with R8; R3 is H, F, O, Br, I, CFj, NH2, NO,, OH, OCF3, Cwalkyl, OC^alkyl, SC,^aIkyl, Nalkyl, SC^NH,, C(=O)Oalkyl; Rs is H or optionally substituted Cj^alkyl; R6 and R7 are independently selected from: H, F, d, Br, I, CF3, CN, NH2, NOa, OH, CH2OH, OCF3, Ci^alkyl, OCi^ alkyl, SCi^ alkyl, SOzNHa, C(=O)OCi.6alkyl, Cs^aryl Cs-Cvheterocyclyl or R6 and R7 in combination form an optionally substituted fused 5 or 6-membered aryl or heteroaromatic ring, said heteroaromatic ring having at least one nitrogen, oxygen or sulfur atoms, but no more than 2 oxygen atoms or 2 sulfur atoms or 1 oxygen and 1 sulfur atom or two nitrogen atoms wherein such fused ring is optionally substituted with R8; R8 is H, F, Cl, Br, I, CF3, CN, NH2, NOz, OH, CH2OH, OCF3, Cj^alkyl, OCW alkyl, SO,.* alkyl, SOaNHz, C(=O)OCi.6alkyl, C5^aryl, C5-C7 heterocyclyl, optionally substituted Ci^alkyl, optionally substituted cycloalkyl, optionally substituted Ci-gether, optionally substituted Ci^amine; optionally substituted, optionally substituted Chester, or optionally substituted Ci^amide. In a further aspect of the invention there is provided a compound of formula (I) wherein: A is a direct bond or Q.^tkylene; wherein said C].2alkylene may be optionaUy substituted by one or more R22; Ring C is carbocyctyl or heterocyclyl; R1 and R4 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifhioromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Ci^alkyl, Cj^alkenyl, C2^alkynyl, Ci^aOcaxy, Ci^alkanoyl, Ci^alkanoyloxy, AHCi-6aIkyl)amino, , Ci^aDcanoylamino, iV-(Ci^a]iyl)carbamoyl, j^alkylS(O), wherein a is 0 to 2, Ci^alkoxycarbonyl, i^alkylsulphonylainino, carbocycryl or he^exocycryl; wherein R1 andR4indqpca6^a^of cachotiiermaybeoptknalrysubstin^ on carbon by one or more R*; and wherein if sud heterocycryi contains «n -NH- moiety th»t nitrogen may be optionally sobetitnted by a group selected fromR9; R2 is selected from halo, nitro, cyano, hydroxy, trifluoromemoxy, amino, carboxy, carbamoyl, mercapto, snhphamoyl, Ci^aB^l, C^alkenyl, Ca^aftynyl, ^alkanoyloxy, M(Cj^aIkyi)ammo, Ci^alkanoylamino, wherein a is 0 to 2, Ci-«alkoxycarbonyl, A^Ci^aDcyOsulphamoyl, MJV-(Ci^alkyl)2Sulphamoyl, Ci^all^lsuh^honylamino, carbocyclyl or heterocycryi; wherein R2 may be optionally substituted on carbon by one or more R10; and wherein if said heterocyclyl contains an -NH- moiety mat nitrogen may be optionally substituted by a group selected fromR11; R3 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Cj^alkyl, C^alkenyl, Cj^alkynyl, Cj-galkoxy, Ci^alkanoyl, Ci.6alkanoyloxy, N-( Ci^alkanoylamino, JV-(Ci wherein a is 0 to 2, Ci^alkoxycarbonyl, AKCi^alkyl)sulphamoyl, JV.TV-CCi^alkyl^sulphamoyl, Ci^alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R3 may be optionally substituted on carbon by one or more R12; and wherein if said beterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R"; R5 is hydrogen or optionally substituted Ci^aDcyl; wherein said optional substrtuents are selected from one or more R14; R* and R7 are independently selected from selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Ci^aDcyl, L, Cj^alkynyl, Ci^alkoxy, Ci-^aQcanoyl, Ci^alkanoyloxy, W-(Ci-«aDcyl)amino, Ci^aIkylS(O), wherein a is 0 to 2, Ci^alkoxycarbonyl, JV^Ci-$aIkyl)sulphamoyl, MAKCi-6alkyl)jsulphamoyl, Ci^alkylsulphonylamino, carbocyclyi or heterocyclyl; wherein R6 and R7 independently of each other may be optionally substituted on carbon by one or more R15; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected fromR16; or R* and R7 together with Ac pyrimkfine bond to which they are attached fixm a 5 or 6 membered carbocyctic ring or heterocyclic ring wherein said ring is fused to ttepyrhnklme offormn)a(I);andwb£xemsaidcarbocycforingw substituted on carbon by one or more R17; and wherein if said hetexocycKc ring contains an -NH- moiety that nitrogen may be optionally substitirted by a group selected fromR1*; • = 0, 1, 2 or 3; wherein the values of R3 may be the same or different; R', Rw, Rn, R14, RM, R17 and RM are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Ci^alkyl, Qz^alkenyl, Qz-salkynyl, Cj^alkoxy, Ci^aDcanoyl, Ci^alkanoyloxy, ^- R9, R11, R13, R16, R18 and R20 are independently selected from Ci-6alkyl, Ci^alkanoyl, Ci^alkylsulphonyl, Ci^alkoxycarbonyl, carbamoyl, 7^-(Ci^alkyl)carbamoyl, M7V-(C|^alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; wherein R9, Rn, R13, R16, R18 and R20 independently of each other may be optionally substituted on carbon by on or more R21; R19 and R21 are independently selected from halo, nitro, cyano, hydroxy, trifiuoromethoxy, ammo, carboxy, carbamoyl, mercapto, sulphamoyL, Ci^alkyl, Ca^alkenyl, Cz-^aDcynyl, Ci^aDcoxy, Ci^alkanoyl, Ci^alkanoyloxy, JV^Ci-«alkyl)amino, M^-(Ci^alkyl)2amino, Ci^alkanoylamino, Af-(Ci^alkyl)carbamoyl, JV^T-(Ci^alkyl)2carbamoyl, Ci^alkylS(O), wherein a is 0 to 2, Ci^alkoxycarbonyl, jV-(Ci^aIkyl)sulphamoyl, ^JVr-(Ci^alkyl)2Sulphamoyl, Ci^alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R19 and R21 independently of each other may be optionally substituted on carbon by one or more R23; and wherein if said heterocyctyl contains an -NH-moiety mat nitrogen may be optionally substituted by a group selected from R24; R23 is selected from halo, nitro, cyano, hydroxy, trifiuoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyL, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, memylamino, ethylammo, dimeAylamino, diemylamino, Afnnnemyl^-^mylammo, acetylamino, J^-inemylcarbemoyl, J^dhyfcarbamoyi, ^^-dimeth ^AT-diemylcarbamoyl, N-mc&^N-**bytoafimaayl, memyimio, ettiyimio, memylsulphmyl, ethylsulphmyl, mesyl, emylsulphonyl, memoxycarbonyl, etiioxycarbonyl, // mcthy Isulphamoyl, A^-cthylsulphamoyl. N^-diineuiylsulpbamoy L, AC^diethy Isulphamoyl orM^niethyl-TV-ethylsuhAamoyl; and R24 is selected from Ci^aDcyl, Ci^aDtanoyL, Q^alkylsmphonyl, Ci^alkoxycarbonyl, carbamoyl, JV-(Ci^alkyl)carbamoyl, JV^-{Ci-6alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; or a pharmaceutically acceptable salt thereof, with the proviso that said compound is not: S-bromo-N^S-mernyl-lH-pyrazoW-yiyN2^ 5-cUoro-N4-(5-memyl-lH-pyrazol-3-yl)-N2-[l-(2-pyridmyi)propyl]-2,4-pyrm^ 5-bromo-N2-[H3-memyl-5-isoxaz»lyl)emyl]->^^5-memyl-lH-pyrazol-3-yl)-2,4-pyrimidinediamine; pyrimidinediamine; 5^hloro-]Srt-(5-memyl-lH-pyrazol-3-yl)-N2-[l-(3-pyridmyl)propyl]-2,4-pyrinu^ 5-c^on>->^-(5-memyl-lH-pyrazol-3-yl)-N2-[l-(3-pyridinyl)emyl]-2,4-pyrimidme^ S-btomo-N^S-methyl-lH-pyrazol-S-yl)-^ S-bronw-N^S-methyl-lH-py^ Preferred values of the variable groups contained in formula (I) are as follows. Such values may be used, where appropriate, with any of the definitions, claims or embodiments defined hereinbefore or hereinafter. A is a direct bond. A is Ci-2alkylene. A is Ci_2alkylene optionally substituted by one or more R22. Ring C is carbocyclyl. Ring C is heterocyclyl. Ring C is phenyl or thienyl. Ring C is phenyl. Ring C is thienyL Ring C is tirienyl, pyridyl, thiazolyL Ring C is thien-2-vl, pyrid-2-yl, thiazol-2-yL Ring C is phenyl or mien-2-yL Ring C is phenyl, thienyl, pyridyl, fhiazotvL Ring C is phenyU thien-2-yU pyrid-2-yl, thiazo^-yL Ring C is not pyridyl or JsoxazotvL Ring C is not pyrid-2-yl, pyrid-3-yl or isoxazol-5-yL Ring C and (R3),, together are 4-fluorophenyl. R1 is selected from hydrogen, Ci^alkyl, Ci^alkoxy, JV^-(Ci-6alkyl)2amino, Ci_6alkylS(O)» wherein a is 0 or carbocyclyl; wherein R1 may be optionally substituted on carbon by one or more R8; wherein R8 is selected from halo or carbocyclyl. R1 is selected from hydrogen, Ci^alkyl, Ci^alkoxy, //,J\^(Ci_6alkyl)2amino, Ci^alkylS(O)a wherein a is 0 or carbocyclyl. R1 is selected from hydrogen, methyl, ethyl, isopropyl, r-butyl, methoxy, ethoxy, propoxy, isopropoxy, sec-butoxy, dimemylamino, methylthio or cyclopropyl; wherein R8 is selected from fluoro, cyclopropyl or phenyl. R1 is selected from hydrogen, methyl, ethyl, t-butyl, methoxy, ethoxy, dimethylamino, methylthio or cyclopropyl. R1 is selected from hydrogen, methyl, ethyl, isopropyl, f-butyl, tnfluorometnyi, cyclopropyhnethyl, benzyl, methoxy, ethoxy, propoxy, isopropoxy, sec-butoxy, dimethylamino, mefhyfthio or cyclopropyl. R1 is selected from hydrogen, methyl, ethyl, t-butyl, methoxy, dimethylamino, methylthio or cyclopropyl. R1 is cyclopropyL R4 is hydrogen. R2 is selected from Ci.6alkyl. R2 is selected from methyl, ethyl or isopropyL R2 is selected from Ci^alkyl; wherein R2 may be optionally substituted on carbon by one or more R10. R2 is selected from methyl, elhyl or isopropyl; wherein R2 may be optionally substituted on carbon by one or more R10. R2 is selected from Q^alkyl; wherein R2 may be optionally substituted on carbon by one or mote R10; Rie is selected from halo, hydroxy, carboxy, ammo, Ci^aDcoxy, , //-(Ci^alkyl)carbamoyl, or heterocycryl; wherein R10 may be optionally substituted on carbon by one or more R19; and wherein if said heterocycryl contains an -NH- moiety mat nitrogen may be optionally substituted by a group selected from R20; R19 is selected from hydroxy or Ci-^alkoxy; R20 is selected from Ci^alkyl. R2 is selected from Ci-salkyl; wherein R2 may be optionally substituted on carbon by one or more R10; wherein R10 is selected from hydroxy, carboxy, Ci^alkoxy, MW-CCi-ealkyl^amino or heterocyclyl; wherein R10 may be optionally substituted on carbon by one or more R19; and wherein if said heterocyclyl contains an -NH- moiety mat nitrogen may be optionally substituted by a group selected from R20; R20 is selected from Ci^alkyl; and R19 is selected from hydroxy or Ci^alkoxy. R2 is selected from methyl, ethyl or isopropyl; wherein R2 may be optionally substituted on carbon by one or more R10; R10 is selected from fluoro, hydroxy, carboxy, amino, methoxy, dirnethylarnino, N- mino, acetylamino, ^methylcarbamoyl, ^-ethylcarbamoyl, A^V-dimethylcarbamoyl, pyrrolidin-1-yl, ptperaztnyl CM: morpholino; wherein R10 may be optionally substituted on carbon by one or more R19; and wherein if said piperazinyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R20; R19 is selected from hydroxy or methoxy; R20 is selected from methyl. R2 is selected from methyl, ethyl or isopropyl; wherein R2 may be optionally substituted on carbon by one or more R10; wherein R10 is selected from hydroxy, carboxy, methoxy, ^-methyl-AT-ethylamino, diethylamino, pyrrolidinyl, piperazinyl or morpholinyl; wherein R10 may be optionally substituted on carbon by one or more R19; and wherein said piperazinyl may be optionally substituted on nitrogen by a group selected from R20; R24 is selected from methyl; and R1* is selected from hydroxy ormethoxy. R2 is selected from methyl, ethyl or isopropyl; wherein R2 maybe optionally substituted on carbon by one or more R ;wherem R10 is selected from hydroxy, carboxy, methoxy, ^Hooemyl-Memylammo, diemylamino, pyrronctin-l-yi, piperazin-l-yl or morpholino; wherein R>0 may be optionally substituted on carbon by one or more R19; and wherein said piperazinyl may be optionally substituted on nitrogen by a group selected from R20; R20 is selected from methyl; and R19 is selected from hydroxy or methoxy. R2 is selected from methyl, ethyl, trifluoromethyl, hydroxymethyl, carboxymethyl, aminomethyl, methoxymethyl, morpholinomethyl, 1-hydroxyethyl, 2-hydroxyethyl, 1-carboxyethyl, 2-dimethylarninoethyl, 2^emylaminoethyl, acetamidomethyl, 2-[#-methyl-#-(2-methoxyethyl)amino]ethyl, 2-[JV"-methyl-^-(2-hydroxyerhyl)amino]ethyl, 2-(N-methylcarbamoyl)ethyl, 2-[JV-(2-hydroxyethyl)carbamoyl]ethyl, 2-(N,N-dimethylcarbamoyl)ethyl, 2-morpholmoemyl, 2-pyrrolidin-l-ylethyl or 2-(l-methylpiperazui-4-yl)ethyl, l-methyl-2-hydroxyethyl. R2 is selected from methyl; wherein R2 may be optionally substituted on carbon by one or more R10; wherein R10 is selected from hydroxy. R3 is selected from halo, nitro, Ci^alkyl or Ci-^alkoxy; wherein R3 may be optionally substituted on carbon by one or more R12; wherein R12 is selected from halo. R3 is selected from halo, nitro or Ci^alkoxy. R3 is selected from fluoro, nitro, methyl or methoxy ; wherein R3 may be optionally substituted on carbon by one or more R12; wherein R12 is selected from fluoro. R3 is selected from fluoro, nitro, trifluoromethyl or methoxy. R3 is selected from fluoro, nitro or methoxy. R3 is selected from fluoro. R5 is hydrogen. R5 is optionally substituted Ci-^alkyl; wherein said optional substituents are selected from one or more R . R5 is hydrogen or optionally substituted Ci^adkyl; whexein said optkmal snbstituents are selected from one or more RM; wherein R14 is selected from hydroxy. R5 is hydrogen, methyl or optionally substituted ethyl; wherein said optional substituents axe selected from one or more R14; wherein R14 is selected from hydroxy. R5 is hydrogen or optionaUy substituted ethyl; wherein said optional substituents are selected from one or more R14; wherein R14 is selected from hydroxy. R5 is hydrogen, methyl or 2-hydroxyethyl. R5 is hydrogen or 2-hydroxyethyl. R5 is hydrogen. R6 and R7 are independently selected from hydrogen, halo, nitro, cyano, amino, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Ci^alkyl, C2^alkenyl, Q^alkynyl, Ci^alkoxy, Ci^alkanoyl, Ci^alkanoyloxy, JV-(Ci^alkyl)amino, ino, Ci^alkanoylamino, JV-(Ci^alkyl)carbamoyl, wherein a is 0 to 2, Ci^alkoxycarbonyl, lamino, carbocyclyl or heterocyclyl; wherein R6 and R7 independently of each other may be optionally substituted on carbon by one or more R1S; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R16. R6 and R7 arc independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromemoxy, amino, carboxy, carbamoyL, mercapto, sulphamoyl, Ci^alkoxy, Q^alkanoyl, Ci^alkanoyloxy, ^-(Ci^al amino, Ci^alkanoylamrno, JVr-(Ci-6alkyl)carbamoyl, JV,JV-(Ci^aBcyl)2carbamoyl, CwalkylS(O). wherein a is 0 to 2, Ci^alkoxycarbonyl, ^-(Ci^alkyl)sulphamoyl, JV^^Ci-^alkyl^sulphamoyl, Ci^alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R6 and R7 independently of each other may be optionally substituted on carbon by one or more R15; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R16. R6 and R7 are independently selected from hydrogen, halo, Ci^alkyl, JV- R6 and R7 are independently selected from hydrogen, fluoro, chloro, bromo, methyl, methylamino, ethylamino, propylamino, 7^-(ethyl)carbamoyl, methoxycarbonyl, ethoxycarbonyl or butoxycarbonyl; wherein R6 and R7 independently of each other may be optionally substituted on carbon by one or more R15. R6 and R7 are independently selected from hydrogen, fluoro, chloro, bromo, nitro, cyano, amino, methyl, methylamino, ethylamino, propylamino, isopropylamino, dimethylamino, #-merayl-W-propylarnino, N-ethylcarbamoyl, methoxycarbonyl, ethoxycarbonyl, butoxycarbonyl, morpholino, pyrrolidinyi or piperazinyl; wherein R6 and R7 independently of each other may be optionally substituted on carbon by one or more R15; and wherein said piperazinyl may be optionally substituted on nitrogen by a group selected from R16. R6 and R7 are independently selected from hydrogen, fluoro, chloro, bromo, methyl, ethylarnino, propylamino, #-(ethyl)carbamoyl, methoxycarbonyl, ethoxycarbonyl or butoxycarbonyl; wherein R6 and R7 independently of each other may be optionally substituted on carbon by one or more R1S. R6 andR7 together with the pyrimidine bond to which they are attached form a 5 or 6 membered carbocyctic ring or a 5 or 6 membered heterocyclic ring wherein said ring is fused to the pynmidine of formula (I); wherein the double bonds of the resulting bicyclic ring may be further delocalised across the whole of the bicyclic ring; and wherein said carbocyclic ring or heterocyclic ring may be optionally substituted on carbon by one or more R17; and wherein if said heterocyclic ring contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R18. R6 and R7 together with the pyrimidme bond to which they are attached form a 5 or 6 membered carbocyclic ring or heterocyclic ring wherein said ring is fused to the pyrimidine of formula (I); and wherein said carbocyctic ring or heterocyclic ring may be optionally substituted on carbon by one or more R17; and wherein if said heterocyclic ring contains an -1TO~ moiety ttonftxogm may be optknattysi^^ R andR together with Ac pynmadme bond to which they are attached fccm a 5 or 6 membered carbocyclic ring or heterocyclic ring wherein said rh% is fused to me pyrimtdine of fonnula (I); aixiwherem said carbocyctic rmg or hete^ substituted on carbon by one or more R17. R* and R7 together with the pyrimidine to which they are attached form a bicyclic ring selected from quinazotinyl, tMem>[3,2-d]pyriinidinyl, thieno[23-d]pyrimidinyl, \H-pyrazolo[3,4-d]pyrimidinyl, thieno[3,4-d]pyrimidinyL, pyrido[2,3-d]pyrimidinyl, 5,6,7,8-tetrahydro-pyrido[43^pyrimidinyl, 5,6,7,8-tetrahydro-pyrido[2,3-^yrimidinyl or 5,6,7,8-tetrahydro-pyrido[3,4-d]pyrimidinyl; and wherein said bicyclic ring may be optionally substituted on carbon by one or more R17; and wherein said 5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidinyl, 5,6,7,8-tetrahydro-pyrido[2,3-rfJpyriniidinyl or 5,6,7,8-tetrahydro-pyrido[3,4-d]pyrimidinyl may be optionally substituted on nitrogen by a group selected from R18. R6 and R7 together with the pyrimidine to which they are attached form quinazolinyl, 1hieno[3,2-d]pyriinidinyl, thieno[23-d]pyrimidinyl, tMenotS^-dlpyrimidinyl, \H-pyrazolo[3,4-d]pyrimidinyl or pyrido[2,3-d]pyrinaidinyl; and wherein said quinazolinyl, thieno[3,2-d]pyrimidinyl, mieno[2,3-d]pyrimidinyl, thieno[3,4-d]pyrimiduiyl, IH-pyra2»lo[3,4-d]pyrimidinyl or pyrido[23-d]pyrimidinyl may be optionally substituted on carbon by one or more R17. R6 andR7 axe independently selected from hydrogen, halo, nitro, cyano, amino, Ci^alkoxycaibonyl or heterocyctyl; wherein R6 and R7 independently of each other may be optionally substituted on carbon by one or more R15; and wherein if said heterocyclyl contains an -NH- moiety mat nitrogen may be optionally substituted by a group selected from R16; orR6 andR7 together with the pyrimidine bond to which they are attached form a 6 membered carbocyclic ring or a 5 or 6 membered heterocyclic ring wherein said ring is fused to the pyrimidine of formula (I); wherein the double bonds of the resulting bicyclic ring may be farther delocalised across the whole of the bicyclic ring; and wherein said carbocyclic ring or heterocyclic ring may be optionally substituted on carbon by one or moreR17; and wherein if said heterocyclic ring contains an -NH- moiety mat nitrogen may be optionally substituted by a group selected from R18. R6 andR7 are independently selected from hydrogen, halo, Ci^alkyl, T/^Ci^alkyQunmo, N-(Ci^aIkyl)caxtwBQoyl or Ci^adkoxycarbonyl; wherein R* and R7 independently of each other may be optionally substituted on caibon by one or more R15; or R* and R7 together wim the pyrimidre 6 membered carbocyclic ring or heterocyclic ring wherein said rmg is fused to ite pyrimidine of formula (I); and wherein said carbocyclic ring or heterocyclic ring may be optionally substituted on carbon by one or more R17. R6 and R7 are independently selected from hydrogen, fluoro, chloro, bromo, nitro, cyano, amino, methyl, methylamino, ethylamino, propylamino, isopropylamino, dimethylamino, ^memyl-^-propylamino, ^-emylcarbamoyl, methoxycarbonyl, ethoxycarbonyl, butoxycarbonyl, morpholino, pyrroUdinyl or piperazinyl; wherein R6 and R7 independently of each other may be optionally substituted on carbon by one or more R15; and wherein said piperazinyl may be optionally substituted on nitrogen by a group selected from R"; or R6 and R7 together with the pyrimidine to which mey are attached form a bicyclic ring selected from quinazolinyl, tMeno[3,2-d]pyrimidinyl, thieno[2,3-d]pyrimidmyl, IH-pyrazolo[3,4-d]pyrimidinyl, thieno[3>4-d]pyrimidinyl, pyrido[23-d]pyrimidinyl, 5,6,7,8-tetrahydro-pyrido[4^-d]pyrimidinyl, 5,6 J,8-tetrahydro-pyrido[2,3-^yrirnidinyl or 5,6,7,8-tetrahydro-pyrido[3,4-cf|pyrimidinyl; and wherein said bicyclic ring may be optionally substituted on carbon by one or more R17; and wherein said S^JjS-t d]pyrimidmyl, 5,6 J,8-tetoahydro-pyrido[2,3-rflpyrimidinyl or 5,6 J,8-tetrahydro-pyrido[3,4-JJpyrimidinyl may be optionally substituted on nitrogen by a group selected from R18. R6 and R7 are independently selected from hydrogen, fluoro, chloro, bromo, methyl, rnethylamino, ethylamino, propylamino, 7V-(ethyl)carbamoyl) methoxycarbonyl, ethoxycarbonyl or butoxycarbonyl; wherein R6 and R7 independently of each other may be optionally substituted on carbon by one or more R15; or R6 and R7 together with the pyrimidine to which they are attached form quinazolinyl, tmrao[3,2- R6 and R7 are independently selected from hydrogen, ftuoro, chloro, bromo, methyl, emylamino, pcopytamino, ^ethyl)carb«moyl, methoxycarbonyl, ethoxycarbonyl or butoxycarbonyl; wherein R* and R7 independently of each other may be opticnatty substituted on carbon by one or more R15; or R6 and R7 together wim the pyrimidine to which they ace attached form quinazoUnyL, mienop^-^Ipyrimidmyl, mieno[23-dlpyrimidinyl, tbieno[3,4-d]pyrimidmylt l/f-pyrazolo[3,4-d}pynmidinyl or pyrio^[23-dlpyrimidinyl; and wherein said quinazoKnyl, tMeno[3^-d]pyrimidinyl, lMeno[23-olpyrinudmyl, mieno[3,4-d]pyrimidinyl, IH-pyrazolo[3,4-d]pyrimidinyl or pyri6^[2,3^]pyrimidinyl may be optionally substituted on carbon by one or more R17. R6 and R7 are independently selected from hydrogen, halo, nitro, cyano, amino, Ci^alkoxycarbonyl or heterocyclyl; wherein R6 and R7 independently of each other may be optionally substituted on carbon by one or more R15; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R16; or R6 and R7 together with the pyrimidine bond to which they are attached form a 6 membered carbocyclic ring or a 5 or 6 membered heterocyclic ring wherein said ring is fused to the pyrimidine of formula (I); wherein the double bonds of the resulting bicyclic ring may be further delocalised across the whole of the bicyclic ring; and wherein said carbocyclic ring or heterocyclic ring may be optionally substituted on carbon by one or more R17; and wherein if said heterocyclic ring contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R18; R15 is selected from halo, hydroxy, amino, Ci^alkoxy, M^KCi-salkyl^amino, carbocycryl or heterocyclyl; wherein R15 may be optionally substituted on carbon by one or more R19; and wherein if said heterocycryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R20; R17 is selected from halo, Ci^alkyl or Cj^alkoxy; wherein R17 may be optionally substituted on carbon by one or more R19; R16 is selected from Ci^alkyU R18 is selected from Ci^alkanoyl; R19 is selected from halo, hydroxy, Ci^alkoxy or heterocyclyl; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R34; R20 is selected from Ci.«alkyl; and R24 is selected from Ci^alkyL R* and R7 are independently selected from hydrogen, halo, Ci^aDcyl, ^-{Ci^alkyQammo, N^Ct^aIkyi)carbamoyl or Ci- R15 is selected from halo, hydroxy, carbocyclyl or heterocyclyl; wherein R15 may be optionally substituted on carbon by one or more R19; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R20; R17 is selected from halo, Ci^alkyl or Ci^alkoxy; wherein R17 may be optionally substituted on carbon by one or more R19; R20 is selected from Ci^alkyl; R19 is selected from halo, Ci-salkoxy or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R24;and R24 is selected from Ci-«alkyl. R6 and R7 arc independently selected from hydrogen, ftuoro, chloro, bromo, mtro, ;yano, amino, methyl, methylamino, ethylamino, propylamino, isopropylamino, dimethylamino, //-methyl-W-propylamino, tf-ethylcarbamoyL, methoxycarbonyl, ethoxycarbonyl, butoxycarbonyl, morpholino, pyrrolidinyl or piperazinyl; wherein R6 and R7 independently of each other may be optionally substituted on carbon by one or more R15; and wherein said piperazinyl may be optionally substituted on nitrogen by a group selected from R16; or R6 and R7 together with the pyrimidine to which they are attached form a bicyclic ring selected from quinazolinyl, thieno[3,2^]pyriinidinyl, thieno[2,3^]pyraindinyl, IH~ pyrazolo[3,4-d}pyrimidinyl, tbieno[3,4-d]pyrunidinyl, pyrido[23^]pyrunidinyl, 5,6,7,8-tetrahydrc-pyrido[43^]pyrimidinyl, 5,6,7,8-tetrahydro-pyrido[23-d]pyrimidinyl or 5,6,7,8-tetrahydro-pyrido[3,4-i/lpyrimidmyl; and wherein said bicyctic ring may be optionally substituted on carbon by one or more R17; and wherein said 5>6,7>8-tetrahydro-pyrido[43-dlpyrimidinyU 5,6 J,8-trtrahydro-pyrkk)(23-rflpyrirmdinyl or 5&7,8-tc*rahydco-i»yrido[3,4-d]pyiimidinyl may be optionally substituted on nitrogen by a group selected from Ru; R15 is selected from ftuoro, bydroxy, amino, dfaoxy, di pytrofidmyl, piperazinyl or morpholino; wherein R15 inay be ofrtknalry substituted oa carbon by one or moieR1*; and wherein said pyerazinylmay be optionally substituted on nitrogen by a group selected from R20; R17 is selected from fhioro, chloro, methyl, methoxy, ethoxy or propoxy, wherein R17 may be optionally substituted on carbon by one or more R19; R16 is selected from methyl; R18 is selected from acetyl; R19 is selected from fluoro, hydroxy, methoxy, piperazinyl, pyrrolidinyl or morpholino; and wherein said piperazinyl may be optionally substituted on nitrogen by a group selected from R24; R20 is selected from methyl; and R24 is selected from methyl. R6 and R7 are independently selected from hydrogen, fluoro, chloro, bromo, methyl, ethylamino, propylamino, #-(ethyl)carbamoyl, methoxycarbonyl, ethoxycarbonyl or butoxycarbonyl; wherein R6 and R7 independently of each other may be optionally substituted on carbon by one or more R15; or R6 and R7 together with the pyrimidine to which they are attached form quinazolinyi, ttueoo[3^-d]pyriinidinyl, tMeno[23-d]pyrimidinyl, thieno[3,4-djpyrimidinyl, lff-pyrazolo[3,4-d]pyrimidinyl or pyrido[23-d]pyrimidinyl; and wherein said quinazolinyi, thienofS^-dlpyrimidinyl, thieno[2,3-dlpyrimidinyl, thieno[3,4-d]pyrimidmyl, \H-pyrazolo[3,4-d]pyrinTidinyl or pyrid^23-d]pyrimidinyl may be optionally substituted on carbon by one or more R17; wherein R15 is selected from fluoro, hydroxy, phenyl, piperazinyl, pyrrolidinyl or morpholino; wherein R15 may be optionally substituted on carbon by one or more R19; and wherein if said piperazinyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R20; R17 is selected from fluoro, chloro, methyl, methoxy or ethoxy; wherein R17 may be optionally substituted on carbon by one or more R19; R20 is selected from methyl; Rw is selected from fmoro, memory, piperazinyl, pyrrolklmyl or n»rpholino; wherein if said ptperazmyi contains «n -NH- moiety that mta>gen may be optkmatty substituted by a group selected from R3*; and RM is selected from methyL R* and R7 are independently selected from hydrogen, chloro, bromoorpropylamino; wherein R6 and R7 independently of each other may be optionally substituted on carbon by one or more R15; wherein R15 is selected from hydroxy; or R6 and R7 together with the pyrimidine to which they are attached form quinazolinyi. R10 is selected from halo, hydroxy, carboxy, amino, Ci^aDcoxy, /"/^-(Ci^alkyl^ammo, Ci^alkanoylamino, JV-(Ci^alkyl)carbamoyl, ^,JV-(Ct^alkyl)2carbamoyl or heterocych/1; wherein R10 may be optionally substituted on carbon by one or more R19; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R20. R10 is selected from hydroxy, carboxy, Ci^alkoxy, M^CCi^alkyl^amino or heterocyclyl; wherein R10 may be optionally substituted on carbon by one or more R19; and wherein if said heterocyclyl contains an -NH- moiety mat nitrogen may be optionally substituted by a group selected from R20. R10 is selected from fluoro, hydroxy, carboxy, amino, methoxy, dimethylamino, N-methyl-N-ethylamino, acetylamino, J^-methylcarbamoyl, J^-ethylcarbamoyl, A^-dimetbylcarbamoyl, pyrrolidin-1-yl, piperazmyl or morpholino; wherein R10 may be optimally substituted on carbon by one or more R19; and wherein if said piperazinyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R20. R10 is selected from hydroxy, carboxy, methoxy, A^methyl-AT-ethylamino, ttiethylamino, pyrrolidinyl, piperazinyl or morpholinyl; wherein R10 may be optionally substituted on carbon by one or more R19; and wherein said piperazinyl may be optionally substituted on nitrogen by a group selected from R20. R10 is selected from hydroxy, carboxy, methoxy, AT-methyl-^-etiiylamino, diethylamino, pyrrolidin-1-yl, piperazin-1-yl or morpholino; wherein R10 may be optionally substituted on carbon by one or more R19; and wherein said piperazinyl may be optionally substituted on nitrogen by a group selected from R20. R14 is selected from hydroxy. R15 is selected from halo, hydroxy, carbocych/1 or heterocycryl; wherein R15 may be optionally substituted on carbon by one or mote Rw; and wheiem if said beterocycryl contains an -NH- moiety mat nitrogen may be optionally substituted by a group selected from R20. R13 is selected from fluoro, hydroxy, phenyl, pipaazinyi, pyrrolidmyl or morpholino; wherein R15 may be optionally substituted on carbon by one or more R19; and wherein if said piper azinyi contains an -NH- moiety mat nitrogen may be optionally substituted by a group selected from R2*. R17 is selected from halo, Ci^alkyl or Ci^alkoxy, wherein R17 may be optionally substituted on carbon by one or more R19. R17 is selected from fluoro, chloro, methyl, methoxy or ethoxy; wherein R17 may be optionally substituted on carbon by one or more R19. R20 is selected from Ci^alkyl. R20 is selected from methyl. R19 is selected from halo, Ci^aDcoxy or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R24. R19 is selected from fluoro, methoxy, piperazinyl, pyrrolidinyl or morpholino; wherein if said piperazinyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R24. R19 is selected from hydroxy or Cj^alkoxy. R19 is selected from hydroxy or methoxy. R24 is selected from Q^alkyl. R24 is selected from methyl. n = 0orl. n = 0. n=l. Therefore in a further aspect of the invention there is provided a compound of formula (I) (as depicted herein above) wherein: A is a direct bond; Ring C is carbocyclyl or heterocycryl; R1 is selected from hydrogen, Ci^alkyl, Ci^alkoxy, JV^-(Ci^alkyl)2amino, Ci-6alkylS(O)» wherein a is 0 or carbocyclyl; wherein R1 may be optionally substituted on carbon by one or more R8; R2 is selected from Q^alkyl; wherein R2 may be optionally substituted on carbon by one or more R10; substituted on carbon by one or more Rn; R4 is hydrogen; R5 is hydrogen or optionally substituted Ci^aflcyl; wherein said optional substituents are selected from one or more R14; R6 and R7 are independently selected from hydrogen, halo, nitro, cyano, amino, Ci^alkoxycarbonyl or heterocyclyl; wherein R6 and R7 independently of each other may be optionally substituted on carbon by one or more R15; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R16; or R6 and R7 together with the pyrimidine bond to which they are attached form a 6 membered carbocyclic ring or a 5 or 6 membered heterocyclic ring wherein said ring is fused to the pyrimidine of formula (I); wherein the double bonds of the resulting bicyclic ring may be further delocalised across the whole of the bicyclic ring; and wherein said carbocyclic ring or heterocyclic ring may be optionally substituted on carbon by one or more R17; and wherein if said heterocyclic ring contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R18; R8 is selected from halo or carbocyclyl; R10 is selected from halo, hydroxy, carboxy, ammo, , Ci^alkanoylamino, or heterocyclyl; wherein R10 may be optionally substituted on carbon by one or more R19; and wherein if said heterocyclyl contains an -NH- moiety mat *>A nitrogen may be optionally substituted by a group selected from R ; R12 is selected from halo; R14 is selected from hydroxy; R15 is selected from halo, hydroxy, arnino, Ci^alkoxy, N^V-(Ci^alkyl)2amino, carbocyclyl or heterocyclyl; wherein R15 may be optionally substituted on carbon by one or more R19; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R2*; R16 is selected from Ci^attyl; R17 is selected from halo, Ci^alkyl or Ci^alkoxy, wherein R17 may be optionally substituted on carbon by one or mote R19; Rn is selected from R19 is selected from halo, hydroxy, Ci^alkoxy orheterocycryU and wherein if said heterocyclyl contains an -NH- moiety mat nitrogen rnay be optknalry substituted by a group selected from R24; R20 is selected from d^alkyl; R24 is selected from Ci^aDcyl; and n = 0orl. or a pharmaceutically acceptable salt thereof; with the proviso mat said compound is not: 5-bromo-N2-[l-(3-memyl-5-isoxazolyl)emyl]-N4-(5-me1hyl-lH-pyrazol-3-yl)-2,4- pyrirrudlnea^amine; 5-cWoro-N2-[l-(3-me%l-5-isoxazolyl)ethyl]->^-(5-memyl-lH-pvrazol-3-yl)-2,4- pyrimidinediamine; HS-pyrioMnyl^ropyll^^pyrirm l-CS-pyridmy^propy^^py^ 5-cUoiro-N4-(5-memyl-lH-pyrazx)l-3-yl>N2-[l-(3-pyridmyl)emyl]-2,4-py^^ ^ 5-brcmo~N*-(5-me A is a direct bond; Ring C is carbocycryl or heterocyclyl; R1 is selected from hydrogen, Q^alkyl, Ci^aDcoxy, JV^-(Ci_«aIkyl)2amino, Ci-«alkylS(O)» wherein a is 0 or carbocycryl; R2 is selected from Ci^alkyl; wherein R2 may be optionally substituted on carbon by one or more R10; R3 is selected from halo, nitro or Ci^alkoxy; R4 is hydrogen; R3 is hydrogen or optionally substituted Ci^aDcyl; wherein said optional substituents are selected from one or more R14; R* and R7 are independently selected from hydrogen, halo, Ci^alkyl, J^Ci-cancyQamina, ^Ci^alky])carbnnoyi or Ci^aDcoxycarbonyl; wberein R* and R7 independently of each other way be optionally substituted on carbon by one or more R15; or R* and R7 together with the pvnmidme bond to which they axe attached form a 5 or 6 membered carbocycBc ring or hetexocycfic ring wherdoisaki ring is fined to the pyrimadme of formula (I); and wbeiein said carbocycKc ring or heterocyclic ring may be optionally substituted on carbon by one or more R17; R10 is selected from hydroxy, carboxy, Ci^alkoxy, JS^^Ci^aliyl^amino or heterocyclyl; wherein R10 may be optionally substituted on carbon by one or more hydroxy or Ci^alkoxy; and wherein if said heterocyclyl contains an -NH- moiety mat nitrogen may be optionally substituted by a group selected from R20; R14 is selected from hydroxy; R15 is selected from halo, hydroxy, carbocycryl or heterocyclyl; wherein R15 may be optionally substituted on carbon by one or more R19; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R20; R17 is selected from halo, Chalky! or Cj-galkoxy; wherein R17 may be optionally substituted on carbon by one or more R19; wherein R19 is selected from halo, Q-galkoxy or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R24; R20 is selected from R24 is selected from Chalky!; and n = 0orl; or a pharmaceutically acceptable salt thereof; with the proviso that said compound is not Therefore in a further aspect of the invention there is provided a compound of formula (I) (as depicted herein above) wherein: A is a direct bond; Ring C is phenyl, thienyl, pyndyl, thiazotyl; R1 is selected from hydrogen, methyl, ethyl, isopropyl, ^botyl, triftooromethyl, cyctopropyhnethyi, benzyl, methoxy, ethoxy, propoxy, isopropoxy, sec-butoxy, dimethylamino, memylmio or cyclopropyl; R2 is selected from methyl, emyl, trifluoromethyl, hydroxymethyl, carboxymethyl, aminomethyl, methoxymethyl, morpholinomethyl, 1-hydroxyethyl, 2-hydroxyethyl, 1-carboxyethyl, 2-dimethylaminoethyl, 2-diethylaminoethyl, acetamidomethyl, 2-[JV-methyl-Af-(2-methoxyethyl)ainino]ettiyl, 2-[7/-n^thyl-//-(2-hydroxye1hyl)amino]ethyl, 2-(N-methylcarbamoyl)ethyl, 2-[^-(2-hydroxyethyl)carbanioyi]ettiyl, 2-(N,N-dimethylcarbamoyl)ethyl, 2-morpholinoethyl, 2-pyrrolidin-l-ylethyl or 2-(l-methylpiperazia-4-yl)ethyl, l-metibyl-2-hydroxyethyl; R3 is selected from fluoro, nitro, trifluoromethyl or mettioxy; R4 is hydrogen; R5 is hydrogen, methyl or 2-hydroxyethyl; R6 and R7 are independently selected from hydrogen, fluoro, chloro, bromo, nitro, cyano, amino, methyl, methylamino, ethylamino, propylamino, isopropylamino, dimethylamino, N-methyl-^-propylamino, ^-ethylcarbamoyl, methoxycarbonyl, ethoxycarbonyl, butoxycarbonyl, morphohno, pyrroUdinyl or piperazinyl; wherein R6 and R7 independently of each other may be optionally substituted on carbon by one or more R15; and wberein said piperazmyl may be optionally substituted on nitrogen by a group selected from R16; or R6 and R7 together with the pyiimidtne to which they are attached form a bicyclic ring selected from quinazolinyl, mieno[3,2^I]pyrinridinyl, tibieno[23-d]pyrimidinyl, IH-pyrazolo[3,4-d]pyrimidinyl, thieno[3,4-d]pyrhnidinyl, pyrido[2,3-d]pyriiniclmyl, 5,6,7,8-tetrahydro-pyrido[43^1]pyrnTridmyl> 5,6,7,8-tetrahydro-r^do[23-^yrimidinyl or 5,6,7,8-tetrahydro-pyrido[3,4- R15 is selected from fluoro, hydroxy, ammo, ethoxy, dimethylammo, phenyl, pyrroUduryl, piperazinyl or morpholino; wherein R15 may be optionally substituted on carbon by one or mote Rw; and wherein said piperazinyl may be optionally substituted on nitrogen by a group selected from R20; R16 is selected from methyl; R17 is selected from fmoro, chloro, methyl, metihoxy, ethoxy or propoxy; wherein R17 may be optionally substituted on carbon by one or moieR19; R11 is selected from acetyl; R19 is selected from fluoro, hydroxy, methoxy, pqperazinyl, pyrrolidinyl or morpholino; and wherein said piperazinyl may be optionally substituted on nitrogen by a group selected from R34; R20 is selected from methyl; R24 is selected from methyl; n = 0orl; or a pharmaceutically acceptable salt thereof, with the proviso that said compound is not: 54>n)mo-N4-(5-memyl-lH-pyraz»l-3-yiyN2-[1^2-pyridmyl)propyl]-2,4-pyrirm 5-chloro-N4-(5-methyl- lH-pyrazol-3-yl)-N2-[ 1 -(2-pyridmyl)propyl]-2,4-pyrimidmediamine; 5-bromo-N4-(5-memyl-lH-pyrazol-3-yl)-N2-[l-(3-pyriduiyl)propyl]-2,4-pyrirm -lH-pyrazol-3-yl)-N2-[ 1-(3-^^ l- lH-pyrazol-3-yl)-N2-[ 1 -(3-pyridmyl)ethyl]-2,4-pyrirnidmediamine; S-bromo-^-^S-memyl- !H-pyrazol-3-yl)-N2-[1^3-pyridmyl)e1hyl]-2,4-pyrinndmediamine; or Therefore in a further aspect of the invention there is provided a compound of formula (I) (as depicted herein above) wherein: A is a direct bond; Ring C is phenyl or thien-2-yl; R1 is selected from hydrogen, methyl, ethyl, t-butyl, merhoxy, dimethylamino, methyhhio or cyclopropyl; R2 is selected from methyl, ethyl or isopropyl; wherein R2 may be optionally substituted on carbon by one or more R10; R3 is selected from fluoro, nitro or memoxy; R4 is hydrogen; R5 is hydrogen or 2-hydroxyemyl; R6 and R7 are independently selected from hydrogen, fluoro, chloro, bromo, methyl, ethylamino, propylammo, JVr-(ethvl)caib«moyl, methoxycarbonyL, ethoxycarbonyl or botoxycarbonyl; wherein R* and R7 independently of each other rray be optiomlb/substituted on carbon by one or more R15; or R6 and R7 together with the pyrimidrne to which Ihey arc attached form qumazDlinyl, tbiem>[3,2^pyrimidinyl, mierK)[23-d]pyrirnidinyl, tibieDo[3>4-d]pyrimidmyl, l^^yrazoloj[3>4-d]pyrimidmyl or pyrido(23-d}pynmidmyl; and wherein said qumazohnyl, triierK^S^-djpyrimidinyl, thieno[23-d]pvrimidinyl, mieno[3,4-d]pyrimidinyl, IH-y^razolo[3,4^]pyrirnidinyl or pyrido[23-d]pyrimidinyl may be optionally substituted on carbon by one or more R17; R10 is selected from hydroxy, carboxy, methoxy, 7/-me1hyl-JV-ethylamino, diethylamino, pyrrolidin-1-yl, piperazin-1-yl or morpholino; wherein R10 may be optionally substituted on carbon by one or more hydroxy or methoxy; and wherein said piperazinyl may be optionally substituted on nitrogen by a group selected from R20; R15 is selected from fluoro, hydroxy, phenyl, piperazinyl, pyrrolidinyl or morpholino; wherein R15 may be optionally substituted on carbon by one or more R19; and wherein if said piperazinyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R20; R17 is selected from fluoro, chloro, methyl, methoxy or ethoxy; wherein R17 may be optionally substituted on carbon by one or more R19; R19 is selected from fluoro, methoxy, piperazinyl, pyrrolidinyl or morpholmo; wherein if said piperazinyl contains an -NH- moiety mat nitrogen may be optionally substituted by a group selected from R24; R20 is selected from methyl; R24 is selected from methyl; n = 0orl; or a pharmaceutically acceptable salt thereof. Particular values of the variable groups contained in formula (la) arc as follows. Such values may be used, where appropriate, with any of the definitions, claims or embodiments defined hereinbefore or hereinafter. In an additional embodiment the present invention provides a compound having a formula (la) as recited above wherein A is a valence bond. In an additional embodiment me present invention provides a compound having a formula (la) as recited above wherein C is Cv^aryL In an additional embodiment the present invention, prowdes a compound having a formula (La) as recited above wherein R1 is Cj^cycloalkyL Mmlvwttmmt thf. prrsi-nt mvfarttifin proyujfty a fmmpmmri having a formula (la) as recited above wherein R2 is -C(=O)OH, -C(=O)OCH3, C(=O)NHCHj, -C(==0)N(CH3)2, -CX^NHSOjCHa, C(=O)NHSO2CF3, C(=O)NHSO2Pn) or Ci^alkyl optionally substituted with -OH, -NHCHj, -N(CH3)i, heterocycle or Q^erner optionally substituted with heterocycle or examine optionally substituted with heterocycle. In an additional embodiment the present invention provides a compound having a formula (la) as recited above wherein R3 is F, Cl, Br, I, CFs. In an additional embodiment the present invention provides a compound having a formula (la) as recited above wherein R4 is H or optionally substituted Ci^alkyl. In an additional embodiment the present invention provides a compound having a formula (la) as recited above wherein R5 is H. In an additional embodiment the present invention provides a compound having a formula (la) as recited above wherein. R6 is H, F, Cl, Br, I, CF3, Ci-e alkyl, OCi^alkyl, or C(=O)OCi-6alkyl. In an additional embodiment the present invention provides a compound having a formula (la) as recited above wherein. R7 is H, F, Cl, Br, I, CF3, d-s alkyl, OCi^alkyl, or In an additional embodiment the present invention provides a compound having a formula (la) as recited above wherein R6 and R7 in combination form a fused phenyl which is optionally substituted with F, d, Br, I, Ci^alkyl, OCi-4aIkyl OCi^alkylOCHj. In an additional embodiment the present invention provides a compound having a formula (la) as recited above wherein R6 and R7 in combination form a fused 5-membered heteroaromatic ring having at least one nitrogen or one sulfur atom, but no more man 2 nitrogen atoms or 2 sulfur atoms or 1 nitrogen and 1 sulfur atom. hi an additional embodiment the present invention provides a compound having a formula (la) as recited above wherein R6 and R7 in combination form a fused 6-membered heteroaromatic ring having at least one nitrogen or one sulfur atoms, but no more man 2 nitrogen atoms or 2 sulfur atoms or 1 nitrogen and 1 sulfur atom. hi an additional embodiment the present invention provides a compound having a formula (la) as recited above wherein: A is » valence bond; C is C«aryl, Cj R1 is C3^cycloalkyl, C^ary!; R2 is -C(=O)OH, -C^OyOCR* -C(=O)NHC%, -C^OMCHsfc, -C(=O)NHSQzCH3, Q=O)NHSO2CF3, C(=O)NHSOIPh, or Q^alkyl optionally substituted with -OH, -IJHCHs, -N(CH3)2, heterocycle or C^emer optionally substituted with heterocycle or (famine optionally substituted with heterocycle; R3 is F, d, Br, I, CF3. NH2, NOi, OH, OCF3. Ci* alkyl, OCi^ alkyl; R4 is H, or optionally substituted Ci-^alkyl; R5 is H, or optionally substituted Ci-4alkyl; R6 and R7 are independently selected from: H, F, O, Br, I, CF3, Ci-6 alkyl, OCi^alkyl, orC(=0)OCi^alkyL In an additional embodiment the present invention provides a compound having a formula (la) as recited above wherein: A is a valence bond; C is Cj-saryl, Cs-^heteroaryl; R1 is Ca^cycloalkyl; R2 is -C(=O)OH, -C(=O)OCH3, -C(=O)NHCH3, -C(=O)N(CH3)2, -C(=O)NHSO2CH3, C(=O)NHSO2CF3, C(=O)NHSO2Ph, or C!^alkyl optionaUy substituted with -OH,- NHCH3, -N(CH3)2, morpholine, piperazrne, pyrrohne or Ci-sether optionally substituted with morpholine, piperazine, pyrroline or Ci-samme optionally substituted with morpholine, piperazine, pyrroline; R3isF,d,Br,I,CFOH,OCF3; R4isH; Rs is H, or Ci.4alkyl optionally substituted with -OH; R6 and R7 are independently selected from: H, F, O, Br, I, CF3, C^ alkyl, or In an additional embodiment the present invention provides a compound having a formula (la) as recited above wherein: A is a valence bond; C is phenyl; R1 is cyclopropyU R2 is Ci^alkyl optionally substituted with -OH; R3isF,C3,Br>orI; R4andR5areH; R6 andR7 are independently selected from: H, F, d, Br, I, CPj, CM alkyl, or OCi.talkyL In an additional embodiment the present invention provides a compound having a formula (la) as recited above wherein: A is a valence bond; C is Cs-9aryl, Cs^heteroaryl; R1 is Cs-ficycloalkyl, C5-9aryi; R2 is -C(=0)OH, -C(=OpCH3, ^(=o)NHCH3, -C(=O)N(CH3)2, -C(=O)NHSO2CH3, C(=O)NHSO2CF3, C(=O)NHSO2Ph, or Ci^alkyl optionaUy substituted with -OH, -NHCH3) -N(CH3)2, heterocycle or Ca.sether optionally substituted with heterocycle or C^samine optionaUy substituted with heterocycle; R3 is F, O, Br, I, CF3. NHa, NOj, OH, OCF3, Ci^ alkyl, OCi^ alkyl; R4 is H, or optionally substituted Ci^alkyl; R5 is H, or optionally substituted Ci^alkyl; R6 and R7 in combination form a fused phenyl, which is optionally substituted with CH3, OCH3, F, Cl, Br, I or OCi.3OCHj or R6 and R7 in combination, form a fused 5 or 6-membered heteroaromatic ring having 1 or 2 nitrogen atoms or 1 sulfur atom. In an additional embodiment the present invention provides a compound having a formula (la) as recited above wherein: A is a valence bond; C is Cs^aryl, C5-9heteroaryl; R1 is C3^cycloalkyl; R2 is -C(=O)OH, -C(=O)OCH3, -C^NHCHB, -C(=O)N(CH3)2, -C(=O)NHSO2CH3, C(=O)NHSO2CF3> C(=O)NHSO2Ph, or Ci^alkyl optionally substituted with -OH,- NHCHs, -N(CH3)2, morpholine, piperazine, pyrroline or C^sether optionally substituted with morpholine, piperazine, pyrroline or examine optionally substituted with morpholine, piperazine, pyrroline; R3 is F, d, Br, I, CF, OH, OCF3; R4isH; R5 is H, or d^alkyl optionally substituted with -OH; R* and R7 in combination farm a fused phony), which is optionally substituted wim heteroaromatic ring having 2 nitrogen atoms or 1 sulfur atom. In an additional embodiment the present mventioa provides a «xnr>oundlumng a formula (la) as recited above wherein: A is a valence bond; C is phenyl; R1 is cyclopropyl; R2 is Ci_4alkyl optionally substituted with -OH; R3isF,Cl,Br,orI; R4andR5areH; R6 and R7 in combination form a fused phenyl, which is optionally substituted with CH3 or OCH3. In an additional embodiment the present invention provides a compound having a formula (la) as recited above wherein: A is a valence bond; C is phenyl; R1 is cyclopropyl; R2 is Cj.4alkyl optionally substituted with -OH; R3 is F, d, Br, or I; R4andR5areH; R6 and R7 in combination form a fused 5-membered heteroaromatic ring having 2 nitrogen atoms or 1 sulfur atom. Additional embodiments of the invention are as follows. These embodiments relate to compounds of formula (T) and (la) and it is to be understood were compounds of formula (I) are referred to mis statement also applies in the alternative to compounds of formula (la). In another aspect of the invention, preferred compounds of the invention are any one of the Examples or a pharmaceutically acceptable salt thereof. hi an additional embodiment the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use as a medicament. hi an additional embodiment the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for use in the inhibition of Trk activity. * compound of formula (I), or a phannaceuticalry acceptable salt thereof, for vac m Ae mamdk&ire of a inedkainent for use m the treatment or prophylaxis of cancer. In an additional embodiment the present invention provides a compound of the formula (I), or a pharmaceutically acceptable salt mereof, for use m the manufacture of a medicament for use in the treatment of cancer in a warm-blooded animal such as man. hi an additional embodiment the present invention provides a compound of the formula (I), or a pharmaceutically acceptable salt mereof, for use in the manufacture of a medicament for use hi the treatment or prophylaxis of cancers (solid tumors and leukemia), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation hi a warm-blooded animal such as man. hi an additional embodiment the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt mereof, for use hi the manufacture of a medicament for use in the production of an anti-proliferative effect. In an additional embodiment the present invention provides a method of inhibiting Trk activity comprising adininistering to a host in need of such treatment a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof. In an additional embodiment Hie present invention provides a method for the treatment of cancer comprising administering to a host in need of such treatment a therapeuticalry effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof. In an additional embodiment the present invention provides a method for the treatment or prophylaxis of cancer comprising administering a therapeuticalry effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. In an additional embodiment the present invention provides a method for the treatment or prophylaxis of cancers (solid tumors and leukemia), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation in a warm-blooded animal such as man comprising administering a therapeutically effective amount of a compound of formula (I) or a pharniacewticalry acceptable sah thereof. In an additional embodiment ihe present inventim provides a me&od of producing an anu-proUfietative effect in a warm-blooded animal, such as ma% in need of such treatment xuhirfr fjumpi-igfy ajtmrnjgtermg in taaA monoA mn effective amonnt of a mmpniind of formula CO, or a pharmaceutically acceptable salt thereof. In an additional embodiment the present invention provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, diluent or excipient In an additional embodiment the present invention provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, diluent or excipient for use in the inhibition of Trk activity. In an additional embodiment the present invention provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, diluent or excipient for use in the treatment of cancer. In an additional embodiment the present invention provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, diluent or excipient for use in the treatment or prophylaxis of cancer. In an additional embodiment the present invention provides a pharmaceutical composition comprising a compound of formula (T), or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, diluent or excipient for use in the treatment or prophylaxis of cancers (solid tumors and leukemia), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation. La an additional embodiment the present invention provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, diluent or excipient for use in the production of an anti-proliferative effect in a warm-blooded animal such as man. In an additional embodiment the present invention provides a compound of formula (I), or apharmaceoticalry acceptable sah thereof for use m me inhibition of Tdc activity. In an additional embodiment the present invention pcovioVs a compound of foromla (I), or a pharmaceutically acceptable salt thereof, for use m the treatment or prophylaxis of cancer. In an additional embodiment the present invention provides a compound of the formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer in a warm-blooded animal such as man. In an additional embodiment the present invention provides a compound of the formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment or prophylaxis of cancers (solid tumors and leukemia), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation in a warm-blooded animal such as man. In an additional embodiment the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in tile production of an anti-proliferative effect Where the inhibition of Trk activity is referred to particularly this refers to the inhibition of TrkB activity. Where the treatment (or prophylaxis) of cancer is referred to, particularly it refers to the treatment (or prophylaxis) of oesophageal cancer, myeloma, hepatocettular, pancreatic, cervical cancer, ewings tumour, neuroblastoma, kaposis sarcoma, ovarian cancer, breast cancer, colorectal cancer, prostate cancer, bladder cancer, melanoma, lung cancer - non small cell lung cancer (NSCLC), and small cell lung cancer (SCLC), gastric cancer, head and neck cancer, renal cancer, rymphoma, leukaemia, tumours of the central and peripheral nervous system, melanoma, fibrosarcoma and osteosarcoma. More particularly it refers to prostate cancer. In addition, more particularly it refers to SCLC, NSCLC, colorectal cancer, ovarian cancer and / or breast cancer. In a further aspect it refers to hormone refractory prostate cancer. In an additional embodiment the present invention provides a process for preparing a compound of structural formula (I) as claimed in claim 1 or a pharmaceutically acceptable salt thereof which process comprises: (Figure Remove) In a further aspect of the present invention provides a process for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof which process (wherein variable groups are, unless otherwise specified, as defined in formula (I)) comprises of: Process a) reaction of a pyrimidine of formula (II): (Figure Remove) wherein L is a displaceable group; with an pyrazole amtne of formula (CO): (Figure Remove) Process b) reacting a pyrimidme of formula (IV): (Figure Remove) wherein L is a displaceable group; with a compound of formula (V): (Figure Remove) Process c) reacting a compound of formula (VI): (Figure Remove) with a compound of formula (VH): (Figure Remove) wherein X is an oxygen atom and q is 1; or X is a nitrogen atom and q is 2; and wherein each R20 independently represents a Ci-jalkyl group; or Process d) reacting a compound of formula (Vni): (Figure Remove) with hydrazine; or and thereafter if necessary: i) converting a compound of the formula (I) into another compound of the formula (I); ii) removing any protecting groups; iii) forming a pharmaceutically acceptable salt. L is a displaceable group, suitable values for L are for example, a halo or sulphonyloxy group, for example a chloro, bromo, methanesulphonyloxy or toluene-4-sulphonyloxy group. Specific reaction conditions for the above reactions are as follows. Process a) Pyrimidines of formula (D) and pyrazole amine of formula (III) may be reacted together a) in the presence of a suitable solvent for example a ketone such as acetone or an alcohol such as ethanol or butanol or an aromatic hydrocarbon such as toluene or Af-methyl pyrrolid-2-one, optionally in the presence of a suitable acid for example an inorganic acid such as hydrochloric acid or sulphuric acid, or an organic acid such as acetic acid or formic acid (or a suitable Lewis acid) and at a temperature in the range from 0°C to reflux, particularly reflux; or b) under standard Buchwald conditions (for example see J. Am. Chem. Soc., 118,7215; J. Am. Chem. Soc.y 119,8451; J. Org. Chem., 62,1568 and 6066) for example in the presence of palladium acetate, in a suitable solvent for example an aromatic solvent such as toluene, benzene or xyfene, with a suitable base for example an inorganic base such as caesium carbonate or an organic base such as potasshnn-4-butoxide, in the presence of a suitable hgand such as 2,2'-bis(diphenylplK>sphmo)-l>r-binaphthyl and at a temperature in the range from 25 to80°C. Pyrimidines of the formula (El) may be prepared according to Scheme 1: (Figure Remove) Pyrazole amines of formula (TO) and compound of formula (lEa) and (Ub) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art Process b) Compounds of formula (TV) and formula (V) may be reacted together under the same conditions as outlined in Process a). Compounds of the formula (TV) may be prepared according to Scheme 2: Compounds of the formula (V) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art. Process c) may conveniently be carried out in a suitable solvent such as JV-methylpyrrolidinone or butanol at a temperature in the range from 100-200°C, in particular in the range from 150-170°C. The reaction is preferably conducted in the presence of a suitable base such as, for example, sodium methoxide or potassium carbonate. Compounds of the far«»Ja (VI) may be prepared according to Scheme 3: (VIb) Scheme 3 Compounds of the formula (VET) may be prepared according to Scheme 4: (Figure Remove) Scheme 4 wherein Pg is a suitable nitrogen protecting group. Suitable values for Pg are defined below. Compounds of the formula (Via), (VIb), (Vila) and (VHb) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art Process d) may be carried out in a suitable solvent, for example, an alcohol such as ethanol or butanol at a temperature in the range from 50-120°C, in particular in the range from 70-100°C. Compounds of the formula (VIII) may be prepared according to Scheme 5: (Figure Remove) It win be appreciated that certain of the various ring substituentsm the compounds of the present invention may be introduced by standard aromatic substitution reactions or generated by conventional functional group modifications eimer prior to or immediately following the processes mentioned above, and as such are included in the process aspect of the invention. Such reactions and modifications include, for example, introduction of a substituent by means of an aromatic substitution reaction, reduction of substituents, alkylation of substituents and oxidation of substituents. The reagents and reaction conditions for such procedures are well known in the chemical art. Particular examples of aromatic substitution reactions include the introduction of a nitro group using concentrated nitric acid, the introduction of an acyl group using, for example, an acyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; the introduction of an alkyl group using an alkyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; and the introduction of a halogeno group. Particular examples of modifications include the reduction of a nitro group to an amino group by for example, catalytic hydrogenation with a nickel catalyst or treatment with iron in the presence of hydrochloric acid with heating; oxidation of alkylthio to alkylsulphinyl or alkylsulphonyl. It will also be appreciated that in some of the reactions mentioned herein it may be necessary/desirable to protect any sensitive groups in the compounds. The instances where protection is necessary or desirable and suitable methods for protection are known to those skilled in the art. Conventional protecting groups may be used in accordance with standard practice (for illustration see T.W. Green, Protective Groups in Organic Synthesis, John Wiley and Sons, 1991). Thus, if reactants include groups such as amino, carboxy or hydroxy it may be desirable to protect the group in some of the reactions mentioned herein. A suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or f-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl. The deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an acyl group such as a f-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifbxxoacetic add and an aryfane&oxycarboayl group such as abenzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladhim-on-carbon, or by treatment with a Lewis acid for example bacon tris(tnffaacoac**ate). A suitaU^ for a primary ammo group is, for example, a pbrbaloyi group which may be removed by treatment with an alkylamine, for example dime&vlaminorm>pylaminc, or withhydrazine. A suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon. A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a f-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as tiifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon. The protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art. Definitions In this section the definition applies to both compounds of formula (I) and compounds of formula (la) unless otherwise stated. In this specification the term "alky!" includes both straight and branched chain alkyl groups but references to individual alkyl groups such as "propyl" are specific for the straight chain version only. For example, "Ci-galkyl" and "Ci^alkyl" include methyl, ethyl, propyl, isopropyl and r-butyl. However, references to individual alkyl groups such as 'propyl' are specific for the straight-chained version only and references to individual branched chain alkyl groups such as 'isopropyl' are specific for the branched-chain version only. A similar convention applies to other radicals. The term "halo" refers to fluoro, chloro, bromo and iodo. Where optional substituents are chosen from "one or more" groups it is to be understood that this definition includes all substituents being chosen from one of the specified groups or the substituents being chosen from two or more of the specified groups. A "heterocyclyl" is a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 4-12 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a -CH2-group can optionally be replaced by a -C(O)-, and a ring sulphur atom may be optionally oxidised to form the S-oxides. Examples and suitable values of the term "heterocyclyl" are morpholino, piperidyl, pyridyl, pyranyl, pyrrolyl, isothiazolyl, indolyl, quinolyl, thienyl, 1,3-benzodioxolyl, thiadiazolyl, piperazinyl, thiazolidinyl, pyrrolidinyl, thiomorpholino, pyrrolinyl, homopiperazinyl, 3,5-dioxapiperidinyl, tetrahydropyranyl, imidazolyl, pyrimidyl, pyrazinyl, pyridazinyl, isoxazolyl, W-methylpyrrolyl, 4-pyridone, 1-isoquinolone, 2-pyrrolidone, 4-thiazolidone, pyridine-Af-oxide and quinoline-W-oxide. Further examples and suitable values of the term "heterocyclyl" are morpholino, piperazinyl and pyrrolidinyl. In one aspect of the invention a "heterocyclyl" is a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 5 or 6 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, it may, unless otherwise specified, be carbon or nitrogen linked, a -group can optionally be replaced by a -C(O)-and a ring sulphur atom may be optionally oxidised to form the S-oxides. A "carbocyclyl" is a saturated, partially saturated or unsaturated, mono or bicyclic carbon ring mat contains 3-12 atoms; wherein a -CHa- group can optionally be replaced by a -C(O)-. Particularly "carbocyclyl" is a monocyclic ring containing 5 or 6 atoms or a bicyclic ring containing 9 or 10 atoms. Suitable values for "carbocyclyr include cyclopropyl, cyclobutyl, 1-oxocyclopentyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, phenyl, naphthyl, tetralinyl, indanyl or 1-oxoindanyl. Where "R6 and R7 together with the bond to which they are attached form a 5 or 6 membered heterocyclic ring" said ring is a partially saturated or unsaturated, mono or bicyclic carbon ring that contains 5 or 6 atoms two atoms of which are shared with the pyrimidine ring of formula (I); of which at least one atom is chosen from nitrogen, sulphur or oxygen; wherein a -CH.2- group can optionally be replaced by a -C(O)-, and a ring sulphur atom may be optionally oxidized to form the S-oxides. Said ring is fused to the pyrimidine ring of formula (I) to make a 9 or 10 membered bicyclic ring. Suitable values for "R6 and R7 together with the bond to which they are attached form a 5 or 6 membered heterocyclic ring wherein said ring is fused to die pyrimidine of formula (I)" are pteridinyl, purinyi, aueno[3,2-djpyrimidhryU micno(23-d]pyrhTHdmYl, OMeno[3,4^]pyrimidmylJ Lff-pyrazok>[3,4-djpyrumdinyl or r^rrido(2^-d]pyrimidinyL Further suitable values for "R* and R7 together •witti the bond to which (hey are attached form a 5 or 6 membered heterocydk: ring wherein said ring is fused to the pyrimidine of formula (I)" are ouenop,2-d]pyrimklinyl, mieno(2^-d]pyrimidinYi, mieno(3,4-d]pyrimidmyU lH-pyraz»lo[3,4-dlpyrimtdinYl orpyrido[2,3-d]pyrimidinyL Additional suitable values for "R6 and R7 together with the bond to which they are attached form a 5 or 6 membered heterocyclic ring wherein said ring is fused to the pyrimidine of formula (I)" are tMeno[3^-d]pyrimidinyl, tMeno[2,3-d]pyrimidinyl, IH-pyra2»lo[3,4-d]pyrimidinyl, tMeno[3,4-4]pyrimidinyl, pyrido[2,3-d]pyrimidinyl, 5,6,7,8-tetrahydro-pyrido[4,3 Where "R6 and R7 together with the bond to which they are attached form a 5 or 6 membered carbocyclic ring" said ring is a partially saturated or unsaturated, mono or bicyclic carbon ring that contains 5 or 6 atoms two atoms of which are shared with the pyrimidine ring of formula (T); wherein a -CHj- group can optionally be replaced by a -C(O)-. Said ring is fused to the pyrimidine ring of formula (I) to make a 9 or 10 membered bicyclic ring. Suitable values for "R6 and R7 together with the bond to which they are attached form a 5 or 6 membered carbocyclic ring wherein said ring is fused to the pyrimidine of formula (I)" are quinazolinyl. The term "CW1 or "Cnm group" used alone or as a prefix, refers to any group having m to n carbon atoms. For compounds of formula (la) the term "hydrocarbon" used alone or as a suffix or prefix, refers to any structure comprising only carbon and hydrogen atoms up to 14 carbon atoms. For compounds of formula (la) the term "hydrocarbon radical" or "hydrocarbyr used alone or as a suffix or prefix, refers to any structure as a result of removing one or more hydrogens from a hydrocarbon. For compounds of formula (la) the term "alky!" used alone or as a suffix or prefix, refers to monovalent straight or branched chain hydrocarbon radicals comprising 1 to about 12 carbon atoms. Unless otherwise specified, "alkyl" general includes both saturated alkyl and unsaturated alkyl. For compounds of formula (I*) the term "cycloalkyV used alone or as suffix or prefix, refers to a monovalent ring-containing hydrocarbon n^lical coinprising at least 3 up to about 12 carbon atoms. Forc»inpoundsoffortnuU(U)atetain"aryruseda to a hydrocarbon radical having one or more polyunsataivtiedcaibon rings having aromatic character, (e.g., 4n + 2 delocalized electrons) and comprising 5 up to about 14 carbon atoms, wherein the radical is located on a carbon of the aromatic ring. For compounds of formula (la) the term "non-aromatic group" or "non-aromatic" used alone, as suffix or as prefix, refers to a chemical group or radical mat does not contain a ring having aromatic character (e.g., 4n + 2 delocalized electrons). For compounds of formula (la) the term "heterocycle" used alone or as a suffix or prefix, refers to a ring-containing structure or molecule having one or more multrvalent heteroatoms, independently selected from N, O, P and S, as a part of the ring structure and including at least 3 and up to about 20 atoms in the ring(s). Heterocycle may be saturated or unsaturated, containing one or more double bonds, and heterocycle may contain more than one ring. When a heterocycle contains more than one ring, die rings may be fused or unfused. Fused rings generally refer to at least two rings share two atoms there between. Heterocycle may have aromatic character or may not have aromatic character. For compounds of formula (la) the term "heteroaromatic" used alone or as a suffix or prefix, refers to a ring-containing structure or molecule having one or more multivalent heteroatoms, independently selected fromN, O, P and S, as a part of the ring structure and including at least 3 and up to about 20 atoms in the ring(s), wherein the ring-contaming structure or molecule has an aromatic character (e.g., 4n + 2 delocalized electrons). For compounds of formula (la) the term "heterocyclo" used alone or as a suffix or prefix, refers to a radical derived from a heterocycle by removing one or more hydrogens therefrom. For compounds of formula (la) the term "heterocyclyl" used alone or as a suffix or prefix, refers a radical derived from a heterocycle by removing one hydrogen from a carbon of a ring of the heterocycle. For compounds of formula (la) the term "heteroaryr used alone or as a suffix or prefix, refers to a heterocyclyl having aromatic character, wherein the radical of the heterocyclyl is located on a carbon of an aromatic ring of die heterocyclyl. For compounds of formula (la) the teem "srx-membered" used as prefix refers to a group having a ring mat contains six ting atoms. For compounds of formula (la) the term "five-mcmbered" used as prefix refers to a group baving a ring mat contains five ring atoms. For compounds of formula (la) the term "substituted** used as a prefix refers to a structure, molecule or group, wherein one or more hydrogens are replaced with one or more Ci-nhydrocarbon groups, or one or more chemical groups containing one or more heteroatoms selected from N, O, S, F, Cl, Br, I, and P. Exemplary chemical groups containing one or more heteroatoms include heterocyclyl, heterocycle, -NOa, -OR, -Cl, -Br, -I, -F, -CFs, -C(=O)R, -C(=O)OH, -NHz, -SH, -NHR, -NR2, -SR, -SOsH, -SOiR, -SOjCFj. -SC^Ph, -S(=O)R, -CN, -OH, -C(=O)OR, -C(=O)NR2. -NRC(=O)R, oxo (=O), irnino (=NR), thio (=S), and oximino (=N-OR), wherein each "R" is a Ci-iahydrocarbyl. For example, substituted phenyl may refer to nitrophenyl, pyridylphenyl, methoxyphenyl, chlorophenyl, aminophenyl, etc., wherein the nitro, pyridyl, merhoxy, chloro, and amino groups may replace any suitable hydrogen on the phenyl ring. For compounds of formula (la) the term "substituted** used as a suffix of a first structure, molecule or group, followed by one or more names of chemical groups refers to a second structure, molecule or group, which is a result of replacing one or more hydrogens of the first structure, molecule or group with the one or more named chemical groups. For example, a "phenyl substituted by nitro" refers to nitrophenyl. The term "optionally substituted" refers to either groups, structures, or molecules that are substituted and those that are not substituted. For compounds of formula (la) heterocycle includes, for example, monocyclic heterocycles such as: aziridine, oxirane, thiirane, azetidine, oxetane, thietane, pyrrolidine, pyrroline, imidazolidine, pyrazolidine, pyrazoline, dioxolane, sulfolane 2,3-dihydrofuran, 2,5-dihydrofuran tetrahydrofuran, thiophane, piperidine, 1^,3,6-tetrahydro-pyridine, piperazine, morpholine, thiomorpholine, pyran, thiopyran, 2,3-dihydropyran, tetrahydropyran, 1,4-dihydropyridine, 1,4-dioxane, 1,3-dioxane, dioxane, homopiperidine, 2,3,4,7-tetrahydro-l/f-azepine homopiperazhae, 1,3-dioxepane, 4,7-dihydro-l,3-dioxepin, and hexamethylene oxide. For compounds of formula (la) in addition, heterocycle includes aromatic heterocycles, for example, pyridine, pyrazine, pyrimidme, pyridazine, thiophene, furan, furazan, pyrrole, imidazole, thiazole, oxazole, pyrazole, iaothiazole, isoxazole, 1^,3-triazole, tetrazok, l^-thiadiazole, 1,2,3-oxadiazole, 1,2,4-triazole, 1^,4-thiadiazole, 1,2,4-oxadiazole, 13,4-triazole, 13,4-tiiiadiazole, and 1^,4- oxadiazolc. For ooncpounds of formula (la) additionally, hcterocycle eoooo^ass polycyclic hetcrocydes, for example, indole, mAt&mf.^ iaomdoltne. qoinolme, iaoqumoline, tetrahydroisoquinoline, 1,4-bcnosodioxaii, ooutnann, dihydrocoumann, benzofuran, 2^-dihydrobenzofuran, isoben2»curan, chromcne, chroman, isochroman, xanmene, phenoxamiin, thianthrene, indoHzine, isoindole, indazole, purine, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, pteridine, phenanthridine, perimidine, phcnanthroline, phenazine, phenothiazine, phenoxazine, 1^2-benzisoxazole, benzotbiophene, benzoxazole, benzthiazole, benzimidazole, benztriazole, tnioxanmine, carbazole, carboline, acridine, pyroUzidine, and quinoUzidine. For compounds of formula (la) in addition to the polycyclic heterocycles described above, heterocycle includes polycyclic heterocycles wherein the ring fusion between two or more rings includes more than one bond common to bom rings and more than two atoms common to bom rings. Examples of such bridged heterocycles include quinuclidine, diazabicyclo[2.2.1]heptane and 7-oxabicyclo[2-2.1]heptane. For compounds of formula (la) heterocyclyl includes, for example, monocyclic heterocyclyts, such as: aziridinyl, oxiranyU tbiiranyl, azetidinyl, oxetanyU thietanyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, pyrazolidinyl, pyrazolinyl, dioxolanyl, sulfolanyl, 2,3-dihydrofuranyl, 2,5-dihydrofuranyl, tetrahydrofuranyl, thiophanyl, piperidinyl, 1,2,3,6-tetrahydro-pyridinyl, piperazinyl, morpholinyl, thiomorpholinyl, pyranyl, thiopyranyl, 2,3-dihydropyranyl, tetrahydropyranyl, 1,4-dihydropyridinyl, 1,4-dioxanyl, 1,3-dioxanyl, dioxanyl, homopiperidinyl, 2,3,4,7-tetrahydro-l//'-azepinyl, homopiperazinyl, 1,3-dioxepanyl, 4,7-dihydro-l,3-dioxepinyl, and hexamethylene oxidyl. For compounds of formula (la) in addition, heterocycly 1 includes aromatic heterocyclyls or heteroaryl, for example, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl, furyl, furazanyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1,2,3-triazolyl, tetrazolyl, 1,2,3-thiadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-triazolyl, 1,2,4-thiadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-triazolyl, 1,3,4-thiadiazolyl, and 1,3,4 oxadiazolyl. For compounds of formula (la) additionally, heterocyclyl encompasses polycyclic heterocyclyls (including both aromatic or non-aromatic), for example, indolyl, indolinyl, isoindolinyl, quinolinyl, tetrahydroquinolinyl, isoquinolinyl, tetrahydroisoquinolinyl, 1,4-benzodioxanyl, coumarinyl, dihydrocoumarinyl, benzofuranyl, 2,3-dihydrobenzofuranyl, isobenzofuranyl, chromenyl, chromanyl, isochromanyl, xanthenyl, phenoxathiinyl, thianthrenyl, indolizinyl, isoindolyl, indazolyl, purinyl, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, pteridinyl, phenanthridinyl, perimidinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxazinyl, 1,2-benzisoxazolyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benzimidazolyl, benztriazolyl, thioxanthinyl, carbazolyl, carbolinyl, acridinyl, pyrolizidinyl, and quinolizidinyl. For compounds of formula (la) in addition to the polycyclic heterocyclyls described above, heterocyclyl includes polycyclic heterocyclyls wherein the ring fusion between two or more rings includes more than one bond common to both rings and more than two atoms common to both rings. Examples of such bridged heterocycles include quinuclidinyl, diazabicyclo[2.2.1]heptyl; and 7-oxabicyclo[2.2.1]heptyl. For compounds of formula (la) the term "amine" or "amino" used alone or as a suffix or prefix, refers to radicals of the general formula -NRR', wherein R and R' are independently selected from hydrogen or a hydrocarbon radical. An example of "Ci_6alkanoyloxy" is acetoxy. Examples of "Ci.6alkoxycarbonyl" include CMalkoxycarbonyl, methoxycarbonyl, ethoxycarbonyl,«- and f-butoxycarbonyl. Examples of "Q-ealkoxy" include Ci-4alkoxy, Ci.salkoxy, methoxy, ethoxy andpropoxy. Examples of "Ci.galkoxyimino" include Ci^alkoxyimino, Ci.3alkoxyimino, methoxyimino, ethoxyimino and propoxyimino. Examples of "Ci-ealkanoylamino" include formamido, acetamido and propionylamino. Examples of "Ci-6alkylS(O)a wherein a is 0 to 2" include Ci-4alkylsulphonyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl and ethylsulphonyl. Examples of "Ci^alkylthio" include methylthio and ethylthio. Examples of "Ci-galkylsulphonylamino" include memylsulphonylamino and ethylsulphsulphonylamino. Examples of "Ci^alkanoyl" include Cj^alkanoyl, propionyl and acetyl. Examples of *W-(Ci^aIkyl)ammo" include methylamino and ethylamino. Examples of 'W,A^(Ci^alkyl)2amino" inchide di-JV-methylamino, di-(^-ethyl)amino and ^-ernyl-W-methylarnino. Examples of "C2^alkenyl" are vinyl, allyl and 1-propenyL Examples of "Q-ealkynyl" are ethynyl, 1-propynyl and 2-propynyl. Examples of 'W-(Ci^alkyl)sulphamoyr' are #-(methyl)sulpharnoyl and A^-(ethyl)sulphamoyl. Examples of "#-(Ci-6alkyl)2Sulphamoyr are JV^-(dmiemyl)sulphamoyl and JV-(memyl)-^-(ethyl)sulphamoyl. Examples of'W-(Ci-6alkyl)carbamoyr> are //-(CiwtalkyOcarbamoyL, methylaminocarbonyl and ethylaminocarbonyl. Examples of "A^M{Ci-4alkyl)2carbarjaoyl>> are ^^-(CMaflcyOzcarbamoyi, dmethylaxninocarbonYl and inethylethylanimocarbonyL "RT" or "rt" means room temperature. A first ring group being "fused" with a second ring group means the first ring and the second ring share at least two atoms there between. A suitable pharmaceutically acceptable salt of a compound of the invention is, for example, an acid-addition salt of a compound of the invention which is sufficiently basic, for example, an acid-addition salt with, for example, an inorganic or organic acid, for example hydrochloric, hydrobromic, sulphuric, phosphoric, trifluoroacetic, citric or maleic acid. In addition a suitable pharmaceutically acceptable salt of a compound of the invention which is sufficiently acidic is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a physiologically-acceptable cation, for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpboline or tris-(2-hydroxyethyl)amine. It should be noted that the pyrazoles claimed in this invention are capable to exist in different resonance structures and thus the pyrazoles claimed herein include all possible •esonance structures, for example optical isomers, diastereoisomers and geometric isomers 1 all tautomeric forms of the compounds of the formula (I). It is also to be understood that certain compounds of the formula (I) can exist in sorvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such sorvated forms. Formulations Compounds of the present invention may be administered orally, parenteral, buccal, vaginal, rectal, inhalation, insufflation, sublingually, intramuscularly, subcutaneously, topically, intranasally, intraperitoneaUy, intrathoracially, intravenously, epidurally, intrathecally, intracerebroventricularly and by injection into the joints. The dosage will depend on the route of administration, the severity of the disease, age and weight of the patient and other factors normally considered by the attending physician, when determining the individual regimen and dosage level as the most appropriate for a particular patient An effective amount of a compound of the present invention for use in therapy of cancer is an amount sufficient to symptomaticalry relieve in a warm-blooded animal, particularly a human the symptoms of cancer, to slow the progression of cancer, or to reduce in patients with symptoms of cancer the risk of getting worse. For preparing pharmaceutical compositions from the compounds of mis invention, inert, pharmaceutralty acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets, and suppositories. A solid carrier can be one or more substance, which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or tablet disintegrating agents; it can also be an encapsulating material. In powders, the carrier is a finely divided solid, which is in a mixture with the finely divided active component. In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired. For preparing suppository compositions, a low-melting wax such as a mixture of fatty acid glycerides and cocoa butter is first melted and the active ingredient is dispersed therein by, for example, stirring. The molten homogeneous mixture is then poured into convenient sized molds and allowed to cool and solidify. Suitable carriers include magnesium carbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low-melting wax, cocoa butter, and the like. Some of the compounds of the present invention are capable of forming salts with various inorganic and organic acids and bases and such salts are also within the scope of mis invention. Examples of such acid addition salts include acetate, adipate, ascorbate, benzoate, benzenesulfonate, bicarbonate, bisulfate, buryrate, camphorate, camphorsulfonate, choline, citrate, cyclohexyl sulfamate, diethylenediamine, ethanesulfonate, fumarate, glutamate, glycolate, hemisulfate, 2-hydroxyethylsulfonate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, hydroxymaleate, lactate, malate, maleate, methanesulfonate, meghnnine, 2-raphthalenesulfonate, nitrate, oxalate, pamoate, persulfate, phenylacetate, phosphate, diphosphate, picrate, pivalate, propionate, quinate, salicylate, stearate, succinate, sulfamate, sulfianilate, sulfate, tartrate, tosylate (p-tomenesulfonate), trifluoroacetate, and undecamoate. Base sates indtude ammonium salts, atkaH metal salts such as sodium, lithium and potassium salts, alkaline earth metal salts such as ahmunum, calcium and magntsiom salts, salts with organic bases such as dicyckthexylamine salts, N-me^yl-D-gmcainmc, and salts with ammo acids such as arginme, tysme, orniihme, and so forth. Also, basic mtrogen-^ontaming groups may be quatenttzed wim such agents as: lower alkyi halides, such as methyl, ethyl, propyl, and butyl halides; diaDcyl sulfates like dimethyl, diethyl, dibutyl; diamyl sulfates; long chain halides such as decyl, lauryl, myristyl and stearyl halides; aralkyl halides like benzyl bromide and others. Non-toxic physiologically-acceptable salts are preferred, although other salts are also useful, such as hi isolating or purifying the product The salts may be formed by conventional means, such as by reacting the free base form of the product with one or more equivalents of the appropriate acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water, which is removed in vacua or by freeze drying or by exchanging the anions of an existing salt for another anion on a suitable ion-exchange resin. In order to use a compound of the formula (I) or a pharmaceutically acceptable salt thereof for the therapeutic treatment (including prophylactic treatment) of mammals including humans, it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition. In addition to the compounds of the present invention, the pharmaceutical composition of this invention may also contain, or be co-administered (simultaneously or sequentially) .vith, one or more pharmacological agents of value in treating one or more disease conditions referred to herein. The term composition is intended to include the formulation of the active component or a phannaceutically acceptable salt with a pharmaceutically acceptable carrier. For example this invention may be formulated by means known in the art into the form of, for example, tablets, capsules, aqueous or oily solutions, suspensions, emulsions, creams, ointments, gels, nasal sprays, suppositories, finely divided powders or aerosols or nebulisers for inhalation, and for parenteral use (including intravenous, intramuscular or infusion) sterile aqueous or oily solutions or suspensions or sterile emulsions. Liquid form compositions include solutions, suspensions, and emulsions. Sterile water or water-propylene gtycol solutions of the active compounds may be mentioned as an example of liquid preparations suitable for parenteral administration. Liquid compositions can also be formulated in solution in aqueous polyethylene gtycol solution. Aqueous solutions for oral administration can be prepared by dissolving the active component in water and adding suitable cotorants, flavoring agents, stabilizers, and midcening agents as desired. Aqucoas suspensions for oral use can be made by dispersing the finery divided active component in water together with a viscous material such as natural synthetic gums, resins, methyl cellulose, sodium carboxymethyl cellulose, and other suspending agents known to the pharmaceutical formulation art The pharmaceutical compositions can be in unit dosage form. In such form, the composition is divided into unit doses containing appropriate quantities of the active component The unit dosage form can be a packaged preparation, the package containing discrete quantities of the preparations, for example, packeted tablets, capsules, and powders in vials or ampoules. The unit dosage form can also be a capsule, cachet, or tablet itself, or it can be the appropriate number of any of these packaged forms. Combinations The anti-cancer treatment defined herein may be applied as a sole therapy or may involve, in addition to the compound of the invention, conventional surgery or radiotherapy or chemotherapy. Such chemotherapy may include one or more of the following categories of anti-tumour agents: (i) antiproliferative/antineoplastic drugs and combinations thereof, as used in medical oncology, such as alkylating agents (for example cis-platin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan and nitrosoureas); antimetabolites (for example antifolates such as fluoropyrimidines like 5-fhiorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside and hydroxyurea); antitumoitr antibiotics (for example anthracyclines like adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, rnitomycin-C, dactinomycin and mithramycin); antimitotic agents (for example vinca alkaloids like vincristine, vinblastine, vindesine and vinorelbine and taxoids like taxol and taxotere); and topoisomerase inhibitors (for example epipodophyllotoxins like etoposide and teniposide, amsacrine, topotecan and camptothecin); (ii) cytostatic agents such as antioestrogens (for example tamoxifen, toremifene, raloxifene, droloxifene and iodoxyfene), oestrogen receptor down regulators (for example fulvestrant), antiandrogens (for example bicalutamide, flutamide, nilutamide and cyproterone acetate), LHRH antagonists or LHRH agonists (for example goserelin, leuprorelin and buserelin), progestogens (for example megestrol acetate), aromatase inhibitors (for example as anastrozole, letrozole, vorazole and exemcstane) and inhibitors of 5ct-reductase such as finastetidei (iii) agents which inhibit cancer ceB invasion (for example mrrtalloproteinasc inhibitois like marimastat and inhibitors of nrokmase plasim^aogen activator receptor timctioti); (iv) inhibitors of growth factor function, for example such inhibitors include growth factor antibodies, growth iactor receptor antibodies (for example the anti-erbb2 antibody trastuznmab [Herceptin1**] and the anti-erbbl antibody cetuximab [C225]) , faxnesyl transferase inhibitors, tyrosine kinase inhibitors and serine/threonine kinase inhibitors, for example inhibitors of the epidermal growth factor family (for example EGFR family tyrosine kinase inhibitors such as (gefitinib, AZD1839), N-(3^mynylphenyl)^,7-bis(2-methoxyemoxy)qtima2»lm^arnine (erlotinib, OSI-774) and 6-acrylamido-N-(3-chloro-4-fluorophenyl)-7-(3 -morphoh^opropoxy)quma2»lin-4-arnine (CI 1033)), for example inhibitors of the platelet-derived growth factor family and for example inhibitors of the hepatocyte growth factor family; (v) antiangiogenic agents such as those which inhibit the effects of vascular endothelial growth factor, (for example the anti- vascular endothelial cell growth factor antibody bevacizumab [Avastin™], compounds such as those disclosed in International Patent \pplications WO 97/22596, WO 97/30035, WO 97/32856 and WO 98/13354) and compounds that work by other mechanisms (for example linorrride, inhibitors of integrin ctvp3 function and angiostatin); (vi) vascular damaging agents such as Combretastatin A4 and compounds disclosed in International Patent Applications WO 99/02166, WO 00/40529, WO 00/41669, WO 01/92224, WO 02/04434 and WO 02/08213; (vii) antisense therapies, for example those which are directed to the targets listed above, such as ISIS 2503, an anti-ras antisense; (viii) gene therapy approaches, including for example approaches to replace aberrant genes such as aberrant p53 or aberrant BRCA1 or BRCA2, GDEPT (gene-directed enzyme pro-drug therapy) approaches such as those using cytosine deaminase, thymidine kinase or a bacterial nitroreductase enzyme and approaches to increase patient tolerance to chemotherapy or radiotherapy such as multi-drug resistance gene therapy; and (ix) immunotherapy approaches, including for example ex-vivo and in-vivo approaches to increase die hnrramogenicity of patient tumour cells, such as transfection with cytokines such as mtfrfcaalcm 7^ mterigaJrin 4 nr graanmlnrytps-ina^rrylmgft colrnny KHnrnlatjug factor, approaches to decrease T-ceH anergy, approaches using transfected mumme cells such as cytokme-transfected dendritic cells, approaches using cytokme-transfected tumour cell fines and approaches using anti-idiotypic antibodies. Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate dosing of the individual components of the treatment Such combination products employ the compounds of this invention, orpharmaceutically acceptable salts thereof, within the dosage range described hereinbefore and the other pharmaceutically-active agent within its approved dosage range. Synthesis The compounds, or pharmaceutically acceptable salts thereof, of the present invention can be prepared in a number of ways well known to one skilled in the art of organic synthesis. The compounds, or pharmaceutically acceptable salts thereof, of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art. Such methods include, but are not limited to, those described below. All references cited herein are hereby incorporated in their entirety by reference. The novel compounds, or pharmaceutically acceptable salts thereof, of this invention be prepared using the reactions and techniques described herein. The reactions are performed in solvents appropriate to the reagents and materials employed and are suitable for the transformations being effected. Also, in the description of the synthetic methods described below, it is to be understood that all proposed reaction conditions, including choice of solvent, reaction atmosphere, reaction temperature, duration of the experiment and workup procedures, are chosen to be the conditions standard for that reaction, which should be readily recognized by one skilled in the art. It is understood by one skilled in the art of organic synthesis mat the functionality present on various portions of the molecule must be compatible with the reagents and reactions proposed. Such restrictions to the substituents, which are compatible with the reaction conditions, will be readily apparent to one skilled in the art and alternate methods must men be used. The invention will now be further described with reference to the following illustrative examples in which, unless stated otherwise: (i) temperatures are given in degrees Celsius (°C); operations are carried out at room temperature or ambient temperature, mat is, in a range of 1 8-25 *C; (n) organic solutions were dried over anhydrous sodium sul&te; evaporation of organic with a bam temperature of up to 60 °C; (in) chromatography means flash chromatography on silica gel; thin layer chromatography (TLC) was carried out on silica gel plates; (iv) in general, the course of reactions was followed by TLC or liquid chromatography/mass spectroscopy (LC/MS) and reaction times are given for illustration only; (v) final products have satisfactory proton nuclear magnetic resonance (NMR) spectra and/or mass spectra data; (vi) yields are given for illustration only and are not necessarily those which can be obtained by diligent process development; preparations were repeated if more material was required; (vii) when given, NMR data is in the form of delta values for major diagnostic protons, given in part per million (ppm) relative to tetramethylsilane (TMS) as an internal standard, determined at 300 MHz in d6-DMSO unless otherwise stated; (viii) chemical symbols have their usual meanings; (be) solvent ratio was given in volumervolume (v/v) terms. (x) Purification of the compounds were carried out using one or more of the following methods: a) flash chromatography on regular silica gel; b) flash chromatography on silica gel using Isco Combiflash® separation system: RediSep normal phase flash column, flow rate, 30-40 ml/min; c) Gilson semiprep HPLC separation system: YMC pack ODS-AQ column, 100x20 mm, S Sum 12 nm, water (0.1% trifluoroacetic acid) and acetonitrile (0.1% trifluoroacetic acid) as solvents, 20 min run; and (xvi) me following abbreviations have been used: DMF dimemylformamide; EtOAc ethyl acetate; ether diethyl ether; EtOH ethanol; THF tetrahydroruran; MeOH metbanol; and DCM didbJoromethane. Example 1 S-CMcH^NVS-cyclopropyl-lff-pyrazol-^^ A mixture of l-phenylethylamme (73 uL, 0.56 mmol), 2,5-dichloro-4-(5-cyclopropyl-lJT-pyra2»le-3-ylammo)pyrimidine (Method 1,76 mg, 0.28 mmol) in 1-butanol (1.0 ml) was heated at 110°C for 18 hrs. The solvent was removed and EtOAc was added. The solution was washed with water and was concentrated. Semi-prep HPLC (Gilson system) provided product as a solid (91 mg, 92 %). !H NMR (CDC13): 0.72 (m, 2 H), 0.96 (m, 2 H), 1.56 (d, 3 H), 1.85 (m, 1 H), 5.08 (m, 1 H), 5.41 (br s, 1 H), 6.08 (br s, 1 H), 7.22-7.41 (m, 5 H), 7.92 (s, 1 H). Example 2-127 Following a similar procedure to Example 1, the following compounds were synthesized via reaction of a suitable pyrimidine (method of production of which is also listed) and a suitable amine. (Table Remove) Trans-esterification occurred. Example 128 JV2-[(l#')-2-Amino-1 -C4-fluorophenyI')ethvn-S-chIoro-A^4-(5-cvcIopropvl- l/f-pyrazol-3-vl)pvrimidine-2.4-diamine A mixture of 2,5-dichloro-4-(5-cyclopropyl-l/f-pyrazole-3-ylamino)pyrimidine (Method 1; 150 mg, 0.56 mmol) and tert-butyl [(2fl)-2-amino-2-(4-fluorophenyl)ethyl] carbamate (Method 136, 178 mg, 0.70 mmol) in n-butanol was heated at 120°C for 48 hours. Reverse phase HPLC (Gilson) gave the f-butoxycarbonyl protected title compound which was then dissolved in DCM (10 ml) and to it was added trifluoroacetic acid (10 ml) and the mixture was stirred at room temperature for 2 hours. Solvent was evaporated. Reverse phase HPLC (Gilson) gave the desired product that was then transformed to HC1 salt. *H NMR (CD3OD): 5 0.80 (m, 2 H), 1.20 (m, 2 H), 1.10 (m, 2 H), 1.95 (m, 1 H), 5.25 (m, 1 H), 6.10 (m, 2 H), 7.13 (m, 2 H), 7.40 (m, 2 H), 8.13 (s, 1 H). Example 129 A^-('5-Cvclopropvl-lJ/-pvrazol-3-vlV^-[a^-l-r4-fluorophenvDethvl1pvrimiduie-2.4.S-triamine A flask with 10% palladium on carbon (66 mg, 0.06 mmol) was evacuated and refilled with Hz (balloon). To it was added a solution of ^-(S-cyclopropyl-l/if-pyrazol-S-yl)-^-^!^)-l-(4-fluorophenyl)emyl]-5-rjitropyrimidme-2>4^arnine (Example 101, 120 mg, 0.31 mmol) in EtOH (5 ml). The reaction mixture was stirred at room temperature for 20 hours. Filtration followed by concentration gave the desired product as a solid (100 mg, 91%). *H NMR: 5 0.70 (m, 2 H), 0.98 (m, 2 H), 1.47 (m, 3 H), 1.92 (m, 1 H), 5.03 (m, 1 H), 6.20 (m, 2 H), 7.13 (m, 2 H), 7.40 (m, 2 H), 8.83 (s, 1 H), 10.40 (br s, 1 H). Examples 130 Following a similar procedure to Example 129, the following compound was synthesized via reaction of a suitable aminopyrimidine (method of production of which is also listed) and palladium on activated carbon. Example 131 4-[f5-Cyclopropvl-l//-pvrazol-3-vnamino]-2-{[(l^-l-r4-fliiorophenvlkthvl1amino} pyrimidine-5-carbonitrile To a solution of 5-bromo-N4-(3-cyclopropyl-l//-pyrazol-5-yl)-N2-[(15)-l-(4-fluorophenyl)ethyl]pyrimidine-2,4-diamine (Example 5, 250 mg, 0.6 mmol) in quinoline (2 ml) was added copper (I) cyanide (75 mg, 0.84 mmol) and the mixture was heated in microwave at 180°C for 5 hours. Reverse phase HPLC (Gilson) purification gave the desired product as a solid (67 mg, 30%). ]H NMR: 6 0.60 (m, 2 H), 0.90 (m, 2 H), 1 .47 (m, 3 H), 1.80 (m, 1 H), 5.10 (m, 1 H), 5.95 (m, 0.4 H), 6.20 (m, 0.6 H), 7.13 (m, 2 H), 7.35 (m, 2 H), 7.70 (s, 1 H), 8.80 (m, 1 H), 10.95 (br s, 1 H). Example 132 fhioropheaivlk!tnvlTpvrimidine-2.4-diamme Example 133 fluorophenvl')ethylTpvriniidine-2 The title compounds were syntheisised by purification of 5-chloro-7V*-(5-cyclopropyl-l/f-pyrazol-3 -yl)-Jv*-[2^^-trifiuoro- 1 ^4-fluorophenyl)emyl]pyrirnidine-2,4-diamine (Example 1 87) with a chiral HPLC with Diode Array Detection at 220 nm: Column: Chiralcel OJ, 250 x 20 mm, lOu Conditions: 50% EtOH 50% MeOH 0.1% diethylamine; Flow rate 10 ml/min Chiral purity determined using chiral HPLC with Diode Array Detection at 220 nm: Column: Chiralcel OJ, 250 x 4.6 mm, lOu Conditions: 50% EtOH 50% MeOH 0.1% diethylamine; Flow rate 0.5 ml/min Enantiomeric excess (e.e.) > 99% fro each isomer, calculated using area percent at 220 nm for each enantiomer. OS)-isomer: (H NMR: 8 0.73 (m, 2 H), 0.94 (m, 2 H), 1.92 (m, 1 H), 5.96 (m, 1 H), 6.16 (m, 2 H), 7.24 (m, 2 H), 7.63 (m, 2 H), 8.01 (s, 1 H), 8.16 (br s, 1 H), 8.80 (br s, 1 H). CR)-isomer: ]H NMR: 5 0.65 (m, 2 H), 0.86 (m, 2 H), 1.80 (m, 1 H), 5.90 - 6.10 (m, 2 H), 7.20 (m, 2 H), 7.55 (m, 2 H), 7.95 (s, 1 H), 8.40 (br s, 1 H), 9.35 (br s, 1 H). Example 134 N4-(5-Cvclopropvl-lH-pvrazol-3-vlVN2-rn^-l-(4-fluorophenvnethvl1-7-(2-methoxvethoxv)quinazoline-2.4-diamine A mixture of ^-(S-cyclopropyl-l^-pyrazol-S-y^-T-fluoro^-tCl fluorophenyl) ethyl]quinazoline-2,4-diamine (Example 77, 25 mg, 0.06 mmol), 2-methoxyethanol (0.18 ml, 2.26 mmol), potassium terf-butoxide (60 mg, 0.53 mmol) was heated at 120°C for 18 hours. EtOAc was added to the reaction mixture. The solution was washed with water and was concentrated. Flash column chromatography (pure EtOAc to EtOAc/MeOH = 9:1) provided product as a solid (30 mg, 60 %). *H NMR (CD3OD): 0.73 (m, 2 H), 1.02 (m, 2 H), 1.61 (d, 3 H), 1.95 (m, 1 H), 3.41 (s, 3 H), 3.78 (m, 2 H), 4.26 (m, 2 H), 5.22 (m, 1 H), 6.14 (br s, 1 H), 6.95 (m, 1 H), 7.06 (m, 3 H), 7.34 (m, 2 H), 8.18 (d, 1 H). Examples 135-140 Following a similar procedure to Example 134, the following compounds were synthesized via reaction of a suitable quinazoline (method of production of which is also listed) and a suitable alcohol. (Table Remove) Example 141 (2^-3-r(4-ff5-Cvclopropvl-lH-pvrazol-3-vnamino1-2-(rri^)-l-f4-fluorophenvn-2-hydroxyethvl] amiao} qtiinazolin-7-vl)oxv1propane-1.2-diol A mixture of (2R)-2-({4-[(5-cyclopropyl- l#-pyrazol-3-yl)amrno]-7-fluoroquinazolin-2-yl}amino)-2-(4-fluorophenyl)ethanol (Example 78, 50 mg, 0.12 mmol), [(4/?)-2,2-dimethyl-l,3-dioxolan-4-yl]methanoI (0.4 ml) and potassium terf-butoxide (100 mg, 0.9 mmol) was stirred at 120°C overnight. Aqueous work up provided a residue. To a solution of this residue in MeOH (2 ml) was added two drops of water and para-toluenesulfonic acid monohydrate (7 nog, 0.037 nomol) and the reaction mixture was stirred at room temperature for 20 hours. Reverse phase HPLC (Gilson) purification gave the desired product as a solid. !H NMR: 5 0.70 (m, 2 H), 0.97 (m, 2 H), 1.91 (m, 1 H), 3.45 (m, 2 H), 3.60 - 4.00 (m, 4 H), 4.18 (m, 1 H), 5.14 (m, 1 H), 6.09 (m, 1 H), 6.90 - 7.50 (m, 6 H), 8.50 (m, 1 H), 8.63 (m, 1 H), 11.22 (m, 1 H), 12.21 (br s, 1 H). Example 142 Following a similar procedure to Example 141, the following compound was synthesized via reaction of a suitable quinazoline (method of production of which is also listed). Example 143 r2J?V2-((5-(^oro^-r(3-cvclopropvl-l/f-pwazol-5-vl)amino]-6-[r2-morpholui-4-vlethvn ammo1pyrimidin-2-vUaraino)-2-(4-fluorophenvl')ethanol A mixture of (2-morpholin-4-ylethyl)amine (44 ^1, 0.34 mmol), (2/?)-2-({4,5-dichloro-6-[(3-cyclopropyl-l/f-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-2-(4-fluorophenyl)ethanol (Example 84,70 mg, 0.16 mmol) in 1-butanol (1.0 ml) was heated at 120°C for 18 hours. The solvent was removed and EtOAc was added. The solution was washed with water and was concentrated. Semi-prep HPLC (Gilson system) provided product as a solid (92 mg). *HNMR (CDC13): 0.67 (m, 2 H), 0.92 (m, 2 H), 1.86 (m, 1 H), 3.01 (m, 2 H), 3.22 (m, 2 H), 3.46 (m, 2 H), 3.63 (m, 4 H), 3.86 (m, 2 H), 3.98 (m, 2 H), 4.89 (m, 1 H), 5.93 (s, 1 H), 7.14 (m, 2 H), 7.38 (m, 2 H), 7.95 (br s, 1 H), 9.15 (br s, 1 H), 9.54 (br s, 1 H). Example 144-176 Following a similar procedure to Example 143, the following compounds were synthesized via reaction of a suitable pyrimidine or quinazoline (method of production of which is also listed) and a suitable amine. (Table Remove) (2RV3-rr5-Chloro-6-r(3-ethoxv-lH-pvrazo1-5-Yl)aminnl-2-(rflSVl-r4-fluorophenyDethyl]amino}pyrimidin-4-vl)amino]propane-1.2-diol A mixture of 5,6-dichloro-7V4-(5-ethoxy-ljyr-pyrazol-3-yl)-A^-[(l,S)-l-(4-fluorophenyl)ethyl]pyrimidine-2,4-diamine (Example 191; 188 mg, 0.46 mmol), (2#)-3-aminopropane-l,2-diol (96 mg, 1.05 mmol) in n-butanol (2.5 ml) was heated at 112°C for 2 days. The mixture was concentrated. Reverse phase HPLC (Gilson) purification gave the title compound (18 mg). !H NMR (CDC13): 5 1.29 (t, 3 H), 1.40 (d, 3 H), 3.18 - 3.61 (m, 5 H), 4.08 (q, 2 H), 4.93 (m, 1 H), 5.44 (s, 1 H), 6.59 (br s, 1 H), 7.11 (m, 2 H), 7.38 (m, 2 H), 7.86 (brs, 1H), 9.27 (brs, 1 H). Example 178-181 Following a similar procedure to Example 177, the following compounds were synthesized via reaction of a suitable pyrimidine (method of production of which is also listed) and a suitable amine. (Table Remove) Example 182 N4-(5-Cvclopropvl-2H-pvrazol-3-vn-N2-rrSVl-r4-flnorophenvlVethvn-5.6.7.8-tctrahvdro-rryrido[43-d1pvrimidine-2.4-diamine 4-(5-Cyclopropyl- l/f-pyrazol-3-ylamino)-2- [(5)- 1 -(4-fluoro-phenyl)-ethylamino]-7,8- \ dihydro-5#-pyrido[4,3-^pyrirmdme-6-carboxylic acid benzyl ester (Example 188; 0.06 g, 0.1 1 mmol) was dissolved in absolute EtOH (4 ml), to which was added Pd/C (0.012 g, 0.005 mmol). The reaction mixture was then purged with Nj, evacuated, purged with Hb, and stirred under Ha at atmospheric pressure for 15 hours. The Pd/C was removed by filtration and washed with MeOH (2x2 ml). The filtrate was concentrated under reduced pressure and purified by column chromatography (DCM: MeOH = 20: 1) to give the title compound as a white solid (0.02 g, 44%). 1U NMR (400 MHz, CDC13) 5 0.62 - 0.66 (m, 2 H), 0.87 - 0.91 (m, 2 H), 1.47 (d, J= 6.4 Hz, 3 H), 1.73 - 1.81 (m, 1 H), 2.51 - 2.59 (m, 2 H), 2.99 - 3.09 (m, 2 H), 3.58 - 3.67 (m, 2 H), 4.99 - 5.06 (m, 1 H), 5.19 (br s, 2 H), 5.89 (br s, 1 H), 6.74 (br s, 1 H), 6.94 - 6.98 (m, 2 H), 7.29 - 7.33 (m, 2 H). MS: CalcA: 393; Found: [M+Hf 394. Example 183 pyrido[2.3- To an EtOH (20 ml) solution of N4-N2-[(15)-l-(4-fluorophenyl)emyi]pyrido[2,3-d]pyrimidine-2,4-diamine (Example 65; 0.3 g, 0.77 mmol) was added platinum oxide (0.017 g, 0.077 mmol). The reaction was then purged with Na, evacuated, and then purged with Ha, and stirred for 15 hours. The reaction was then diluted with MeOH (20 ml) and filtered to remove platinum. The filtrate was concentrated under reduced pressure and purified by column chromatography (DCM: MeOH = 40: 1) to give the title compound as a solid (0.25 g, 83%). >H NMR (400 MHz, CDC13) S 0.62 - 0.66 (m, 2 H), 0.84 - 0.87 (m, 2 H), 1.44 (d, J= 6.4 Hz, 3 H), 1.79 - 1.84 (m, 1 H), 1.85 - 1.91 (m, 2 H), 2.30 (t, J= 6.2 Hz, 2 H), 3.24 - 3.26 (m, 2 H), 4.79 (br s, 1 H), 4.98 (br s, 2 H), 6.54 (br s, 1 H), 6.93 - 6.97 (m, 2 H), 7.29 - 7.33 (m, 2 H). MS: Calcd.: 393; Found: [M+H]+394. Example 184 pyridor3 .4- Example 185 A solution of /^5^clopropyl-2H-pyrazol-3-yl)-[(iS^ 5,6,7,8-tetrahydro-pyrido[43^pyrraridme-2,4^amine (Example 182, 0.03 g, 0.08 mmol) in DCM-THF (3 ml, 1 : 1, v/v) was agitated together with acetic acid loaded TFP (tetrafmorophenyl) resin (1.4 mmol/g, 1.0 eq.) for 40 minutes. The resin was filtered and washed with DCM (2x5 ml). The combined organic was concentrated and purified by prep. TLC (DCM: MeOH =15:1) to give the title compound (0.027 g, 81%). 1H NMR (400 MHz, CDC13) 5 0.71 - 0.72 (m, 2 H), 0.90 - 0.92 (m, 2 H), 1.47 (d, J= 6.4 Hz, 3 H), 1.84 - 1.89 (m, 1 H), 2.20 (s, 3 H), 2.63 - 2.73 (m, 2 H), 3.56 - 3.77 (m, 2 H), 4.43 (d, J = 15.8 Hz, 1 H), 4.70 (d, J = 15.8 Hz, 1 H), 5.07 - 5.15 (m, 2 H), 5.99 (br s, 1 H), 6.94 - 6.99 (m, 2 H), 7.24 - 7.32 (m, 2 H), 9.28 (br s, 1 H). MS: Calcd.: 435; Found: [M-fH]+436. Example 186 l-(4-(5-CyclopropyI-l/f-pvrazol-3-vtaminoV2-[(iy)-l-(4-fluoro-phenvD-ethylamino]-5.8-dihvdro-6//-pyrido[3.4-cf|pvrimidin-7-vl}-etfaanone A solution of y-(5-cyciopropyl-l#-pyrazol-3-yl)- ^-[(.S^-l-^-fluoro-phenyty-ethyl]-5,6,7,8-telrahydro-pyrido[2,3-^pyrimidine-2,4-diamine (Example 184; 0.05 g, 0.13 mmol) in DCM: THF (3 ml, 1 : 1, v/v) was agitated together with acetic acid loaded TFP resin (1.4 mmol/g, 1.0 eq.) for 40 minutes. The resin was filtered and washed with DCM (2x5 ml). The combined organic was concentrated and purified by prep. TLC (DCM: MeOH =13:1) to give the title compound (0.023 g, 41%). 'HNMR (400 MHz, CDC13) 6 0.68 - 0.70 (m, 2 H), 0.93 -0.95 (m, 2 H), 1.52 (d, J= 6.2 Hz, 3 H), 1.82 - 1.85 (m, 1 H), 2.14 (s, 3 H), 2.36 - 2.46 (m, 2 H), 3.65 - 3.90 (m, 2 H), 4.31 - 4.49 (m, 2 H), 5.07 - 5.17 (m, 2 H), 6.05 (br s, 1 H), 6.96 -7.01 (m, 2 H), 7.30 - 7.36 (m, 2 H). MS: Calcd.: 435; Found: [M+Hf 436. Example 187 pyrimio1ine-2.4-diamine The title compound was synthesized in a similar fashion to Example 1 using [2,2,2-trifluoro-l-(4-fluorophenyl)ethyl]amine (synthesized following the procedure of Tetrahedron Asymmetry 2002, 73, 2335-44). 'H NMR: 8 0.73 (m, 2 H), 0.94 (m, 2 H), 1.92 (m, 1 H), 5.96 (m, 1 H), 6.16 (m, 2 H), 7.24 (m, 2 H), 7.63 (m, 2 H), 8.01 (s, 1 H), 8.16 (hr s, 1 H), 8.80 (br Eiample 188 4-(5-Cvclopropvl-l#-pvrazol-3-vlaiidpoV^^ dihvdro-5H-pvridor43-|pvrimidine-6-carboxvlic acid benzyl ester A solution of 4-(5-cyclopropyl-l//-pyrazol-3-ylamino)-2-methanesulfonyl-7,8-dihydro-5//-pyrido[4,3-cTlpyrimidine-6-carboxylic acid benzyl ester (Method 144; 0.10 g, 0.21 mmol), (S)-l-(4-fluoro-phenyl)-ethylamine (0.30 g, 2.1 mmol), and DIPEA (0.27 g, 2.1 mmol) in n-BuOH (3 ml) was heated to 1 10 °C in a sealed tube for 48 hours. The reaction was cooled to 25 °C, concentrated under reduced pressure, acidified with 0.5 N HC1 (50 ml), and extracted with DCM (3 x 50 ml). The combined organic layer was dried over MgSOij, concentrated, and purified by column chromatography (DCM: MeOH = 80: 1) to give the title compound (0.6 g, 54%). MS: Calcd.: 527; Found: [M+H]+ 528. Example 189 ^(5-Cyclopropyl-l/f-pvra2ol-3-vlarninoV2-[(5^-l-r4-fluoro-phenylVethvlamino1-5.8-HihydrQ-6//-pvrido[3,4-t/]pyrimidiDe-7-carboxylic acid benzyl ester A mixture of 4-(5-cyclopropyl-l/f-pyrazol-3-ylamino)-2-methanesulfonyl-5,8-dihydro-6fl-pyrido[3,4-^pyrimidine-7-carboxyUc acid benzyl ester (Method 149; 2.0 g, 4.3 mmol), (S>l-(4-fluoro-phenyl)-ethylamine (0.30 g, 2.1 mmol), and DIEA (5.5 g, 42.6 mmol) n-BuOH (1 5 ml) was heated to 1 10 °C in a sealed tube for 48 hours, cooled to 25 °C, concentrated, acidified with 0.5 N HCI (100 ml), and extracted with DCM (3 x 150 ml). The combined organic layer was dried over MgSCU, concentrated, and purified by column chromatography (DCM: MeOH = 80: 1) to give the title compound (0.7 g, 31%). MS: Calcd.: 527; Found: [M+H]+ 528. Example 190 6-Chloro-JV2-rf LSV-1 -(4-fluorophenvl')etfavll-JV*-(5-mettivl- lH-pvrazol-3-yl^yrimidine-2.4-diamine This title compound was prepared in a similar way to the preparation of Example 1 using 2,6^cMoro-#^5-memyl-l/f-pyrazol-3-yl)pyr^ (Method 150) and [(15)- l-(4-fluorophenyl)ethyl]amine. 'HNMR: 5 1.45 (s, 3 H), 2.20 (m, 3 H), 5.10 (m, 1 H), 5.85 -6.10 (m, 2 H), 7.10 (m, 2 H), 7.40 (m, 2 H), 7.80 (m, 1 H), 8.60 (m, 1 H). Example 191 2.4-diamine A mixture of 2,5,6-tricUoro-7^-(3-ethoxy-l/f-pyrazol-5-yl)pyrimidin-4-amine (Method 40; 300 mg, 0.98 mmol), [(15)-l-(4-fluorophenyl)ethyl]amine (163 mg, 1.2 mmol) and triethylamine (0.16 ml) in n-butanol (2 ml) was heated at 106°C for 3 days. The mixture was concentrated. Reverse phase HPLC (Gilson) purification gave the title compound (198 mg). !HNMR (CDC13): 6 1.40 (m, 3 H), 1.52 (m, 3 H), 4.18 (m, 2 H), 4.93 - 5.50 (m, 2 H), 7.11(m,2H),7.38(m,2H). Example 192-193 Following a similar procedure to Example 1, the following compounds were synthesized via reaction of a suitable pyrimidine (method of production of which is also listed) and a suitable amine. Preparation of starting materials: The starting materials for the Examples contained herein are either commercially available or are readily prepared by standard methods from known materials. For example the following reactions are illustrations but not limitations of the preparation of some of the starting materials and examples used herein. Method 1 2J-DicMoro^-(5-cvclopropvl-l/f-pyrazole-3-vlammo)pvrimidme A solution of 2,4,5-rrichloropyrimidine (533 mg, 2.93 mmol), 3-amino-5-cyclopropyl-Iff-pyrazole (360 mg, 2.93 mmol) and triethylamine (0.49 ml) in EtOH (5 ml) was stirred at room temperature for 10 hours. Solvent was removed and EtOAc was added. The solution was washed with water and dried over anhydrous sodium sulfate and was concentrated to give title compound as a white solid (546 mg, 69%). The compound was carried to the next step without further purification. 'HNMR 5 0.92 (m, 2 H), 1.20 (m, 2 H), 2.18 (m, 1 H), 6.40 (s, 1 H), 8.60 (s, 1 H), 9.90 (s, 1 H), 12.60 (s, 1 H). Method 2-19 The following compounds were prepared by the procedure of Method 1 using the appropriate starting materials. (Table Remove) The reaction is similar to Method 1 except that the reaction was performed at -20 °C b The reaction is similar to Method 1 except that the reaction was performed at 70 °C c The ethoxy group resulted from transesterification with solvent Method 20 TV-Methyl-1 -pvridin-2-ylethanamine To l-pyridin-2-ylethyl methanesulfonate (Tetrahedron Asymmetry 1994, 5,1973-78; 800 mg, 4 mmol) was added methylamine (2.0 M in THF, 10 ml, 20 mmol) and the reaction mixture was stirred at 50°C overnight. The solvent was removed to give the desired product as an oil (544 mg, quantitative yield). ]H NMR (CDC13): 5 1.40 (m, 3 H), 2.35 (s, 3 H), 3.75 (m, 1 H), 7.15 (m, 1 H), 7.25 (m, 1 H), 7.63 (m, 1 H), 8.56 (m, 1 H). Method 21 1 -Amino-1 -phenylpropan-2-ol The diasteroisomeric mixture was prepared according in a similar fashion to a known procedure (/. Org. Chem. 1991, 56, 6939-6942). Method 22 3-fTrifluoroniethylV Lff-pyrazol-5-ainine A solution of 4,4,4-trifhioro-3-oxo-butyronitrile (Method 23; 11.0 g, 0.080 mol) and hydrazine monohydrate (3.89 ml, 0.080 mol) in EtOH (400 ml) was heated at reflux for 5 hours. After cooling to 25 °C, the solvent was removed under reduced pressure. The resulted residue was dissolved in DCM (500 ml), washed with brine (2 x 200 ml), and dried over Na2SO4. After evaporation of the solvent, the resulted residue was purified by column chromatography (hexane: EtOAc = 1: 1) to give the title compound as a pale yellow solid (1.93 g, 16%). 'H NMR (400 MHz): 8 5.35 (s, 2 H), 5.56 (s, 1 H), 12.10 (br s, 1 H). Method 23 4.4.4-Trifluoro-3-oxo-butvronitrile 60% NaH (9.6 g, 0.24 mol) was suspended in dioxane (400 ml), to which was added acetonitrile (12.62 ml, 0.24 mol) dropwise. The reaction mixture was stirred at 25 °C for 30 minutes, followed by addition of ethyl trifloroacetate (23.8 ml, 0.2 mol). The reaction mixture was heated to reflux for 3 hours, cooled to 25 °C, and quenched with water (400 ml). The unreacted starting material was extracted with DCM (100 ml). The aqueous layer was acidified with 10% HC1 to pH 3 and extracted with DCM (100 ml). The organic layer was dried over Na2SO4, concentrated under reduced pressure, and purified by chromatography (hexane: EtOAc = 5: 1) to give the title compound as a white solid (1 1 .0 g, 40%). *H NMR (400 MHz, CDC13) 8 4.72 (s, 1 H). Method 24 ( 1 -PyridiD-2-vlethvDamine To a mixture of l-pyridin-2-yl-ethanone (0.20 g, 1.65 mmol) and ammonium choride (0.88 g, 16.5 mmol) in MeOH (5 ml) was added sodium cyanoborohydride (0.125 g, 1.98 mmol). The reaction was stirred at 25 °C for 64 hours and quenched by addition macroporous polystyrene sulfonic acid (MP-TsOH) (4.08 g, 16.5 mmol) resin. The suspension was agitated for 1 hour. The resin was collected by filtration and washed with MeOH (3 x 20 ml, 20 minute shaking per wash). The resulted resin was then treated with NHa/MeOH solution (7 M, 15 ml) for 20 minutes, filtered, and washed with MeOH (2x15 ml). The combined filtrate was concentrated until the crude weighed 200 mg. The crude product contained about 30% desired product, 35% alcohol, and 35% dimmer as indicated by LC/MS, and was directly used without further purification. Method 25 The solution of 2,4,5-tri Method 26 3-Oxo-4-phenvl butvronitrile NaH (60% in mineral oil, 0.48 g, 12.0 mmol) of) was suspended in dioxane (20 ml), to which was added acetonitrile (0.63 ml, 12 mmol) dropwise. The reaction was stirred for 20 minutes, followed by addition of ethyl phenylacetate (10 mmol) solution in dioxane (8 ml). The mixture was refluxed for 4 hours, cooled to 25 °C, and quenched with HjO (40 ml). The unreacted starting material was extracted with DCM (40 ml). The aqueous layer was acidified with 1 N HC1 to pH 5 and extracted with DCM (40 ml). The organic layer was dried over anhydrous NajSO^ concentrated, and purification by column chromatography (hexane: EtOAc = 3:2) to afford the title compound (0.58 g, 36%). !H NMR (400 MHz, CDC13) 6 3.45 (s, 2 H), 3.85 (s, 2 H), 7.2 - 7.28 (m, 5 H). MS: Calcd.: 159; Found: [M-H]' 158. Method 27 5-Benzyl-2H-pyrazol-3-vlamine A solution of 3-oxo-4-phenyl buryronitrile (Method 26; 0.58 g, 3.64 mmol) and hydrazine monohydrate (0.177 ml, 3.64 mmol) in EtOH (16 ml) was heated to reflux for 3 hours. After cooling to 25 °C, the reaction was concentrated under reduced pressure, extracted with DCM (15 ml), and washed twice with brine. The organic layer was dried over anhydrous Na2SC>4 and concentrated to give an orange solid. The resulted solid was triturated with hexanes: ether (1:1) solution and collected by filtration to afford the title compound as a yellow solid (0.38 g, 60%). JH NMR (400 MHz, CDC13) 5 3.9 (s, 2 H), 4.89 (br s, 1 H), 5.44 (s, 1 H), 7.19 - 7.34 (m, 5 H). MS: Calcd.: 173; Found: [M+H]+174. Method 28 f2.S-DicMoro-pvrimidm^yl)-C5-isopropyl-2Jy-p\n^oI-3-yl)-arnine A solution of 5-isopropyl-2jyr-pyrazol-3-ylamine (Method 29; 0.093 g, 0.74 mmol), 2,4,5-trichloropyrimidine (0.150 g, 0.82 mmol), and triethylamine (0.36 ml, 2.6 mmol) in EtOH (5 ml) was heated to 55°C for 5 hours and stirred at 25 °C overnight. The reaction mixture was concentrated under reduced pressure, triturated with DCM to afford the title compound(0.192,95%). !H NMR (400 MHz,CDC13)8 1.34-1.37 (d, J=7.0Hz,6H),3.07 - 3.14 (q, 1 H), 6.72 (s, 1 H), 8.20 (s, 1 H). MS: Calcd.: 271; Found: [M+Hf 272. Method 29 5 -Isopropvl-2#-pvrazol-3 -ylamine A solution of 4-methyl-3-oxo-pentanenitrile (Method 30; 0.42 g, 3.78 mmol) and hydrazine monohydrate (0.183 ml, 3.78 mmol) in EtOH (20 ml) was heated to reflux for 1 hour, cooled, and then concentrated under reduced pressure. The resulted oil was dissolved with DCM, washed with brine, dried over anhydrous Na2SO4, concentrated, and purification by column chromatography (EtOAc: MeOH = 20: 1) to the title compound as an orange solid (0.26 g, 56%). 'H NMR (400 MHz, CDC13) 5 1.21 - 1.23 (d, J= 7.0 Hz, 6 H), 2.82 - 2.89 (q, 1 H), 5.42 (s, 1 H). MS: Calcd.: 125; Found: [M+Hf 126. Method 30 4-Methyl-3 -oxo-pentanenitrile NaH (60% in mineral oil, 0.72 g, 18 mmol) was suspended in dioxane (20 ml), to which was carefully added ethyl isobutyrate (2.0 ml, 15 mmol) followed by addition of acetonitrile (0.95 ml, 18 mmol). The reaction mixture was refluxed for 5 hours, cooled, and quenched with water (40 ml). The unreacted starting material was extracted with DCM. The aqueous layer was acidified with 1 N HQ to pH 5 and extracted with DCM. The organic kyer was dried over Na2SC>4, concentrated, and purification by column chromatography (hexane: EtOAc = 3:2) to give the title compound (0.43 g, 26%). *H NMR (400 MHz, CDC13) 6 1.13 - 1.15 (d,7=7.0, 6H), 2.73-2.79 (q, 1 H), 3.52 (s,2H).MS: Calcd.: Ill; Found: [M-H]' 110. Method 31 5-CVclopropvtoernyl-2#-p\Trazol-3-ylW2»5-dicM^ A solution of 2,4,5-trichloropyrimidine (0.2 g, 1.1 mmol), 5-cyclopropyhnethyl-2ff-pyrazol-3-ylamine (Method 32; 0.14 g, 0.99 mmol), and triethylamine (0.15 g, 1.5 mmol) in EtOH (5 ml) was heated to 55 °C overnight The solvent was removed under reduced pressure and the resulted solid was triturated with DCM to afford the title compound as a white solid (0.206 g, 73%). !H NMR (400 MHz, CDC13) 6 0.008 (m, 2 H), 0.363 (m, 2 H), 0.801 (m, 1 H), 2.36 - 2.38 (d, J= 7.0 Hz, 2 H), 6.49 (s, 1 H), 7.93 (s, 1 H). MS: Calcd.: 283; Found: [M+H]+284. Method 32 5-Cvclopropvlmethvl-2jy-pvrazol-3-vlamine A solution of 4-cyclopyropyl-3-oxo-butyronitrile (Method 33; 1.0 g, 8.1 mmol) and hydrazine monohydrate (0.4 g, 8.1 mmol) in EtOH (35 ml) was heated to reflux for 2 hours, cooled, and concentrated under reduced pressure. The resulted residue was taken up in DCM, washed with brine, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography (EtOAc: MeOH: EtaN = 94 : 5 : 1) to afford the title compound (0.464 g, 42%). 'H NMR (400 MHz, CDC13) 5 0.005 (m, 2 H), 0.370 (m, 2 H), 0.78 (m, 1 H), 2.27 - 2.29 (d, J= 7.0 Hz, 2 H), 5.07 (br s, 1 H), 5.32 (s, 1 H). MS: Calcd.: 137; Found: [M+H]+ 138. Method 33 4-Cvclopropvl-3-oxo-butvronitrile Cyanoacetic acid (8.5 g, 100 mmol) solution in EtOAc (200 ml) was treated with anhydrous MgSO4 and stirred for 20 minutes. MgSO4 was removed by filtration and the filtrate was concentrated under reduced pressure. The resulted white solid was dissolved in THF (166 ml) and 5 mg of 2,2>-bipyridine was added as an indicator. The reaction solution was cooled to -78°C, to which was added n-butyllithium solution (80 ml, 199 mmol). The reaction mixture was allowed to warm to 0 °C gradually then cooled to -78 °C again, to which was added cyclopropyl-acetyl chloride (Method 34; 5.9 g, 50 mmol) in DCM (80 ml) via an addition funnel. The reaction mixture was then stirred at 25 °C for 1 hour, quenched with 2 N HC1 and extracted with chloroform. The organic layer was washed with a saturated sodium bicarbonate solution, brine, dried with MgSC>4, concentrated, and purified by column chromatography (EtOAcrMeOH = 20:1) to give the title compound (1.0 g, 16% yield). !H NMR (400 MHz, CDC13) 6 0.019 (m, 2 H), 0.472 (m, 2 H), 0.832 (m, 1 H), 2.29 - 2.32 (d, J= 7.0 Hz, 2 H), 3.38 (s, 2 H). Method 34 Cvclopropvl-acetvl chloride To the DCM (30 ml) solution of cyclopropyl acetic acid (5.0 g, 49.9 mmol) with 6 drops DMF, was slowly added the solution of oxalyl chloride (5.2 ml, 59.9 mmol) in DCM (5 ml). After completion of the addition, the reaction solution was stirred at 25 °C for 4 hours. Evaporation of the solvent under reduced pressure gave the title compound as a bright yellow solid (5.9 g, 99.6%). 1H NMR (400 MHz, CDC13) 5 0.018 (m, 2 H), 0.421 (m, 2 H), 0.896 (m, 1 H), 2.53 - 2.55 (d, /= 5.85 Hz, 2 H). Method 35 (5-Cvclopropvlmethoxv-l//-pvrazol-3-vlVf2.5-dichloro-pvrimidin-4-vlVamine A solution of 2,4,5-trichloropyrimidine (0.30 g, 1.6 mmol), 5-cyclopropylmethoxy-l/f-pyrazol-3-ylamine (Method 44; 0.23 g, 1.5 mmol), and triethylamine (0.23 ml, 2.2 mmol) in EtOH (8 ml) was heated to 55 °C overnight. The reaction was concentrated under reduced pressure and purification by column chromatography (hexane: EtOAc = 1 : 1) to give the title compound (0.20 g, 6%). ]H NMR (400 MHz): d 0.321 (m, 2 H), 0.552 (m, 2 H), 0.863 (m, 1 H), 3.90 (d, J= 7.0 Hz, 2 H), 5.8 (s, 1 H), 8.41 (s, 1 H). MS: Calcd.: 299; Found: [M+Hf 300. Methods 36-43 The following compounds were prepared by the procedure of Method 35 using the appropriate starting materials. (Table Remove) Method 44 5-CyclopmpylTnethoxy-lff-pvrazol-3-vlamiiie Triphenylphosphine (16.0 g, 61 mmol), 5-amino-2jFf-pyrazol-3-ol (5.5 g, 56 mmol), and cyclopropyl methanol (4.4 g, 61 mmol) were dissolved in THF (100 ml), to which was slowly added the diisopropyl azodicarboxylate (12 ml, 61 mmol) solution in THF (50 ml). The reaction mixture was stirred for 1 hour, diluted with DMF (45 ml), and allowed at 25 °C overnight The solvent was removed under reduced pressure. The resulted residue was treated with water, extracted with EtOAc twice and DCM once. The combined organics were dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by column chromatography (EtOAc) to give the title compound (1.3 g, 15%). MS: Calcd.: 153; Found: [M+H]+ 154. Method 45-48 The following compounds were prepared by the procedure of Method 44 using the appropriate starting materials. (Table Remove) Method 49 iri^-l-[4-(TrifluoromethvlV1.3-thiazol-2-vl]ethvUamme To a solution of (5)-JV-ben2yloxycarbonyl-l-(4-trifluoromethyl-thiazol-2-yl)-ethylamine (Method 50; 0.45 g, 1.36 mmol) in anhydrous CH3CN (5 ml) was added TMS-I (0.23 ml, 1.64 mmol) at 25 °C. The reaction was stirred at room temperature for 30 minutes, quenched with cold HCl/ethyl ether solution (2 N, 10 ml), and diluted with ethyl ether (40 ml). The precipitate was quickly collected by filtration and washed with ether. The resulted solid was treated with 10 ml of saturated NaHCOs, extracted with ethyl ether (3 x 20 ml). The combined organic was washed with brine (20 ml) and dried over Na2SO4- The solvent was evaporated under reduced pressure at below 20 °C (Note: mis product is volatile, high-vacuum should be avoided). The crude product as a light brown, oil (0.24 g, 90%) was used without further purification. Method 50 r^-7V'-BeD2^1oxycarbonvl-1^4-trifluoromemyl-miazol-2-yl)-emylarnine ^-Benzyloxycarbonyi-L-alanine thiamide (Method 51; 1.0 g, 4.2 mmol) and 3-bromo-l,l,l-trifluoro-propan-2-one (0.52 ml, 5.0 mmol) were dissolved in acetone (10 ml) and heated to reflux for 6 hours. The reaction was cooled to 25 °C and the solvent was removed under reduced pressure. The reaction resultant was treated with saturated NaHCOs solution (15 ml), extracted with EtOAc (15 ml), washed with H2O (2x15 ml), brine (15 ml), and dried over Na2SO4. After evaporation of the solvent, the crude material was purified by silica-gel chromatography (hexane: EtOAc = 2: 1) to give the title compound as a yellowish oil (1.1 g,79%). 1HNMR(400MHz,CDCl3)5 1.65 (d, J= 6.4 Hz, 3 H), 5.15 (m, 3 H), 5.31 (br s, 1 H), 7.30 (m, 5 H), 7.68 (s, 1 H), MS: Calcd.: 330; Found: [M+H]+ 331. Method 51 A^-Benzyloxvcarbonyl-L-alanine thiamide JV^-Benzyloxycarbonyl-L-alanine (10.0 g, 44.8 mmol) in THF (150 ml) was treated with l.l'-carbonyldiimidazole (GDI) (21.79 g, 134.4 mmol) at 25 °C for 4 hours. With ice-H2O cooling, NHs was bubbled through for 1 hour. The reaction mixture was allowed to stir at 25 °C overnight. THF was removed at reduced pressure. The resulted residue was extracted with EtOAc (200 ml), washed with H2O (2 x 100 ml), brine (200 ml), and dried over Na2SO4. After evaporation of the solvent, the crude material was passed through a silica-gel column eluted with EtOAc. The desired ^-benzyloxycarbonyl-L-alanine amide was obtained as a white solid (8.10 g, 81% yield). This amide derivative (5.0 g, 22.5 mmol) was dissolved in THF (50 ml) and treated with Lawesson's reagent (5.46 g, 13.5 mmol) at 25 °C for 4 hours. After evaporation of THF, the resultant mixture was directly loaded for column purification eluted with EtOAc to give the title compound as a white solid (4.70 g, 87%). *H NMR (400 MHz, CDCfe) § 1.39 (d, /= 6.8 Hz, 3 H), 4.28 (m, 1 H), 5.11 (s, 2 H), 5.50 (d, /= 6.8 Hz, 1 H), 5.76 (br s, 1 H), 6.19 (br s, 1 H), 7.33 (m, 5 H). MS: Calcd: 238; Found: pVf+Hf 239. Method 52 [fl5V-l-n.3-Thiazol-2-vl>)etfavl1amine To a solution of (5)-A^-benzyloxycarbonyl-l-thiazol-2-yl-etiiylamine (Method 53; 0.50 g, 1.51 mmol) in anhydrous CH3CN (5 ml) was added TMS-I (0.26 ml, 1.82 mmol) at 25 °C. The reaction was stirred at room temperature for 30 minutes, then quenched by addition of cold HCVethyl ether solution (2 N, 10 ml) and diluted with 40 ml of ethyl ether. The precipitate was quickly collected by filtration and washed with ether. The resultant solid was suspended in DCM (1 ml) and treated with 25% of NaOMe/MeOH solution (0.363 ml, 1.59 mmol). The reaction mixture was stirred at 25 °C for 30 minutes, then to which was added 10 ml DCM. The reaction mixture was stirred at 25 °C for 1 hour. The white solid was removed by filtration and the filtrated was concentrated under reduced pressure at below 20 °C to give the crude product as light-brown oil (0.25 g, 84%). (Note: this product is volatile, high-vacuum should be avoided). The crude product was used without further purification. Method 53 {jVAT-Benzvloxycarbonvl-1 -thiazol-2-vl-etfaylamine JV-Benzyloxycarbonyl-L-alanine thiamide (Method 51; 2.1 g, 8.8 mmol) and bromoacetaldehyde dimethyl acetal (2.08 ml, 17.6 mmol) were dissolved in acetone (20 ml), to which was added HCl/dioxane solution (4 N, 0.11 ml, 0.44 mmol). The resultant solution was heated to reflux for 6 hours. The reaction was cooled to 25 °C and the solvent was removed under reduced pressure. The reaction resultant was treated saturated NaHCOa solution (30 ml) and extracted with EtOAc (30 ml). The organic layer was washed with H2O (2 x 30 ml), brine (30 ml), and dried over NaaSC^. After evaporation of the solvent, the crude material was purified by silica-gel chromatography (hexane: EtOAc = 2: 1) to give the title compound as a light brown oil (1.7 g, 74%). 'H NMR (400 MHz, CDC13) 6 1.63 (d, J= 6.8 Hz, 3 H), 5.01 - 5.22 (m, 3 H), 5.54 (br s, 1 H), 7.26 (d, J= 2.8 Hz, 1 H), 7.33 (m, 5 H), 7.71 (d, J= 2.8 Hz, 1 H), MS: Calcd.: 262; Found: [M+Hf 263. Method 54 2.4-Dichloroquinazoline A solution of quinazoline-2,4(l/f, 3#}-dione (1.0 g, 6.17 mmol) and POC13 (20 ml) in DMF (96 ml) was heated at 110°C for 17 hours. The resulting solution was cooled down and poured onto ice with stirring. Once the ice melted, the solid material was filtered and dissolved hi DCM (100 ml). The solution was washed with water once and concentrated to give product as a white solid (970 mg, 79%). 'H NMR 5 7.90 (m, 1 H), 8.03 (m, 1 H), 8.815 (m, 1 H), 8.28 (m, 1 H). Method 55 2-Chloro-Ar-C5-cyclopropyl- l/f-pvrazol-3 -ynquinazolin-4-amine A solution of 2,4-dichloroquinazoline (Method 54; 404 mg, 2.0 mmol), 3-amino-5-cyclopropyl-lH-pyrazole (250 mg, 2.0 mmol) and triethylamine (0.34 ml, 0.24 mmol) in THF (6.0 ml) was stirred at room temperature for 10 hrs. The solid formed was filtered and washed with EtOH (5 ml) and MeOH (5 ml). The solid was dried to give desired product as a white solid (100 mg, 69%. The compound was carried to the next step without further purification. JH NMR 5 0.9 (m, 2 H), 1.1 (m, 2 H), 1.8 -2.1 (m, 1 H), 6.6 (m, 1 H), 7.75 (m, 1 H), 7.85 (m, 1 H), 8.0 (m, 1 H), 9.9 (br s, 1 H), 11.0 (br s, 1 H). Method 56-57 The following compounds were prepared by the procedure of Methods 54-55 using the appropriate starting materials. Method 58 Methyl 3-rfaminocarbonyl)amino]tiiiophene-2-carboxvlate To a solution of methyl 3-amino-2-thiophenecarboxylate (3.43 g, 21.8 mmol) in acetic acid (20 ml) was added a solution of potassium cyanate (3.2 g, 39.4 mmol) in water (15 ml). After stirring for 20 hrs at room temperature, the mixture was filtered and washed by water. The off white solid is the desired product (4.78 g). *H NMR (400 MHz): 6 3.9 (s, 3 H), 6.8 (br s, 2 H), 7.76 (d, J = 4Hz, 1 H), 7.93 (d, J = 4 Hz, 1 H). Methods 59-61 The following compounds were prepared by the procedure of Method 58 using the appropriate starting materials. (Table Remove)Method 62 To a solution of methyl 3-[(aminocarbonyl)aniino]thiophene-2-carboxylate (Method 58, 4.78 g) in MeOH (50 ml) was added the solution of sodium hydroxide (1 .2 g, 30 mmol) in water (15 ml). The reaction mixture was heated to reflux for 1 hr. Water was added to dissolve the solid. 50% sulfuric acid was added to adjust the pH The following compounds were prepared by the procedure of Method 62 using the appropriate starting materials. (Table Remove) Method 66 2,4-pichlorothieno[3,2-d]pvrirnidine A mixture of thieno[3^-d]pyrimidine-2,4(l//,3/0-dione (Method 62, 380 mg, 2.3 mmol), phosphorus oxychloride(10 ml) and diethylaniline (1 ml) was heated at 105°C for 16 hrs. Solvent was then removed and ice was added to the mixture. The solid was filtered and gave pink colour solid product (432.4 mg, 92%). JH NMR (400 MHz): 6 7.98 (d, J = 5.6 Hz, 1 H), 8.94(d,J = 5.6Hz,lH). Methods 67-69 The following compounds were prepared by the procedure of Method 66 using the appropriate starting materials. (Table Remove)Method 70 2-Chloro-N-f 5-cvclopropvl- IH pyrazol-3-ynthieno[3.2-d1t>vrimidin-4-amine A mixture of 2,4-dichlorothieno[3,2-d]pyrimidiDe (Method 66, 100 mg, 0.49 mmol), 3-cyclopropyl-l/f pyrazol-5-amine (150 mg, 1.22 mmol) and triethylamine (0.15 ml, 1.1 mmol) was stirred at room temperature for 24 hrs. Water was added and the solid was filtered to give off white solid product (98 mg, 69%). ]H NMR (400 MHz): 8 0.5 (m, 2 H), 0.8 (m, 2 H), 1.8 (m, 1 H), 6.0 (br s, 1 H), 7.1 (d, J = 6 Hz, 1 H), 8.0 (d, 3 = 6 Hz, 1 H), 10.2 (br s, 1 H), 12.2(brs, IH). Methods 71-73 The following compounds were prepared by the procedure of Method 70 using the appropriate starting materials. (Table Remove) Method 74 Pvridor2.3-d1pwirmdine-2.4q#.3.HVdione A finely powdered mixture of 2-aminonicotinic acid (7.0 g, 50.7 mmol) and urea (13.0 g, 216 mmol) was heated to 180 — 190°C and maintained for 15 minutes at the same temperature. The temperature was gradually raised to 200°C and the clear melt started to solidify. The temperature was raised to 210°C and the heating was discontinued. The mixture was cooled to room temperature and 2 N NaOH solution (70 ml) was added. It was heated at 50 - 55°C to get a clear solution. This warm solution was saturated with carbon dioxide, cooled and filtered and the solid was washed with water (2 x 25 ml) to give desired product (7.71 g, 76%). 'H NMR 5 7.16 (m, 1 H), 8.22 (d, J = 6.4 Hz, 1 H), 8.53 (m, 1 H). Methods 75-81 The following compounds were prepared by the procedure of Method 74 using the appropriate starting materials. (Table Remove) Method 82 2.4-Pichloropyridor2.3-d]pvrimiduie A suspension of pyrido[23-^pyrimidine-2,4(lfir,3J^)-dione (Method 74, 6.52 g, 40 mmol) in POCh (70 ml) was heated under reflux for 18 hours. The black coloured solution was concentrated to dryness under vacuum. The residue was treated with ice (100 g) and quickly extracted with chloroform (3 x 150 ml). Combined organic layer was washed with water (100 ml) and dried over MgSCXt, filtered and evaporated to dryness. The solid obtained was triturated with ether (50 ml), filtered and dried to give desired product (3.2 g, 40%). 'H NMR (CDC13) 6 7.74 (m, 1 H), 8.66 (d, J = 2.9 Hz, 1 H), 9.33 (m, 1 H). MS: m/z 202 (M+3), 200 (M+l). Methods 83-89 The following compounds were prepared by the procedure of Method 82 using the appropriate starting materials. (Table Remove) Method 90 (2-CMoro-pyrido[2J-d1pvriinidin^vl)-f5-cyclopropvl-2H-pvrazol-3-vl)-amme To a solution of 3-amino-5-cyclopropyl-lH-pyrazole (800 mg, 6.5 mmol) and diisopropyl ethyl amine (2.51 g, 3.4 ml, 19.5 mmol) in EtOH (20 ml) was added 2,4-dichloropyrido[2,3-d]pyrimidine (Method 82,1.3 g, 6.5 mmol). The mixture was stirred for 15 minutes and the separated solid was filtered, washed with EtOH (5 ml). The solid was taken in a mixture of CHCls (10 ml) and THF (5 ml) and refluxed for 15 minutes. The residue was filtered and dried to give the desired product (800 mg, 46%). *H NMR 5 0.73 (m, 2 H), 0.98 (m, 2 H), 1.96 (m, 1 H), 6.51 (s, 1 H), 7.61 (m, 1 H), 9.02 (m, 1 H), 9.03 (m, 1 H). MS: m/z 289 (M+3), 287 (M+l). Methods 91-97 The following compounds were prepared by the procedure of Method 90 using the appropriate starting materials. (Table Remove) Method 98 7-Fhioro-2y4-dioxo (Iff. 3 H) quinazoline A finely powdered mixture of 4-fluoroanthranilic acid (24.0 g, 154.8 mmol) and urea (27.0 g, 450 mmol) was heated at 220°C for 1 hour. During the heating a clear solution was obtained at 190°C and solidified on continued heating. The mixture was cooled to 25 °C and water (500 ml) was added to it and boiled for 1 hour and cooled to 25°C. The residue was filtered and dried to give the desired product (21.55 g, 77%). !H NMR 5 6.88 (m, 1 H), 6.91 (m, 1 H), 7.94 (m, 1 H). Method 99 6-Fluoro-2.4-dioxo (1/f, 3 H) quinazoline The title compound was prepared in a similar way to Method 98 from 3-fluoro anthranilic acid. Method 100 7-Flupro-2.4-dichloroqurnazoHne A suspension of 7-fluoro-2,4-dioxo (Iff, 3#) quinazoline (Method 98, 1.8 g, 10 mmol) in POCls (30 ml) was heated under reflux for 72 hours. The brown coloured solution was concentrated to dryness under vacuum. The residue was treated with ice water (50 ml) and filtered. The residue was washed with ice-cold water (10 ml) and dried to give the desired product (1 .7 g, 78%). 5H NMR (CDC13) 5 7.92 (m, 1 H), 7.95 (d, J = 2.9 Hz, 1 H), 8.42 (m, 1 H). MS: m/z 219 (M+3), 217 (M+l). Method 101 6-Fluoro-2.4-dichloroc|uinazoUne The title compound was prepared in a similar way to Method 100 from 6-fluoro-2,4-dioxo (IH, 3 H) quinazoline (Method 99). Method 102 To a solution of 3-amino-5-cyclopropyl-l/r-pyrazole (1.23 g, 10 mmol) and diisopropyl ethyl amine (3.87 g, 52 ml, 30 mmol) in EtOH (40 ml) was added 7-fmoro-2,4-dichloroquinazoline (Method 100, 1.7 g, 7.87 mmol). The mixture was stirred for 45 minutes and the separated solid was filtered, washed with EtOH (5 ml). The solid was taken in a mixture of CHClj (10 ml) and THF (5 ml) and refluxed for 15 minutes. The residue was filtered and dried to give the desired product (1.5 g, 65%). *H NMR 8 0.73 (m, 2 H), 0.97 (m, 2 H), 1.94 (m, 1 H), 6.47 (s, 1 H), 7.52 (m, 2 H), 8.74 (m, 1 H), 10.89 (s, 1 H), 12.40 (br s, 1 H). MS: m/z 306 (M+3), 304 (M+l). Method 103 (2-Chloro-6-fluoro-quinazolin-4ylV(5-cvclopropyl-2/:/:-pvrazol-3-vl)-amuie The title compound was prepared in a similar way to Method 102from 6-fluoro-2,4-dichloroquinazoline (Method 101) andS-amino-S-cyclopropyl-l-ff-pyrazole. Method 104 ^2/?V2-Amino-2-(4-fluorophenyl)etfaanol To a stirred solution of lithium aluminium hydride (1.0 M in THF, 11.9 ml, 11.9 mmol) at 0°C was added 4-(£)-fluorophenylglycine (1.0 g, 5.9 mmol) portion wise over 1 hour. The mixture was stirred at room temperature for 16 hours. Water (0.45 ml), 4 N NaOH (0.45 ml) and water (1.34 ml) was added to the mixture and the mixture was stirred for 10 minutes before being filtered. The filtrate was concentrated to give a yellow residue. Flash chromatography (CombiFlash®, CH2Cl2/MeOH/NH3 = 90/10/1) gave product as a white solid (800 mg, 88%). 'HNMR 6 3.25 (m, 1 H), 3.30 (m, 1 H), 3.40 (m, 1 H), 3.83 (m, 1 H), 4.77 (br s, 1 H), 7.06 (m, 2 H), 7.37 (m, 2 H). Methods 105-111 The following compounds were prepared by the procedure of Method 104 using the appropriate starting materials. (Table Remove) Method 113 £ft)-l-(4-Fhioroph6nylV2-faethoxy)ethylamme The title compound was prepared according to the procedure of Russell, M. G. N et al J. Med. Chem. 1999,42,4981-5001. Method 114 l_(4-FIuorophenvlV2-morpholin-4-yie&anamine To a solution of tert-butyl [l-(4-fluorophenyl)-2-hydroxyethyl]carbamate (Method 110; 1.42 g, 5.58 mmol) in DCM (20 ml) was added triethylamine (1.2 ml) and methanesulfonyl chloride (0.52 ml, 6.69 mmol) and the reaction mixture was stirred at room temperature for 2.5 hours. The reaction mixture was poured into water and extracted with DCM. The combined organic layers were dried and concentrated. Column chromatography (25 %EtOAc to 50% EtOAc in hexanes) gave the desired product as a white solid (1.61 g). To a solution of 2-[(fert-butoxycarbonyl)amino]-2-(4-fluorophenyl)ethyl methanesulfonate obtained above (307 mg, 0.92 mmol) in THF (3 ml) was added morpholine (0.45 ml, 5.2 mmol) and the reaction mixture was heated at 70°C for 14 hours (precipitation was observed during this period). The mixture was concentrated and column chromatography (25% EtOAc to 75% EtOAc in hexanes) gave the desired product as an oil (93.4 mg, 31%). To a solution of this oil (93.4 mg, 0.29 mmol) in DCM (5 ml) was added trifluoroacetic acid (5 ml) and the reaction mixture was stirred at room temperature for 4 hours. Solvent was removed and water was added to the mixture. The solution was basified and extracted with chloroform/2-propanol (3/1). The organic layer was dried (NaaSC^) and concentrated to give a yellow oil (75 mg, quantitative yield). 'H NMR (CDC13): 5 2.25-2.50 (m, 6 H), 3.70-3.75 (m, 4 H), 4.10 (m, 1 H), 6.90 (m, 2 H), 7.25 (m, 2 H). Method 115 5-Bromo-2-cMoro-Ar-(5-methoxv-l//'-pyrazol-3-vl)pvrirnidin-4-arnuie 3-Methoxy-3-(methylthio)acrylonitrile (Method 116; 353 mg, 2.7 mmol) in hydrazine monohydrate (1.5 ml) was heated at 120°C for 1 hour. Hydrazine was removed under vacuum. NMR indicated the major product was S-methoxy-l/f-pyrazol-S-amine.1 To the crude product was added EtOH (5 ml), 5-bromo-2,4-dichloropyrimidine (1.9 g, 8 mmol) and triethylamine (1.2 ml, 8 mmol) and the reaction stirred at room temperature overnight. Solvent was removed and the residue partitioned between EtOAc and EfeO. The organic layer was purified by column chromatography (ISCO system, 20%-50% EtOAc in hexanes) to give the title compound as a solid (94 mg, 11% for two steps). *H NMR (CD3OD): 5 3.87 (s, 3 H), 5.84 (s, 1 H), 8.38 (s, 1 H). ^01047769 Method 116 3-Methoxv-3-(methvlthio)acrylonitrile1 To a solution of n-BuLi (2.5 M in Hexane, 11.0 ml, 0.0275 mol) in THF (17.5 ml) at -78°C was added a solution of CH3CN (1.0 g, 1.3 ml, 0.025 mol) in THF (25 ml). After stirring at -78°C for 1 hour, O^-dimethyl dithiocarbonate (Method 117; 3.05 g, 0.025 mol) in THF (5 ml) was added, and after a further 1 hour at —78°C the reaction mixture was warmed to room temperature and the solvent removed by evaporation. The residue was triturated with hexane and dried under high vacuum to give a pale yellow foam. To a solution of the crude lithium salt (0.025 mol) in EtOH (8 ml) was added CHal (3.9 g, 1.71 ml, 0.0275 mol) and the reaction mixture men stirred at room temperature overnight Solvent was removed and the residue partitioned between Et2O and HzO. The organic layer was washed with brine, dried (NaaSO^ and concentrated, and the residue purified by vacuum distillation to give the title compound as a mixture of E and Z isomers (890 mg, 28 % for two steps). 'H NMR (CDC13): 6 2.37 (s, 3 H), 3.80 (s, 3 H), 4.45 (s, 1 H); the other isomen 5 2.33 (s, 3 H), 4.02 (s, 3 H), 4.28 (s, 1 H). 'Liebigs Ann. Chem. 1973,1637-1643 Method 117 O.iS'-Dimethvl ditniocarbonate1 To a suspension of granulated KOH (9.3 g, 0.166 mol) in dry Et2O and benzene (1:1, 70 ml), was added MeOH (5.3 g, 6.7 ml, 0.166 mol). The reaction mixture was cooled to 6°C and a solution of CS2 (12.6 g, 10.0 ml, 0.166 mol) in benzene (7.5 ml) was added dropwise. After 5 hrs at 6°C, Me2SO4 (20.9 g, 15.7 ml, 0.166 mol) was added and the reaction mixture then stirred at room temperature for 20 hours. The organic layer was decanted, washed sequentially with 0.1 N HC1, saturated NaCl and half saturated NaCl. Solvent was removed and the residue was purified by vacuum distillation to give the title compound (11.5 g, contaminated with about 15 % ^-dimethyl dithiocarbonate, 57 %). !H NMR: 8 2.55 (s, 3 H), 4.14 (s, 3 H). lJ.Org.Chem 1996,4175 Method 118 ^5-Dichloro-JV-[5-(methvltiiioVl/f-pvrazol-3-vl1pvrimidin-4-arnine 3,3-Bis(methylthio)acrylonitrile (Method 119; 300 mg, 2 mmol) in H2NNH2.H2O (1 ml) was heated at 120°C for 1 hour. Hydrazine was removed under vacuum to give a pale green oil (267 mg). NMR indicated the major product was 3-(methylthio)-l//"-pyrazol-5-amine. EtOH (3 ml), 2,4,5-trichloropyrimidine (757 mg, 4 mmol), and Et3N (0.86 ml, 6 mmol) were added to the crude product and the mixture was stirred at room temperature overnight. Solvent was removed and the residue partitioned between EtOAc and HjO. The organic layer was purified by column chromatography (ISCO system, 20%-50% EtOAc in hexanes) to give the title compound as a white solid (272 mg, 48% for two steps). *H NMR (CD3OD): 8 2.49 (s, 3 H), 6.72 (s, 1 H), 8.24 (s, 1 H). Method 119 SJ-BisTmethvlthiolacrylonitrile1 n-Butyllithium (2.5 M hi hexane, 20.0 ml, 0.05 mol) was added dropwise to a solution of N, #-diisopropylamme (7.07 ml, 0.05 mol) in Et2O (32 ml) at -10°C. After stirring for 10 min, the solution was cooled to -70°C and CH3CN (1.3 ml, 0.025 mol) in Et2O (3.8 ml) was added dropwise, maintaining the temperature below -65°C. CSa (1.5 ml, 0.025 mol) in EtzO (3.8 ml) was added dropwise. The reaction mixture turned yellow, with precipitation, and was then stirred at 0°C for 1 hour. The yellow solid was filtered under nitrogen, washed with ether, and dried under vacuum to give 3.67 g orange solid. To a solution of crude dilithium salt (0.025 mol) in DMF (37 ml) at 0°C was added a solution of CHal (4.78 ml, 0.076 mol) in DMF (11 ml) maintaining the temperature below 20C, and the reaction mixture then stirred at RT for 1 hour. The reaction was diluted with water, extracted with ether and the organic layer washed with water and brine, dried (NaaSO^ and concentrated. The crude product was purified by column chromatography (ISCO system, 0%~30% EtOAc in hexanes) to give the title compound as a pale yellow solid (2.1 g, 58% for two steps). 'H NMR: 5 2.47 (s, 3 H), 2.54 (s, 3 H), 5.46 (s, 1 H). }Syn.Comm. 1988, 1103-1110 Method 120 2.5-Dichloro-Ar-(lff-pvrazol-5-yl')pvrimidin-4-amine The title compound was prepared by the procedure of Method 1 using the appropriate starting materials. Method 121 EtOH (3 ml), 2,4,5-trichloropyrimidine (141 mg, 0.77 mmol), and Et3N (0.13 ml, 0.9 mmol) were added to A^^-dimethyl-lH-pyrazole-S.S-diamine (Method 122; 97 mg, 0.77 mol) and the reaction mixture was stirred at room temperature overnight. Solvent was removed and the residue partitioned between EtOAc and H2O. The organic layer was purified by column chromatography (ISCO system, 15%-80% EtOAc in hexane) to give the title compound as a pale yellow solid (76 mg, 36%). 1H NMR (CEHOD): 5 2.86 (s, 6 H), 5.86 (s, 1 H), 8.24 (s, 1 H). Method 122 if J^-Dimetfavl- LJy-pvrazole-S^S-diamine1 (Z>3-(Dimc^ylanu^)-3^memyllMo)acrylonitrile (Method 123; 150 mg, 1.0 mmol) and hydrazine (0.5 ml) in EtOH (5 ml) were refluxed overnight. Solvent was removed and the residue was purified by column chromatography (ISCO system, 3-25% MeOH in CH2C12) to give the title compound (97 mg, 71 %). JHNMR (CD2C12): 8 2.79 (s, 6 H), 4.78 (s, 1 H), 6.99 (br s, 2 H). ^003045379 Method 123 (^-S-lTJimethvlaminol-S-frnethvlthio^acrvlonitrile1 To a solution of 2-cyano-3,3-bis(methylthio)acrylic acid (Method 124, 422 mg, 2.2 mmol) in MeOH (5 ml) was added dimethylamine (2.0 M in THF, 2.0 ml, 4 mmol) and Et3N (31 jj.1, 2.2 mmol). The reaction mixture was stirred at 26°C overnight. Solvent was removed and the residue was purified by column chromatography (ISCO system, 0-20% MeOH in CH2C12) to give the title compound (160 mg, 50%). *H NMR (CDC13): 6 2.39 (s, 3 H), 3.03 (s, 6 H), 4.08 (s, 1 H). 'WO03045379 Method 124 2-Cvano-3,3-bisfmetbylthio)aciylic acid1 To a solution of ethyl cyanoacetate (13.3 ml, 0.125 mol) and CS2 (7.5 ml, 0.125 mol) in EtOH (150 ml) at 0°C was added a solution of NaOH (10 g, 0.25 mol) in water (10 ml) at a rate that the temperature did not exceed 10°C. The reaction mixture was warmed to room temperature for 10 nun, and cooled to 5°C. The resulting precipitate was filtered, washed with EtOH (30 ml) and H2O (100 ml) and dried under high vacuum to afford the disodium salt (29 g). The disodium salt (13 g, 0.05 mol) was added to a solution of NaOH (3.22 g, 0.08 i mol) in water (23 ml) and the reaction mixture stirred at 40°C for 5 hours. After cooling to room temperature, dry EtOH (41 ml) was added, and the mixture stirred at room temperature for 5 minutes. The layers were separated and the lower layer diluted with water to a total volume of 80 ml. The solution was cooled to 5°C and dimethyl sulfate (7.4 ml, 0.078 mol) added at a rate that maintained the temperature at 5-15°C. After stirring at RT for 1 hour, the solution was cooled to 15°C and filtered. The filtrate was acidified to pH 1.5-2 with 4 N HO, and the resulting solid filtered, washed with water, and dried under high vacuum to give the title compound (439 mg, 44% over 3 steps). *H NMR: 5 2.58 (s, 3 H), 2.69 (s, 3 H), 13.43 (br s,lH). 1 Acta Chem. Scand. 1996,432 Method 125 fdiSr)-l-f4-Fluorophenyn-3-morphoun-4-ylpropyl]amine To a solution of tert-butyl [(lS)-l-(4-fluorophenyl)-3-oxopropyl]carbamate (Method 126; 199 mg, 0.744 mmol) in DCM (10 ml) was added morpholine (0.1 ml, 1.14 mmol). To the mixture was added sodium triacetoxyborohydride (250 mg, 1.18 mmol) and the reaction mixture was stirred at room temperature for overnight. The mixture was poured into water and was extracted with DCM. The combined organic layers were washed with brine, dried (Na2SO yield). 'HNMR (CDC13): 6 1.50 (m, 4 H), 2.10-2.40 (m, 6 H), 3.55 (m, 4 H), 3.85 (m, 1 H), 6.85(m,2H),7.15(m,2H). Method 126 tert-Butvl [d iSV 1 -(4-fluorophenyl)-3-oxopropyl]carbamate Oxalyl chloride (0.16 ml, 1.84 mmol) was added to anhydrous DCM (10 ml) and the mixture was cooled to -78°C. DMSO (0.29 ml, 4.09 mmol) was added followed by slow addition of ter/-buryl [(lS)-l-(4-fluorophenyl)-3-hydroxypropyl]carbamate (Method 111; 447 mg, 1.66 mmol) hi DCM (5 ml) to the mixture. The reaction mixture was stirred at -78°C for 15 min and to it was added diisopropylemylamine (1.44 ml, 8.3 mmol). The mixture was further stirred for 6 hours. The mixture was poured into water and extracted with DCM. The combined organic layers were washed with brine and dried (Na2SO.4) and concentrated. Column chromatography (25% EtOAc to 50% EtOAc hi hexanes) gave the desired aldehyde as an oil (397 mg, 90%). !H NMR (CDC13): 6 1.30 (s, 9 H), 2.80 (m, 2 H), 4.90 (m, 1 H), 5.05 (m, 1 H), 6.90 (m, 2 H), 7.20 (m, 2 H), 9.60 (s, 1 H). Method 127-132 Following a similar procedure to Method 125, the following compounds were synthesized via reaction of tert-butyl [(15)-l-(4-fluorophenyl)-3-oxopropyl]carbamate (Method 126) and a suitable amine. (Table Remove) Method 133 (SiS^-S-Ambo-S-^fluorophenvlVTV^-dimgthvlpropananiide A mixture of (3S)-3-[(terf-butoxycarbonyl)amino]-3-(4-fluorophenyl)propanoic acid (200 mg, 0.74 mmol), EDCI (184 mg, 0.96 mmol), HOBT (160 mg, 1.2 mmol) and dimethylamine (2.0 M in THF, 0.48 ml, 0.96 mmol) was stirred at room temperature for 48 hours. To the mixture was added water and the mixture was extracted with DCM. The combined organic layers were dried and concentrated. Reverse phase HPLC (Gilson) purification (monitored at 220 nm) gave the desired product as a white solid (506 mg, 90%). 'H NMR (CDC13): 6 1.50 (s, 9 H), 2.90 (m, 2 H), 3.10 (m, 6 H), 5.15 (m, 1 H), 7.10 (m, 2 H), 7.40 (m, 2 H). To a solution of above solid in DCM (5 ml) was added trifluoroacetic acid (5 ml) and the reaction mixture was stirred for 2 hours. Solvent was removed and the residue was basified with K2CO3/H2O. The mixture was extracted with CHCl3/2-propanol (3:1). The combined organic layers were concentrated to give a yellow oil (130 mg, 93%). 'H NMR (CDC13): 6 1.80 (s, 2 H), 2.50 (m, 2 H), 2.90 (m, 6 H), 4.45 (m, 1 H), 6.90 (m, 2 H), 7.30 (m, 2H). Method 134-5 Following a similar procedure to Method 133, the following compounds were synthesized via reaction of a suitable acid and a suitable amine. (Table Remove) Method 136 ferf-Butyir(2JtV2-amino-2-(4-fluorophenvDethvl]carbamate To a solution of 2-[(l7?)-2-amino-l-(4-fluoropheaiyl)etiiyl]-lJc/'-isoindole-l,3(2/0-dione (Method 138; 774 mg, 2.4 mmol) in THF (10 ml) was added di-ter?-butyl dicarbonate (948 mg, 4.35 mmol) and EtsN (1.1 ml, 7.9 mmol) and the mixture was stirred at room temperature overnight Water was added and the mixture was extracted with EtOAc. The combined organic layers were dried and concentrated to give a colorless oil (1.02 g). To a solution of this oil (720 mg, 1.87 mmol) in EtOH (3 ml) was added 33% MeNH2 in EtOH (6 ml). The reaction mixture was stirred at room temperature for 5 minutes and then was heated at 80°C for 2 hours. Solvent was removed and reverse phase HPLC (Gilson) gave the desired product as a colorless oil (178 mg, 37%). JH NMR (CDCU): 8 1.80 (s, 9 H), 3.10 - 3.25 (m, 2 H), 4.00 (m, 1 H), 4.25 (m, 1 H), 4.80 (m, 1 H), 6.80 (m, 2 H), 7.20 (m, 2 H). Method 137 JV-[(2Rl-2-Arnino-2-(4-fluorophenynetlivl]acetamide The title compound was synthesized in a similar way to Method 136 except that acetyl chloride was used instead of di-tert-butyl dicarbonate. Method 138 24fl^V2-Amipo-l-f4-fluorophenvl')etfavl]-lH-isoindole-1.3('2J!:n-dione To a solution of (31S)-3-(l,3-dioxo-l,3-dihydro-2^'-isoindol-2-yl)-3-(4-fluorophenyl)propanoic acid (Method 139; 1.73 g, 5.5 mmol) in THF (10 ml) was added ethylchloroformate (0.53 ml, 5.5 mmol) and Et3N (0.77 ml, 5.5 mmol) at 0°C. The solution became cloudy and the stirring was continued for 1 hour. A solution of NaNa (729 mg, 11.2 mmol) in water (5 ml) was added and the mixture was stirrd for 1 hour. The mixture was poured into water and was extracted with EtOAc and dried over anhydrous NaaSCU to give a yellow oil (1.567 g). This oil was dissolved in toluene (20 ml) and was heated at 110°C for 1.5 hours. Evaporation of solvent gave a brown oil (1.555 g, 91%). To a solution of the brown oil (1.26 g, 4.1 mmol) in dioxane (10 ml) and water (2 ml) was added concentrated HC1 (0.2 mi) at 0°C. The reaction mixture was stirred at room temperature for 2 hours. Solvent was removed and ether was added. The solid was then filtered to give the desired product as a white solid (1.2 g, 92%). The product was used without further purification. Method 139 (3^-3-fl,3-Dioxo-1.3-dihvdro-2//-isoindol-2-ylV3-(4-fluorophenvl>propanoicacid A mixture of phthalic anhydride (890 mg, 6.0 mmol) and (3S)-3-amino-3-(4-fluorophenyl)propanoic acid (1.1 g, 6.0 mmol) in DMF (5 ml) was heated at 135 °C overnight Water was added and the white solid was filtered and the solid was washed with water and dried to give the title compound (1.73 g, 93%). *H NMR: 5 3.20 (m, 1 H), 3.30 (m, 1 H), 5.50 (m, 1 H), 7.05 (m, 2 H), 7.30 (m, 2 H), 7.80 (m, 4 H). Method 140 4-Oxo-piperidine-1.3-dicarboxylic acid 1-benzvl ester 3-ethvl ester A mixture of l-benzyl-3-carbethoxy-4-piperidone hydrochloride (89.0 g, 298.9 mmol) and palladium hydroxide (4.2 g, 5.9 mmol) in MeOH (700 ml) was degassed and shaken under 40 psi of Kb overnight. The reaction mixture was filtered through a pad of celite, and concentrated. The resulted solid was dissolved in DCM (800 ml), to which was added triethyl amine (90.7 g, 897 mmol). The solution was cooled to 0 °C followed by addition of benzyl chloroformate (56.1 g, 329 mmol). The reaction mixture was stirred at 25 °C for 15 hours, quenched with water (500 ml), extracted with DCM (2 x 400 ml), dried over MgSO4, and concentrated. The crude material was purified by silica-gel chromatography (hexanes: EtOAc = 5:1) to give the title compound (72 g, 78%) and used without further analysis. Method 141 4-Hvdroxv-2-memvlsulfanyl-7.8-dmvdro-5/f-pyrido[4.3-^pyrimidine-6-carboxylic acid benzyl ester Sodium metal (1.36 g, 59 mmol) was added to MeOH (250 ml) and the mixture was stirred until the metal sodium completely disappeared. This was added to a solution of 4-oxo-piperidine-l,3-dicarboxylic acid 1-benzyl ester 3-ethyl ester (Method 140; 10.0 g, 32.8 mmol) in MeOH (50 ml), followed by addition of 2-methyl-2-thiopseudourea sulfate (8.2 g, 29.5 mmol). The reaction was stirred at 25 °C for 15 hours and concentrated under reduced pressure. The resulted residue was treated with water (200 ml), extracted with EtOAc (3 x 200 ml), washed with brine (200 ml), dried over MgSCU, and concentrated to give the title compound (7.0 g, 64%) and used without further analysis. Method 142 4-CMoro-2-memvlsulfanvl-7.8-dihYdro-5jy-pyridor4.3-^]pyrimidine-6-carboxvlic acid benzyl 4-Hydroxy-2-memylsuh^yl-7>8-dihydro-5H-pyrido[4,3-^pyrimidme-6-carboxylic acid benzyl ester (Method 141; 7.0 g, 21 mmol) was dissolved in chloroform (100 ml), to which was added POCls (17.8 g, 116 mmol) slowly. The reaction was refluxed for 15 hours, cooled to 25 °C, quenched by pouring onto ice, and extracted with DCM (3 x 200 ml). The combined organic layer was washed with aqueous NaOH solution (1 N, 100 ml), dried over MgSO4, and concentrated. The resulted residue was then purified by silica-gel column chromatography (DCM: MeOH = 50:1) to give the title compound (4.0 g, 54%) and used without further analysis. Method 143 4-(5^vcIorffopvl-l^-pyrazol-3-vlaminoV2-memvlsulfanvl-7,8-dmvdro-5/jr-pvridor4.3-^pyrimidine-6-carboxylic acid benzyl ester A solution of 4-chloro-2-methylsulfanyl-7,8-dihydro-5/f-pyrido[4,3-^pyrimidine-6-carboxylic acid benzyl ester (Method 142; 2.0 g, 5.7 mmol), 5-cyclopropyl-l/f-pyrazol-3-ylamine (0.7 g, 5.7 mmol) and triethylamine (1.7 g, 17 mmol) in NMP (15 ml) was heated to 110 °C for 48 hours, cooled to 25 °C, quenched with H2O (30 ml), and extracted with methyl terf-butyl ether (4 x 50 ml). The combined organic layer was dried over MgSO4, concentrated under reduced pressure, and purified by column chromatography (DCM: MeOH = 100: 1) to give the title compound (1.4 g, 56%). MS: Calcd.: 436; Found: [M+H]+437. Method 144 4-r5- 4-(5-Cyclopropyl-lJy-pyrazol-3-ylamino)-2-methylsulfanyl-7,8-dihydro-5J:/-pyrido[4,3-cQpyrimidine-6-carboxylic acid benzyl ester (Method 143; 0.35 g, 0.80 mmol) was dissolved in DCM (50 ml) and cooled to 0 °C, to which was added a solution of meta-chloroperoxybenzoic acid (0.99 g, 4.0 mmol) in DCM (30 ml) over 30 minutes. The reaction was then stirred for an additional 2 hours at 0 °C, quenched with 10% NaiS2O3 (100 ml), washed with saturated NaHCO3 (100 ml), and extracted with DCM (2 x 100 ml). The combined organic layer was dried over NaaSO/i, concentrated, and purified by column chromatography (DCM: MeOH = 100 :1) to give the title compound (0.19 g, 51%). MS: Calcd.: 468; Found: [M+H]+469. Method 145 3-Oxo-piperidine-l,4-dicarboxvlic acid 1-benzvl ester 4-ethyl ester Ethyl 7V-benzyl-3-oxo-4-piperidine-carboxylate hydrochloride (75.0 g, 251.9 mmol) was dissolved in 700 ml of MeOH and placed in a Parr container. Palladium hydroxide (4.2 g, 5.9 mmol) was then added. The reaction was shaken under 40 psi of Hfe overnight The reaction mixture was then filtered through a pad of celite and concentrated under reduced pressure. The resulted solid together with triethyl amine (72.6 g, 717 mmol) was dissolved in DCM (800 ml) and cooled to 0 °C, to which was benzyl chloroformate (53.0 g, 311 mmol). The reaction mixture was stirred at 25 °C for 15 hours, diluted with E^O (500 ml), and extracted with DCM (2 x 400 ml). The combined organic layer was dried over MgSO4, concentrated, and purified by silica-gel chromatography (hexane: EtOAc = 5: 1) to give the title compound (73 g, 97%) and used without further analysis. Method 146 4-Hvdroxv-2-methvlsulfanvl-5.8-dihvdro-6/f-pyrido[3.4-^pyrimidine-7-carboxylicacid benzyl ester Sodium metal (1.36 g, 59 mmol) was added to MeOH (250 ml) and stirred until the sodium completely disappeared, to which was added the MeOH (50 ml) solution of 3-oxo-piperidine-l,4-dicarboxylic acid 1-benzyl ester 4-ethyl ester (Method 145; 10.0 g, 32.8 mmol) followed by addition of 2-methyl-2-thiopseudourea sulfate (8.2 g, 29.5 mmol). The reaction was stirred at 25 °C for 15 hours and concentrated under reduced pressure. The resulted residue was dissolved in H2O (200 ml) and extracted with EtOAc (3 x 200 ml). The combined organic layer was dried over MgSC>4 and concentrated to give the title compound (8.0 g, 74%) and used without further analysis. Method 147 4-Chloro-2-methylsulfanyl-S . 8-dibydro-6#-pvridor3 .4-gnpvrimidine-7-carboxylic acid benzyl ester POC13 (22.9 g, 149 mmol) was slowly added to the chloroform (100 ml) solution of 4-hydroxy-2-memylsulfanyl-5,8-d%ydro-6H-pyrido[3,4^pvrimidine-7-carboxylic acid benzyl ester (Method 146; 9.0 g, 27 mmol). The reaction was heated to reflux for 15 hours, cooled to 25 °C, quenched by pouring onto ice, and extracted with DCM (3 x 200 ml). The combined organic layer was washed with aqueous NaOH solution (1 N, 100 ml), dried over MgSO4, and purified by column chromatography (DCM: MeOH = 100: 1) to give the title compound (7.0 g, 73%) and used without further analysis. Method 148 Method 149 4-f5-Cyclopropvl- l/f-pvrazol-3 -ylarnino)-2-methanesulfonvl-5 .8-dihvdro-6fl-pvridor3 A-cT|pvrimidine-7-caiboxvlic acid benzyl ester 4-(5-C^clopropyl-l/f-pyrazol-3-ylamino)-2-methylsulfanyl-5,8-dihydro-6/f-pyrido[3,4-cT|pyrimidine-7-carboxylic acid benzyl ester (Method 148; 2.5 g, 5.75 mmol) was dissolved in DCM (200 ml) and cooled to 0 °C, to which was added a DCM (50 ml) solution of MCPBA (5.0 g, 20.0 mmol) over a period of 1 hour. The reaction was then stirred for an additional 2 hrs at 0 °C, quenched with 10% Na2S2O3 (200 ml), washed with saturated NaHCOj (200 ml), and extracted with DCM (2 x 200 ml). The combined organic layer was dried over Na2SC>4, concentrated, and purified by column chromatography (DCM: MeOH = 100: 1) to give the title compound (2.0 g, 74%). MS: Calcd.: 468; Found: [M+H]+ 469. Method 150 2,6-Dichloro-A^-(5-memyl-lff-pyrazol-3-yl)pyrirnidin-4-aniine A mixture of 2,4,6-trichloropyrimidine (1.00 g, 5.46 mmol), 3-amino-5-methyl-l//-pyrazole (530 mg, 5.46 mmol) and triethylamine (1.1 ml, 8.2 mmol) in EtOH (10 ml) was stirred at room temperature for 1 day. Solvent was removed and the mixture was partitioned between EtOAc and water. The organic layer was concentrated to give the desired product (1.34 g, quantitative). 'HNMR (CDC13): 6 2.30 (m, 3 H), 5.90 (m, 1 H), 7.85 (m, 1 H), 8.50 (brs, 1H). Method 151 [ri^VM4-FluorophenvlV2-morpholin-4-Ylethvl1amine The compound was synthesized following Method 114 using ter/-butyl [(l/Z)-l-(4- fluorophenyl)-2-hydroxyethyl]carbamate (Method 112) as starting material. Utility The compounds of the present invention have utility for the treatment of cancer by inhibiting the tyrosine kinases, particularly the Trks and more particularly Trk A and B. Methods of treatment target tyrosine kinase activity, particularly the Trk activity and more particularly Trk A and B activity, which is involved in a variety of cancer related processes. Thus, inhibitors of tyrosine kinase, particularly the Trks and more particularly Trk A and B, are expected to be active against neoplastic disease such as carcinoma of the breast, ovary, lung, colon, prostate or other tissues, as well as leukemias and lymphomas, tumours of the central and peripheral nervous system, and other tumour types such as melanoma, fibrosarcoma and osteosarcoma. Tyrosine kinase inhibitors, particularly the Trk inhibitors and more particularly Trk A and B inhibitors are also expected to be useful for the treatment other proliferative diseases including but not limited to autoimmune, inflammatory, neurological, and cardiovascular diseases. Compounds of the present invention have been shown to inhibit tyrosine kinases, particularly the Trks and more particularly Trk A and B, as determined by the Trie B Assay described herein. Compounds provided by this invention should also be useful as standards and reagents in determining the ability of a potential pharmaceutical to inhibit tyrosine kinases, particularly the Trks and more particularly Trk A and B. These would be provided hi commercial kits comprising a compound of this invention TrkB Assay Format TrkB kinase activity is being measured against its ability to phosphorylate synthetic tyrosine residues within a generic polypeptide substrate using homogenous time-resolved fluorescence (HTRJF) technology. The intracellular domain of a HIS-tagged human TrkB kinase was expressed in SF9 cells and purified using standard nickel column chromatography. After the kinase is incubated with a biotinylated substrate and adenosine triphosphate (ATP) for 50 minutes at room temperature, the kinase reaction is stopped by the addition of 60 mM ethylenediaminetetraacetic acid (EDTA). The reaction is performed in 384 well microtitre plates and reaction products are detected with the addition of strepavidin-linked and phosphotyrosine-specific antibodies using the Tecan Ultra Evolution Microplate Fluometer after an additional 3-hour incubation at room temperature. (Table Remove) Although the pharmacological properties of the compounds of the formula (I) vary with structural change, in general activity possessed by compounds of the formula (I) may be demonstrated at IC5o concentrations (concentrations to achieve 50% inhibition) or doses in the range of (0.01 uMto 10 |iM). When tested in the above in-vitro assay the Trk inhibitory activity of the following examples was measured at the following ICsos. (Table Remove) We Claim; 1. A compound of formula (I): (Formula Removed) wherein: A is a direct bond; Ring C is carbocyclyl or heterocyclyl; R1 and R4 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy, N-(C1-6alkyl)amino, N,N-(C1-6alkyl)2amino, C1-6alkanoylamino, N-(C1-6alkyl)carbamoyl, N,N-(C1-6alkyl)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, N-(C1-6alkyl)sulphamoyl, N,N-(C1-6alkyl)2sulphamoyl, C1-6alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R1 and R4 independently of each other may be optionally substituted on carbon by one or more R8; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R9; R2 is selected from C1-6alkyl; wherein R2 may be optionally substituted on carbon by one or more R10 ; R10 is selected from halo, hydroxy, carboxy, amino, C1-6alkoxy, N,N-(C1-6alkyl)2amino, C1-6alkanoylamino, N-(C1-6alkyl)carbamoyl, N,N-(C1-6alkyl)2carbamoyl or heterocyclyl; wherein R10 may be optionally substituted on carbon by one or more R19a; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R20a; Rl9a is selected from hydroxy or C1-6alkoxy; R20a is selected from C1-6alkyl; R3 is fluoro; R5 is hydrogen or optionally substituted C1-6alkyl; wherein said optional substituents are selected from one or more R14; R6 and R7 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy, N-(C1-6alkyl)amino, N,N-(C1-6alkyl)2amino, C1-6alkanoylamino, N-(C1-6alky l)carbamoyl, N,N-(C1-6alkyl)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, N-(C1-6alkyl)sulphamoyl, N,N-(C1-6alkyl)2sulphamoyl, C1-6alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R6 and R7 independently of each other may be optionally substituted on carbon by one or more R15; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R16; or R6 and R7 together with the pyrimidine bond to which they are attached form a 5 or 6 membered carbocyclic ring or a 5 or 6 membered heterocyclic ring wherein said ring is fused to the pyrimidine of formula (I); wherein the double bonds of the resulting bicyclic ring may be further delocalised across the whole of the bicyclic ring; and wherein said carbocyclic ring or heterocyclic ring may be optionally substituted on carbon by one or more R17; and wherein if said heterocyclic ring contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R ; n=l; R8, R14, R15 and R17 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkyl, C2-6alkenyl, C2-6lkynyl, C1-6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy, N-(C1-6alkyl)amino, N,N-(C1-6alkyl)2amino, C1-6alkanoylamino, N-(C1-6alkyl)carbamoyl, N,N-(C1-6alkyl)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, N-(C1-6alkyl)sulphamoyl, N,N-(C1-6alkyl)2sulphamoyl, C1-6alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R8, R14, R15 and R17 independently of each other may be optionally substituted on carbon by one or more R19; and wherein if said heterocyclyl contains an -NH-moiety that nitrogen may be optionally substituted by a group selected from R20; R9, R16, R18 and R20 are independently selected from C1-6alkyl, C1-6alkanoyl, C1-6alkylsulphonyl, C1-6alkoxycarbonyl, carbamoyl, N-(C1-6alkyl)carbamoyl, N,N-(C1-6alkyl)2carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; wherein R9, R16, R18 and R20 independently of each other may be optionally substituted on carbon by on or more R21; R19 and 21 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy, N-(C1-6alkyl)amino, N,N-(C1-6alkyl)2amino, C1-6alkanoylamino, N-(C1-6alkyl)carbamoyl, N,N-(C1-6alkyl)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, N-(C1-6alkyl)sulphamoyl, N,N-(C1-6alkyl)2sulphamoyl, C1-6alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R19 and R21 independently of each other may be optionally substituted on carbon by one or more R23; and wherein if said heterocyclyl contains an -NH-moiety that nitrogen may be optionally substituted by a group selected from R24 ; R23 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifiuoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N, N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulphamoyl, N-ethylsulphamoyl, N,N-dimethylsulphamoyl, N,N-diethylsulphamoyl or N-methyl-N-ethylsulphamoyl; and R24 is selected from C1-6alkyl, C1-6alkanoyl, C1-6alkylsulphonyl, C1-6alkoxycarbonyl, carbamoyl, N-(C1-6alkyl)carbamoyl, N,N-(C1-6alkyl)2carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; wherein a "carbocyclyl" is a saturated, partially saturated or unsaturated, mono or bicyclic carbon ring that contains 3-12 atoms; wherein a -CH2- group can optionally be replaced by a -C(O)-; wherein a "heterocyclyl" is a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 4-12 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a -CH2- group can optionally be replaced by a -C(O)-, and a ring sulphur atom may be optionally oxidised to form the S-oxides; wherein when "R6 and R7 together with the bond to which they are attached form a 5 or 6 membered heterocyclic ring" said ring is a partially saturated or unsaturated, mono or bicyclic carbon ring that contains 5 or 6 atoms two atoms of which are shared with the pyrimidine ring of formula (I); of which at least one atom is chosen from nitrogen, sulphur or oxygen; wherein a -CH2- group can optionally be replaced by a -C(O)-, and a ring sulphur atom may be optionally oxidized to form the S-oxides; and wherein where "R6 and R7 together with the bond to which they are attached form a 5 or 6 membered carbocyclic ring" said ring is a partially saturated or unsaturated, mono or bicyclic carbon ring that contains 5 or 6 atoms two atoms of which are shared with the pyrimidine ring of formula (I); wherein a -CH2- group can optionally be replaced by a -C(0)-;or a pharmaceutically acceptable salt thereof. 2. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 1 wherein Ring C is phenyl, thienyl, pyridyl, thiazolyl. 3. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in either claim 1 or claim 2 wherein R1 is selected from hydrogen, C1-6alkyl, C1-6alkoxy, N,N-(C1-6alkyl)2amino, C1-6alkylS(O)a wherein a is 0 or carbocyclyl; wherein R1 may be optionally substituted on carbon by one or more R8 ; wherein R8 is selected from halo or carbocyclyl. 4. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-3 wherein R4 is hydrogen. 5. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as calimed in any one of claims 1-4 wherein R5 is hydrogen or optionally substituted C1-6alkyl; wherein said optional substituents are selected from one or more R14; and R14 is selected from hydroxy. 6. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-5 wherein: R6 and R7 are independently selected from hydrogen, halo, nitro, cyano, amino, C1-6alkyl, N-(C1-6alkyl)amino, N,N-(C1-6alkyl)2amino, N-(C1-6alkyl)carbamoyl, C1-6alkoxycarbonyl or heterocyclyl; wherein R6 and R7 independently of each other may be optionally substituted on carbon by one or more R15; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R16; or R6 and R7 together with the pyrimidine bond to which they are attached form a 6 membered carbocyclic ring or a 5 or 6 membered heterocyclic ring wherein said ring is fused to the pyrimidine of formula (I); wherein the double bonds of the resulting bicyclic ring may be further delocalised across the whole of the bicyclic ring; and wherein said carbocyclic ring or heterocyclic ring may be optionally substituted on carbon by one or more R17; and wherein if said heterocyclic ring contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R18; R15 is selected from halo, hydroxy, amino, C1-6alkoxy, N,N-(C1-6alkyl)2amino, carbocyclyl or heterocyclyl; wherein R15 may be optionally substituted on carbon by one or more R19; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R20; R17 is selected from halo, C1-6alkyl or C1-6alkoxy; wherein R17 may be optionally substituted on carbon by one or more R19; R16 is selected from C1-6alkyl; R18 is selected from C1-6alkanoyl; R19 is selected from halo, hydroxy, C1-6alkoxy or heterocyclyl; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R24; R20 is selected from C1-6alkyl; and R24 is selected from C1-6alky!. 7. A compound of formula (I), as claimed in claim 1, wherein: A is a direct bond; Ring C is phenyl, thienyl, pyridyl, thiazolyl; R1 is selected from hydrogen, methyl, ethyl, isopropyl, t-butyl, trifluoromethyl, cyclopropylmethyl, benzyl, methoxy, ethoxy, propoxy, isopropoxy, sec-butoxy, dimethylamino, methylthio or cyclopropyl; R2 is selected from methyl, ethyl, trifluoromethyl, hydroxymethyl, carboxymethyl, aminomethyl, methoxymethyl, morpholinomethyl, 1-hydroxyethyl, 2-hydroxyethyl, 1-carboxyethyl, 2-dimethylaminoethyl, 2-diethylaminoethyl, acetamidomethyl, 2-[N-methyl-N-(2-methoxyethyl)amino]ethyl, 2-[N-methyl-N-(2-hydroxyethyl)arnino]ethyl, 2-(N-methylcarbamoyl)ethyl, 2-[N-(2-hydroxyethyl)carbamoyl]ethyl, 2-{N,N-dimethylcarbamoyl)ethyl, 2-morpholinoethyl, 2-pyrrolidin-l-ylethyl or 2-(l-methylpiperazin-4-yl)ethyl, 1-methyl-2-hydroxyethyl; R3 is selected from fluoro; R4 is hydrogen; R5 is hydrogen, methyl or 2-hydroxyethyl; R6 and R7 are independently selected from hydrogen, fluoro, chloro, bromo, nitro, cyano, amino, methyl, methylamino, ethylamino, propylamino, isopropylamino, dimethylamino, N-methyl-N-propylamino, N-ethylcarbamoyl, methoxycarbonyl, ethoxycarbonyl, butoxycarbonyl, morpholino, pyrrolidinyl or piperazinyl; wherein R6 and R7 independently of each other may be optionally substituted on carbon by one or more R15; and wherein said piperazinyl may be optionally substituted on nitrogen by a group selected from R16; or R6 and R7 together with the pyrimidine to which they are attached form a bicyclic ring selected from quinazolinyl, thieno[3,2-d]pyrimidinyl, thieno[2,3-d]pyrimidinyl, 1H-pyrazolo[3,4-d]pyrimidinyl, thieno[3,4-d]pyrimidinyl, pyrido[2,3-d]pyrimidinyl, 5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidinyl, 5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidinyl or 5,6,7,8-tetrahydro-pyrido[3,4-d]pyrimidinyl; and wherein said bicyclic ring may be optionally substituted on carbon by one or more R17; and wherein said 5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidinyl, 5,6,7,8-tetrahydro-pyrido[2,3-d]pyrirnidinyl or 5,6,7,8-tetrahydro-pyrido[3,4-d]pyrimidinyl may be optionally substituted on nitrogen by a group selected from R18; R15 is selected from fluoro, hydroxy, amino, ethoxy, dimethylamino, phenyl, pyrrolidinyl, piperazinyl or morpholino; wherein R15 may be optionally substituted on carbon by one or more R19; and wherein said piperazinyl may be optionally substituted on nitrogen by a group selected from R20; R16 is selected from methyl; R17 is selected from fluoro, chloro, methyl, methoxy, ethoxy or propoxy; wherein R17 may be optionally substituted on carbon by one or more R19; R18 is selected from acetyl; R19 is selected from fluoro, hydroxy, methoxy, piperazinyl, pyrrolidinyl or morpholino; and wherein said piperazinyl may be optionally substituted on nitrogen by a group selected from R24; R is selected from methyl; R24 is selected from methyl; n=l; or a pharmaceutical ly acceptable salt thereof. 8. A compound of formula (I), as claimed in claim 1, selected from: (2R)-2-({4-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-5-fluoropyrimidin-2-yl}amino)-2-(4- fluorophenyl)ethanol; 5-bromo-N4-(3-cyclopropyl-lH-pyrazol-5-yl)-N2-[(1S)-l-(4-fluorophenyl)ethyl]pyrimidine- 2,4-diamine; (2R)-2-({5-chloro-4-[(3-cyclopropyl-lH-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-2-(4- fluorophenyl)ethanol; (2R)-2-({5-chloro-4-[(3-isopropoxy-lH-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-2-(4- fluorophenyl)ethanol; (3S)-3-({5-chloro-4-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]pyrimidin-2-yl}amino)-3-(4- fluorophenyl)-N-methylpropanamide; 2-( {5-chloro-2- {[(1S)-1 -(4-fluorophenyl)ethyl]amino} -6-[(5-isopropoxy-1 H-pyrazol-3- yl)amino]pyrimidin-4-yl}amino)propane-l,3-diol; 2-[(5-chloro-6-[(3-cyclopropyl-lH-pyrazol-5-yl)amino]-2-{[(lS)-l-(4-fluorophenyl)ethyl] amino} pyrimidin-4-yl)amino]propane-l,3-diol; 5-chloro-N4-(5-cyclopropyl-lH-pyrazol-3-yl)-N2-[(lS)-(4-fluoro-phenyl)-ethyl]-6-(4-methyl- piperazin-l-yl)-pyrimidine-2,4-diamine; (2R)-2-({4-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-7-fluoroquinazolin-2-yl}amino)-2-(4- fluorophenyl)ethanol; and 2-[(5-chloro-6-[(5-cyclopropyl-lH-pyrazol-3-yl)amino]-2-{[(lR)-l-(4-fluorophenyl)-2- hydroxyethyl]amino}pyrimidin-4-yl)amino]propane-l,3-diol; or a pharmaceutically acceptable salt thereof. 9. A process for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-8, which process comprises of: Process a) reaction of a pyrimidine of formula (II): (Formula Removed) wherein L is a displaceable group; with an pyrazole amine of formula (III): (Formula Removed) or Process b) reacting a pyrimidine of formula (IV): (Formula Removed) wherein L is a displaceable group; with a compound of formula (V): (Formula Removed) Process c) reacting a compound of formula (VI): (Formula Removed) with a compound of formula (VII): (Formula Removed) wherein X is an oxygen atom and q is 1; or X is a nitrogen atom and q is 2; and wherein each R20 independently represents a C1-6alkyl group; or Process d) reacting a compound of formula (VIII): (Formula Removed) with hydrazine; or and thereafter if necessary: i) converting a compound of the formula (I) into another compound of the formula (I); ii) removing any protecting groups; iii) forming a pharmaceutically acceptable salt. 10. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-8, for use as a medicament. 11. A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-8, together with at least one pharmaceutically acceptable carrier, diluent or excipient. |
|---|
2870-DELNP-2006-Abstract-(27-12-2011).pdf
2870-delnp-2006-Claims (04-05-2012).pdf
2870-DELNP-2006-Claims-(04-05-2012).pdf
2870-DELNP-2006-Claims-(27-12-2011).pdf
2870-DELNP-2006-Correspondence Others-(04-05-2012).pdf
2870-DELNP-2006-Correspondence Others-(27-12-2011).pdf
2870-delnp-2006-Correspondence-others (04-05-2012).pdf
2870-delnp-2006-correspondence-others 1.pdf
2870-delnp-2006-description (complete).pdf
2870-DELNP-2006-Form-1-(27-12-2011).pdf
2870-DELNP-2006-GPA-(27-12-2011).pdf
| Patent Number | 253261 | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Indian Patent Application Number | 2870/DELNP/2006 | ||||||||||||||||||||||||||||||
| PG Journal Number | 28/2012 | ||||||||||||||||||||||||||||||
| Publication Date | 13-Jul-2012 | ||||||||||||||||||||||||||||||
| Grant Date | 09-Jul-2012 | ||||||||||||||||||||||||||||||
| Date of Filing | 19-May-2006 | ||||||||||||||||||||||||||||||
| Name of Patentee | ASTRAZENECA AB | ||||||||||||||||||||||||||||||
| Applicant Address | SE-151 85 SODERTALJE,SWEDEN | ||||||||||||||||||||||||||||||
Inventors:
|
|||||||||||||||||||||||||||||||
| PCT International Classification Number | A61K31/506; C07D403/14; C07D413/14 | ||||||||||||||||||||||||||||||
| PCT International Application Number | PCT/GB2004/004784 | ||||||||||||||||||||||||||||||
| PCT International Filing date | 2004-11-15 | ||||||||||||||||||||||||||||||
PCT Conventions:
|
|||||||||||||||||||||||||||||||